View Details

🎙️ HS & Biosimilars: The Switch Pitch — Part 3

Final drop, biggest pearls. 💎

Is HS is the new acne? How can we treat early, treat seriously, and help prevent long-term scarring—physical and emotional?

In Part 3 of our real-world HS conversation, Skin and Joints Podcast F aculty Dr. Lauren Lam and Dr. Marni Wiseman bring the discussion home with practical, clinic-ready insights for dermatologists navigating biosimilars, biologics, comorbidities, obesity, smoking, PSP realities, and the art of building trust over time.

From why GLP-1s are not a substitute for HS-directed biologic therapy, to how to incorporate non-stigmatizing conversations around obesity and smoking cessation in the clinic, this episode gets into the real-world nuance that does not always fit neatly into an algorithm.

And when it comes to choosing between a TNF biosimilar and IL-17 options? How dos comorbidities, contraindications, access, PSP fit, disease severity, and the patient sitting in front of you all factor in for each? Find out here. 👩‍⚕️🧠

Learning Objectives
By the end of this episode, listeners will be able to:

1. Describe practical considerations for managing HS beyond acute flares, including longitudinal disease control and early biologic initiation in appropriate patients.
2. Discuss how GLP-1 therapies may fit as adjunctive care in select HS patients, while recognizing that they do not replace targeted HS biologic or biosimilar therapy.
3. Apply non-stigmatizing, patient-centred approaches when discussing obesity and smoking cessation in HS care.
4. Identify key factors that influence selection between TNF biosimilars and IL-17 therapies, including comorbid IBD, rheumatoid arthritis, contraindications, candidiasis risk, disease severity, and access.
5. Recognize the role of PSPs, samples, dose optimization, and follow-up planning in improving real-world HS treatment continuity.

SkinAndJointsPodcast #HidradenitisSuppurativa #HSawareness #Dermatology #Biosimilars #Biologics #InflammatorySkinDisease #MedicalEducation #DermTwitter #DermatologyEducation #PatientCentredCare #RealWorldDermatology #PSP #IL17 #TNF #ClinicalPearls 💉🧬🎙️

ABOUT Dr. Lauren Lam BScH, MD, FRCPC

​​Medical, Surgical & Cosmetic Dermatologist CALGARY, AB

Dr. Lam is the Vice President of the Canadian Hidradenitis Suppurativa Foundation and a Canadian Board Certified Dermatologist subspecializing in Hidradenitis Suppurativa Deroofing Procedures. She runs a weekly deroofing clinic in Calgary, Alberta, and has done 1500+ cases to date.

Besides collaborating on global HS projects, her other favourite endeavours include being an international explorer, culinary enthusiast and aunt to 5 dogs.

ABOUT Dr. Marni C. Wiseman MD FRCPC DABD

Associate Professor, Section Head Dermatology University of Manitoba

Director, SKiNWISE DERMATOLOGY and Wiseman Dermatology Research

Dr. Marni C. Wiseman began her Dermatology practice in Winnipeg, Manitoba in 2001.She is an Associate Professor and Section Head of Dermatology at the Faculty of Medicine at the University of Manitoba. Dr. Wiseman is the Medical Director of SKiNWISE DERMATOLOGY, where she conducts her private medical practice.

Dr. Wiseman’s areas of clinical and research interest include inflammatory disease: psoriasis, atopic dermatitis, hidradenitis suppuritiva, vitiligo, alopecia areata, urticaria, and acne vulgaris.

Dr Wiseman is Principal Investigator at Wiseman Dermatology Research and has participated in hundreds of clinical trials and registry studies. Dr. Wiseman is a frequent lecturer at meetings and congresses nationally and internationally and is extensively published in areas of inflammatory skin disease, photodermatosis, and cutaneous malignancy. Dr. Wiseman is a supervisor and mentor for medical students and residents, conducts regular rural/remote outreach clinics, has significant volunteer involvement with the Canadian Dermatology Association, the Canadian Hidradenitis Suppuritiva Foundation, and is an editor of the Journal of Cutaneous Medicine and Surgery.

EPISODE SUPPORTED BY CELLTRION CANADA

📻www.skinandjoints.ca

✉️info@skinandjoints.ca

📻www.skinandjoints.ca

✉️info@skinandjoints.ca

View Details

🎙️ PART 2: HS & Biosimilars: The Switch Pitch — Real-World Pearls from the Clinic 💉🔥🧴

In Part 2 of our HS and biosimilars conversation, we’re getting practical — very practical. 🎧🩺

Faculty Dr. Lauren Lam and Dr. Marni Wiseman join the Skin and Joints Podcast to unpack what really matters when biosimilars move from policy, paperwork, and prescribing forms… into the real lives of patients with hidradenitis suppurativa. 📋➡️💪

From the science of biosimilarity and extrapolating evidence across inflammatory diseases, to the clinic-level details dermatologists cannot afford to overlook — injection pain, citrate-free formulations, device ergonomics, dosing convenience, patient support programs, rural drug delivery, reload strategies, and yes… whether the PSP actually calls the patient back. ☎️🚚💉

Because in HS, the best biologic or biosimilar is not just about the molecule. It is about momentum, access, trust, support, and getting treatment into the patient’s hands before they disappear from the care journey. 🧭🤝

The conversation also takes a timely turn into obesity, systemic inflammation, GLP-1/GIP therapies, and whether metabolic care may become part of the next frontier in HS management. ⚖️🔥🔬

Consider this your field guide to biosimilar switching in HS — with clinic hot tips, PSP reality checks, and a reminder that sometimes the smallest formulation detail can make the biggest difference to the person injecting every week. 💡💉🙌

Learning Objectives:
By the end of this episode, listeners will be able to:

1. Explain how biosimilar evidence may be extrapolated across inflammatory diseases and how this applies to real-world HS care. 🔬
2. Identify key formulation and device factors that may influence patient comfort, adherence, and treatment experience with adalimumab biosimilars. 💉
3. Describe the role of patient support programs (PSPs) in treatment initiation, onboarding, access, monitoring, and long-term engagement for patients with HS. 🤝
4. Recognize practical barriers to biosimilar use in HS, including injection training, treatment delays, rural/remote medication delivery, and patient disillusionment. 🚚
5. Discuss emerging considerations around obesity, systemic inflammation, and GLP-1/GIP therapies as part of the evolving HS care conversation. ⚖️🔥=

#SkinAndJointsPodcast #HidradenitisSuppurativa #HSawareness #Dermatology #MedicalDermatology #Biosimilars #Adalimumab #InflammatorySkinDisease #DermatologistEducation #RealWorldDermatology #PatientSupportPrograms #Biologics #ClinicalPearls #DermatologyPodcast #HSManagement 🧴💉🔥🎧🩺

ABOUT Dr. Lauren Lam BScH, MD, FRCPC

​​Medical, Surgical & Cosmetic Dermatologist CALGARY, AB

Dr. Lam is the Vice President of the Canadian Hidradenitis Suppurativa Foundation and a Canadian Board Certified Dermatologist subspecializing in Hidradenitis Suppurativa Deroofing Procedures. She runs a weekly deroofing clinic in Calgary, Alberta, and has done 1500+ cases to date.

Besides collaborating on global HS projects, her other favourite endeavours include being an international explorer, culinary enthusiast and aunt to 5 dogs.

ABOUT Dr. Marni C. Wiseman MD FRCPC DABD

Associate Professor, Section Head Dermatology University of Manitoba

Director, SKiNWISE DERMATOLOGY and Wiseman Dermatology Research

Dr. Marni C. Wiseman began her Dermatology practice in Winnipeg, Manitoba in 2001.She is an Associate Professor and Section Head of Dermatology at the Faculty of Medicine at the University of Manitoba. Dr. Wiseman is the Medical Director of SKiNWISE DERMATOLOGY, where she conducts her private medical practice.

Dr. Wiseman’s areas of clinical and research interest include inflammatory disease: psoriasis, atopic dermatitis, hidradenitis suppuritiva, vitiligo, alopecia areata, urticaria, and acne vulgaris.

Dr Wiseman is Principal Investigator at Wiseman Dermatology Research and has participated in hundreds of clinical trials and registry studies. Dr. Wiseman is a frequent lecturer at meetings and congresses nationally and internationally and is extensively published in areas of inflammatory skin disease, photodermatosis, and cutaneous malignancy. Dr. Wiseman is a supervisor and mentor for medical students and residents, conducts regular rural/remote outreach clinics, has significant volunteer involvement with the Canadian Dermatology Association, the Canadian Hidradenitis Suppuritiva Foundation, and is an editor of the Journal of Cutaneous Medicine and Surgery.

EPISODE SUPPORTED BY CELLTRION CANADA

📻www.skinandjoints.ca

✉️info@skinandjoints.ca

📻www.skinandjoints.ca

✉️info@skinandjoints.ca

View Details

🎙️🇨🇦🇺🇸. Hands On, Gloves Off: Cross-Border Talk on Atopic Hand Eczema

We’re coming to you from the heart of Music City, Nashville 🎸 — but don’t worry, this Cross-Border Talk is not about trade, tariffs, or hockey rivalries. This time, it’s all hands on deck. ✋🇨🇦🇺🇸

In this episode of the Skin and Joints Podcast from RAD 2026, our Cross-Border Dermatologist Faculty Dr. Raj Chovatiya from the U.S. joins Canadian favourite Dr. Melinda Gooderham for a lively, practical, and focused conversation on atopic hand eczema, chronic hand eczema, and fresh week 32 data exploring tralokinumab in this challenging and high-burden body site.

Hands may represent a small body surface area, but they carry an outsized burden. They are exposed, functional, visible, constantly irritated, and central to work, hobbies, caregiving, gardening, handshakes, procedures, and everyday life.

In other words: when the hands are flaring, patients are not just uncomfortable — they are often functionally sidelined. 🧤🌱

This episode goes beyond the usual did the trial hit the endpoint discussion and digs into the real-world so what?

You’ll hear how the week 32 data may help frame expectations, why some patients may need more time before being labelled non-responders, how itch and pain improvements matter alongside clearance, and how shared decision-making can turn clinical trial endpoints into conversations patients actually understand. 📊🩺

The discussion also gets practical on where tralokinumab may fit alongside emerging topical options like delgocitinib, how to think about atopic hand eczema versus broader chronic hand eczema phenotypes, and why a back to basics approach remains timeless advice when patients are not responding as expected. 🔍

From Nashville notes to Monday morning clinic, this Cross-Border Talk offers a hands-on look at atopic hand eczema — with just enough clinical soil turned over to leave you wanting the full episode. 🎙️✋

Learning Objectives 🎯

After listening to this episode, listeners will be able to:

1. Describe the clinical and functional burden of atopic hand eczema✋, including why hands represent a uniquely challenging and high-impact treatment site despite limited body surface area involvement.
2. Summarize key elements of the week 32 tralokinumab data in atopic hand eczema📊, including trial design, patient population, efficacy signals, symptom outcomes, and tolerability considerations.
3. Interpret week 16 versus week 32 response data through a real-world clinical lens🕒, including how to counsel partial responders and avoid prematurely labelling treatment as failure.
4. Integrate patient-reported outcomes into treatment decision-making🗣️, particularly itch, pain, function, visibility, and the patient’s ability to return to meaningful daily activities.
5. Differentiate treatment considerations for atopic hand eczema versus broader chronic hand eczema🧩, including when topical, systemic, or combination strategies may be appropriate.
6. Apply practical clinic-based reassessment strategies for patients with persistent hand eczema🔍, including evaluation for irritant contact dermatitis, allergic contact dermatitis, occupational exposures, and ongoing trigger management.

ABOUT Dr. Raj Chovatiya, MD, PhD, MSCI
Associate Professor | Rosalind Franklin University of Medicine and Science Chicago Medical School
Founder and Director | Center for Medical Dermatology + Immunology Research
Chicago, USA

Raj Chovatiya, MD, PhD, MSCI is Associate Professor at Rosalind Franklin University of Medicine and Science Chicago Medical School and Founder and Director of the Center for Medical Dermatology + Immunology Research in Chicago, Illinois. His clinical and research focus includes the intersection of cutaneous immunology and inflammatory disease. He received his MD and PhD in immunology from Yale and completed his residency, postdoctoral research fellowship, and MS in Clinical Investigation at Northwestern University where he also served as Chief Resident. Dr. Chovatiya has a particular interest in optimizing patient-centered care, understanding chronic disease burden especially in understudied inflammatory diseases, exploring health and social disparities, and improving care across diverse skin types. He has published numerous abstracts and manuscripts and has been nationally and internationally recognized for his contributions as a clinician, educator, researcher, and leader.

ABOUT Dr.Melinda Gooderham, MD, FRCPC ( Dermatology)

Toronto, ON

Melinda Gooderham MD MSc FRCPC Dr. Gooderham is a Dermatologist and Medical Director at the SKiN Centre for Dermatology and an Investigator with Probity Medical Research. She is an Assistant Professor at Queens University and a Consultant Physician at the Peterborough Regional Health Centre. She is a fellow of the Royal College of Physicians and Surgeons of Canada.

Dr. Gooderham has been the principal investigator for over 200 clinical trials and she practices with a focus on inflammatory diseases of the skin. She also contributes to several peer-reviewed dermatology publications as an associate editor, reviewer, and has been an author of 205 articles. She enjoys lecturing to global audiences on new therapies for skin diseases.

Episode supported by and IME Grant from LEO Pharma

📻www.skinandjoints.ca

✉️info@skinandjoints.ca

📻www.skinandjoints.ca

✉️info@skinandjoints.ca

View Details

🎙️ PART 1: Real-World Biosimilar Care in HS with Dr. Lauren Lam and Dr. Marni Wiseman

HS has officially entered the Skin and Joints chat — and it did not come quietly.

In this special Part 1 episode, we welcome back two Skin and Joints Podcast Faculty favourites, dermatologists Dr. Lauren Lam and Dr. Marni Wiseman, for a practical, candid, and refreshingly real-world conversation on hidradenitis suppurativa, biologics, and the evolving role of biosimilars in Canadian care.

From delayed diagnosis and cumulative life-course impact to biologic timing, patient expectations, injection burden, access barriers, and the art of asking, “How sick of this are you?” — this episode digs into the clinical realities that do not always fit neatly into trial endpoints.

Dr. Lam and Dr. Wiseman share frontline insights on why HS is uniquely challenging, why earlier intervention may change the patient journey, and how biosimilars are reshaping access, dosing conversations, and practical treatment decisions. Expect clinical pearls, a few myth-busting moments, and clinic hot tips you can actually use — from identifying the right referral pathway, to setting realistic goals, minimizing injection burden, considering dose optimization, and translating trial endpoints into real-life wins for patients.

Also discussed: tennis dreams, cottage shade, citrate-free formulations, the joy of one injection instead of two, and why HS care is rarely a solo sport. 🎾🌿💉

Learning ObjectivesAfter listening to this episode, learners should be able to:

1. Describe why hidradenitis suppurativa is uniquely challenging to manage compared with other chronic inflammatory skin diseases, including the role of delayed diagnosis, comorbidities, surgery, pain, drainage, scarring, and quality-of-life burden.
2. Identify real-world factors that influence biologic initiation in HS, particularly in moderate disease, including patient-reported impact, flare burden, treatment goals, and the importance of earlier intervention when clinically appropriate.
3. Explain the current relevance of adalimumab biosimilars in Canadian HS care, including access, reimbursement, compassionate support, patient counselling, and confidence in biosimilar efficacy and safety.
4. Apply practical counselling strategies for patients starting or switching to biosimilar therapy, including how to discuss expectations, injection burden, pain, formulation differences, and meaningful patient-centred outcomes.
5. Recognize clinic-ready strategies to optimize HS care, including referral tips, patient-centred goal setting, realistic timelines for improvement, combination therapy considerations, and individualized dose optimization in patients with persistent disease activity.

SkinAndJointsPodcast #HidradenitisSuppurativa #HSAwareness #Biosimilars #Adalimumab #Dermatology #RheumDerm #InflammatoryDisease #RealWorldEvidence #PatientCenteredCare #BiologicTherapy #CanadianDermatology #MedicalPodcast #ClinicianEducation #ClinicHotTips #AccessToCare

Episode supported by Celltrion Canada.

ABOUT Dr. Lauren Lam BScH, MD, FRCPC

​​Medical, Surgical & Cosmetic Dermatologist CALGARY, AB

Dr. Lam is the Vice President of the Canadian Hidradenitis Suppurativa Foundation and a Canadian Board Certified Dermatologist subspecializing in Hidradenitis Suppurativa Deroofing Procedures. She runs a weekly deroofing clinic in Calgary, Alberta, and has done 1500+ cases to date.

Besides collaborating on global HS projects, her other favourite endeavours include being an international explorer, culinary enthusiast and aunt to 5 dogs.

ABOUT Dr. Marni C. Wiseman MD FRCPC DABD

Associate Professor, Section Head Dermatology University of Manitoba

Director, SKiNWISE DERMATOLOGY and Wiseman Dermatology Research

Dr. Marni C. Wiseman began her Dermatology practice in Winnipeg, Manitoba in 2001.She is an Associate Professor and Section Head of Dermatology at the Faculty of Medicine at the University of Manitoba. Dr. Wiseman is the Medical Director of SKiNWISE DERMATOLOGY, where she conducts her private medical practice.

Dr. Wiseman’s areas of clinical and research interest include inflammatory disease: psoriasis, atopic dermatitis, hidradenitis suppuritiva, vitiligo, alopecia areata, urticaria, and acne vulgaris.

Dr Wiseman is Principal Investigator at Wiseman Dermatology Research and has participated in hundreds of clinical trials and registry studies. Dr. Wiseman is a frequent lecturer at meetings and congresses nationally and internationally and is extensively published in areas of inflammatory skin disease, photodermatosis, and cutaneous malignancy. Dr. Wiseman is a supervisor and mentor for medical students and residents, conducts regular rural/remote outreach clinics, has significant volunteer involvement with the Canadian Dermatology Association, the Canadian Hidradenitis Suppuritiva Foundation, and is an editor of the Journal of Cutaneous Medicine and Surgery.

EPISODE SUPPORTED BY CELLTRION CANADA

📻www.skinandjoints.ca

✉️info@skinandjoints.ca

📻www.skinandjoints.ca

✉️info@skinandjoints.ca

View Details

🎙️The Great Dose Debate: Escalate, De-escalate, or Hold Steady?In this final episode of our AAD 2026 atopic dermatitis post-game poster series, we’re joined by dermatologist Dr. Julien Ringuet from Quebec City for a practical, no-fluff breakdown of the JADE REAL analysis — and what flexible abrocitinib dosing may actually mean when Monday morning clinic rolls around.

Because in real life, patients do not always follow a tidy trial algorithm. Symptoms flare, itch keeps people up, adherence shifts, priorities change, and sometimes the “right” dose is less of a fixed destination and more of a GPS recalculating in real time. 🧭

Dr. Ringuet walks us through the clinical “so what” behind dose escalation and de-escalation, explaining why moving from 100 mg to 200 mg — or stepping down from 200 mg to 100 mg — should not automatically be seen as failure, overtreatment, or backpedalling.

Instead, flexible dosing may be part of a thoughtful, shared decision-making strategy that better reflects the messy, dynamic reality of moderate-to-severe atopic dermatitis care.

We cover how early reassessment, patient-reported outcomes, itch, sleep, EASI trends, payer flexibility, and treat-to-target thinking all fit into the bigger picture. And yes, we also discuss the real-world art of knowing when to push, when to pause, and when to test the waters with a lower dose. 🌊

✨ Learning Objectives

By the end of this episode, listeners should be able to:

1. Describe how the JADE REAL study design reflects real-world clinical decision-making in moderate-to-severe atopic dermatitis.
2. Explain why dose escalation and de-escalation with abrocitinib may represent intentional treatment optimization rather than treatment failure.
3. Identify practical clinical scenarios where starting at 100 mg versus 200 mg may be appropriate.
4. Discuss how early follow-up, patient-reported outcomes, itch, sleep, and quality-of-life measures can help guide dose adjustment decisions.
5. Recognize key limitations of open-label, real-world evidence when translating study findings into clinical practice.
6. Apply a treat-and-adjust approach to atopic dermatitis management using shared decision-making and individualized treatment goals.

💡 Key Takeaway

Flexible dosing is not a loophole — it is real-world dermatology. The win is not finding one perfect pathway for every patient; it is learning how to reassess early, individualize thoughtfully, and adjust with purpose. 🩺

🎧 Tune in for practical pearls, real-world nuance, and Dr. Ringuet’s post-game analysis on what these data may mean for dermatologists managing AD in everyday practice.

SkinAndJointsPodcast #AAD2026 #AtopicDermatitis #EczemaCare #Dermatology #PatientReportedOutcomes #JAKInhibitors #abrocitinib #DermatologyEducation #MedicalEducation #HCPeducation #TreatToTarget #InflammatorySkinDisease #ClinicalData #DermTwitter #MedEd #Vodcast #PodcastEpisode #AADDenver #JAK #JAKinhibitor

ABOUT Dr. Julien Ringuet

Dermatologist, Quebec City, QC

Dr Ringuet is a board certified dermatologist who practices in Quebec City as the principal investigator at the Centre de Recherche Dermatologique de Québec (CRDQ).

He completed his medical training (MD) and his post graduate studies in dermatology form Laval University as well as a master in experimental medicine (MSc.) in the field of skin bioengineering at the Laboratoire d’Organogénèse Expérimentale de l’Université Laval (LOEX/CMDGT).

Dr Ringuet and his team of the CRDQ are allowing patient access to quality and innovative clinical research focused on alopecia areata, atopic dermatitis, psoriasis and its variants and vitiligo.

Supported by an IME Grant from PFIZER.

📻www.skinandjoints.ca

✉️info@skinandjoints.ca

View Details

From Clearer Skin to Better Sleep: MDA and Redefining Success in Atopic Dermatitis 🎙️Are We Treating Eczema… or Just Admiring Better Scores? Minimal Disease Activity in Atopic Dermatitis

In this rapid-fire AAD poster recap, dermatologist Dr. Julien Ringuet joins the Skin and Joints podcast to unpack a big idea with a small acronym: MDA — Minimal Disease Activity.

Borrowed from the rheumatology playbook and now making its way into dermatology, MDA asks a deceptively simple question in atopic dermatitis care: Is the patient actually doing well, or do they just look better on paper?

Together, we dive into new treat-to-target data from the AHEAD analysis, comparing abrocitinib and dupilumab through a more holistic lens — one that includes not only skin clearance, but also itch, sleep, quality of life, and the patient’s lived experience. Spoiler: an EASI score may be impressive, but it does not tuck your patient into bed at night.

Dr. Ringuet breaks down how MDA could help clinicians raise the bar in atopic dermatitis management, why early symptom relief matters, where oral JAK inhibitors may fit for selected patients, and why safety, comorbidities, route of administration, patient preference, and long-term strategy still deserve front-row seats in every treatment decision.

This episode is not just about picking a winner between therapies. It is about redefining what “success” should mean in chronic inflammatory skin disease — and avoiding the trap of accepting “better” when patients are still itchy, sleepless, and sidelined from daily life.

🎯 Learning ObjectivesBy the end of this episode, listeners will be able to:

1. Define Minimal Disease Activity in atopic dermatitis using the AHEAD treat-to-target framework, including both clinician-reported and patient-reported outcomes.
2. Explain why MDA may offer a more patient-centred endpoint than traditional skin-only measures such as EASI 75 or EASI 90.
3. Interpret key findings from the abrocitinib versus dupilumab analysis, including the relevance of early response, week-two separation, and multidimensional disease control.
4. Identify patient profiles where rapid and comprehensive symptom control may influence treatment selection, while balancing safety, comorbidities, monitoring needs, access, and patient preferences.
5. Describe practical ways to integrate a treat-to-target MDA approach into dermatology clinics, using manageable tools such as IGA/BSA or EASI, itch NRS, sleep NRS, and DLQI.
6. Recognize the importance of avoiding therapeutic inertia when patients remain itchy, sleep-deprived, or functionally impaired despite partial improvement.

🧠 Key TakeawayMinimal Disease Activity may be the dermatology upgrade we did not know we needed: less “your skin looks better” and more “are you sleeping, functioning, and living better?”

SkinAndJointsPodcast #AAD2026 #AtopicDermatitis #EczemaCare #Dermatology #PatientReportedOutcomes #JAKInhibitors #abrocitinib #DermatologyEducation #MedicalEducation #HCPeducation #TreatToTarget #InflammatorySkinDisease #ClinicalData #DermTwitter #MedEd #Vodcast #PodcastEpisode #AADDenver #JAK #JAKinhibitor

ABOUT Dr. Julien Ringuet

Dermatologist, Quebec City, QC

Dr Ringuet is a board certified dermatologist who practices in Quebec City as the principal investigator at the Centre de Recherche Dermatologique de Québec (CRDQ).
He completed his medical training (MD) and his post graduate studies in dermatology form Laval University as well as a master in experimental medicine (MSc.) in the field of skin bioengineering at the Laboratoire d’Organogénèse Expérimentale de l’Université Laval (LOEX/CMDGT).
Dr Ringuet and his team of the CRDQ are allowing patient access to quality and innovative clinical research focused on alopecia areata, atopic dermatitis, psoriasis and its variants and vitiligo.

Supported by an IME Grant from PFIZER.

📻www.skinandjoints.ca

✉️info@skinandjoints.ca

View Details

JAKs, Flares & Rescue Plans: The Art of the Atopic Dermatitis Dose-Down 🎙️

In this rapid-fire post-AAD recap, dermatologist Faculty Dr. Julien Ringuet joins the Skin and Joints Podcast to tackle a question that comes up all the time in real-world atopic dermatitis care: once a patient is doing well, can we safely step down therapy without sending their skin into rebellion?

Using newly presented data on abrocitinib dose down-titration from the JADE program, Dr. Ringuet walks through what happens when patients who respond to 200 mg transition to 100 mg for long-term maintenance—and what clinicians should do if disease control starts to slip. Spoiler: stepping down is not a cliff dive.

Along the way, we cover the “so what?” behind the numbers: who may be a good candidate for dose reduction, how to define loss of control beyond just visible skin lesions, why itch and sleep still deserve centre stage, and how shared decision-making can turn a dosing conversation into a true treatment partnership.

This episode is for clinicians who want to move beyond poster reading and into practical, exam-room-ready conversations about JAK inhibitors, maintenance dosing, treat-to-target thinking, flare management, and individualized care in atopic dermatitis.

Learning Objectives 📚

After listening to this episode, listeners should be able to:

1. Describe the clinical rationale for considering abrocitinib dose down-titration in selected patients with atopic dermatitis.
2. Interpret key long-term efficacy and flare data from the JADE Regimen/JADE Extend analyses in the context of real-world maintenance therapy.
3. Identify patient factors that may support or discourage dose reduction, including depth of response, flare history, adherence, follow-up reliability, quality-of-life burden, and patient preferences.
4. Explain how to counsel patients that step-down therapy is an option—not a guarantee—and that itch, sleep disruption, visible flare, and increased topical use can all signal loss of control.
5. Apply a treat-to-target mindset using both clinician-reported outcomes, such as EASI, IGA, and BSA, and patient-reported outcomes, including itch, sleep, satisfaction, and quality of life.
6. Recognize key caveats when applying clinical trial data to real-world practice, including responder-enriched populations, rescue therapy design, and as-observed analyses.

SkinAndJointsPodcast #AAD2026 #AtopicDermatitis #EczemaCare #Dermatology #PatientReportedOutcomes #JAKInhibitors #abrocitinib #DermatologyEducation #MedicalEducation #HCPeducation #TreatToTarget #InflammatorySkinDisease #ClinicalData #DermTwitter #MedEd #Vodcast #PodcastEpisode #AADDenver #JAK #JAKinhibitor

ABOUT Dr. Julien Ringuet

Dermatologist, Quebec City, QC

Dr Ringuet is a board certified dermatologist who practices in Quebec City as the principal investigator at the Centre de Recherche Dermatologique de Québec (CRDQ).
He completed his medical training (MD) and his post graduate studies in dermatology form Laval University as well as a master in experimental medicine (MSc.) in the field of skin bioengineering at the Laboratoire d’Organogénèse Expérimentale de l’Université Laval (LOEX/CMDGT).
Dr Ringuet and his team of the CRDQ are allowing patient access to quality and innovative clinical research focused on alopecia areata, atopic dermatitis, psoriasis and its variants and vitiligo.

Supported by an IME Grant from PFIZER.

📻www.skinandjoints.ca

✉️info@skinandjoints.ca

View Details

Skin, joints, and staying power—because in psoriasis, “getting clear” is only half the story.

In this episode of the Skin and Joints Podcast 🎧, dermatologist Dr. Chih-ho Hong and rheumatologist Dr. May Kazem team up again for a lively, multidisciplinary deep dive into new 24-month real-world data from PSoHO 📊, an international prospective observational study of biologic-treated patients with moderate-to-severe psoriasis.

The big question? Not just who gets patients clear ✨—but what gets them clear quickly ⏱️ and keeps them there for the long haul 🏃‍♂️.

This analysis looks at 24-month effectiveness and durability across biologic classes, then zooms in 🔍 on several individual biologics from IL-17 to IL-23 and TNF-I . But here’s the catch—and it’s a clinically juicy one: durability was defined very stringentIly. Patients had to achieve PASI90 or PASI100 by week 12 🎯 and then maintain that same response at months 6, 12, 18, and 24 📆.

In other words, this is not a “looked good once and disappeared” kind of outcome 👻. This is the biologic equivalent of showing up early, staying consistent, and never ghosting the follow-up visit ✅.

Dr. Hong and Dr. Kazem bring the classic Skin and Joints perspective: how should clinicians interpret biologic class comparisons? Within class comparisons? And why does durability sound simple until you realize it rewards treatments that are both fast starters ⚡ and long-distance runners 🏃‍♀️?

Expect practical pearls 💎, careful interpretation 🧠, and a reminder that real-world evidence is incredibly useful 🔬—as long as we read the fine print before declaring a winner 🏆.

Based on the attached podcast conversation emphasizing multidisciplinary care, real-world caveats, patient priorities, and the importance of viewing psoriasis as more than “just skin.”

🎯 Learning Objectives

After listening to this episode, learners should be able to:

1. Describe the PSoHO study design 📊, including its role as an international, prospective, observational study of biologic-treated patients with moderate-to-severe psoriasis.
2. Explain 24-month effectiveness and durability ⏱️, including why maintaining PASI90 or PASI100 across multiple time points is a more demanding measure of sustained treatment success.
3. Interpret stringent durability outcomes with caution 🧠, recognizing that this definition favors therapies that achieve early clearance and then maintain it over time.
4. Compare biologic classes and individual agents 🔍, including how performance may be understood in the context of real-world treatment decisions.
5. Apply a multidisciplinary skin-and-joints lens , considering skin clearance, psoriatic arthritis risk, patient-reported impact, comorbidities, and treatment persistence.
6. Recognize the strengths and limitations of real-world observational data, including confounding by indication, patient selection, and why association does not automatically equal causation

SkinAndJoints #PsoriaticArthritis #Psoriasis #Dermatology #Rheumatology #Ixekizumab #PROSPIRIT #RealWorldEvidence #InflammatoryDisease #Biologics #bDMARDs #tsDMARDs #IL17 #MedEd #HCPeducation #DermRheum #PatientCentredCare #ClinicalPractice #Podcast #Vodcast

Episode supported by an IME Grant from Eli Lilly.

ABOUT Dr. Chih-ho Hong, MD, FRCPC

Dermatologist, Vancouver, BC

Dr. Hong is a board-certified dermatologist working in Greater Vancouver BC, Canada. He runs a busy office-based dermatology clinic with a focus on clinical research. He is a Clinical Associate Professor in the Department of Dermatology and Skin Sciences and teaches at St. Paul’s Hospital in Vancouver, where he is active staff. Dr. Hong is the past head of the BC Section of Dermatology, the current Economics representative for Dermatology at the BCMA, and is the past chair of the Education Committee of the Canadian Dermatology Association. He is also a past examiner in Dermatology for the Royal College of Physicians of Canada residency qualification examination.

He is currently the Canadian representative to SPIN (The Skin Inflammation and Psoriasis International Network) – spindermatology.org

Dr. Hong is active in clinical practice and dermatology research. His main clinical areas of interest are psoriasis and eczema. He has been an investigator in over 150 trials of treatments in dermatology and has over 50 peer reviewed publications. He has lectured locally, nationally, and internationally on dermatology treatments and has been an invited speaker at international dermatology congresses.

ABOUT Dr. May Kazem, MD, FRCPC

Rheumatologist, Vancouver, BC

Dr. Mikameh “May” Kazem is a Canadian rheumatologist based in Vancouver, BC. She holds an undergraduate degree in biotechnology and a Master’s in Health Administration. She completed her Internal Medicine residency at the University of British Columbia, followed by Rheumatology fellowship training at the Schulich School of Medicine at Western University.

Dr. Kazem practices general rheumatology in Vancouver and her areas of interest include management of patients with various inflammatory rheumatologic disorders and complex osteoporosis. She is also actively involved in medical education and patient advocacy, to promote awareness, knowledge-sharing, and improved care for individuals living with rheumatic conditions.

📻www.skinandjoints.ca

✉️info@skinandjoints.ca

📻www.skinandjoints.ca

✉️info@skinandjoints.ca

View Details

🎙️ 💡 When Skin and Joints Actually Mean… Skin AND Joints

In this episode of the Skin and Joints Podcast, we bring together two expert voices — dermatologist Dr. Chih-ho Hong and rheumatologist Dr. May Kazem— for a true cross-specialty conversation on psoriatic arthritis care.

The focus? 🔍

The recent PRO-SPIRIT 12-month real-world study exploring the comparative effectiveness and persistence biologic/targeted synthetic DMARDs in patients with PsA.

And spoiler alert 🚨: this isn’t just another “good skin drug vs good joint drug” debate.

We dive into what the data means when the patient in front of you has plaques, pain, fatigue, stiffness, nail disease, possible axial symptoms, quality-of-life concerns… and a very real desire to just feel like themselves again.

What demonstrated a balanced signal across both skin and joint domains?

✅Dr. Hong brings the dermatology lens: clearing skin matters deeply, and identifying PsA early can change the entire treatment pathway.

✅Dr. Kazem brings the rheumatology lens: PsA is heterogeneous, patient-reported outcomes matter, and treatment decisions need to account for competing domains like GI disease, uveitis, axial symptoms, and inflammatory arthritis burden.

✅Together, they remind us why PsA care works best when dermatology and rheumatology stop playing telephone ☎️ and start sitting at the same table. Preferably with coffee ☕. Possibly with a “skin and joints” drinking game.

🎧 Tune in for a practical, witty, and clinically grounded conversation on how real-world data can help refine real-world decisions.

🎯 Learning Objectives:
After listening to this episode, learners will be able to:

1. Describe the clinical relevance of the 12-month PRO-SPIRIT real-world study evaluating b/tsDMARDs in PsA.
2. Discuss how dermatology and rheumatology perspectives differ — and overlap — when selecting advanced therapies for PsA.
3. Identify key limitations of real-world comparative effectiveness studies, including confounding by indication and baseline phenotype differences.
4. Apply a phenotype-driven approach to treatment selection across skin, joint, axial, enthesitis, nail, GI, and uveitis domains.
5. Recognize the importance of repeat PsA screening in patients with psoriasis and the role of multidisciplinary co-management.
6. Interpret treatment persistence and patient-reported outcomes in the context of real-world clinical practice.

SkinAndJoints #PsoriaticArthritis #Psoriasis #Dermatology #Rheumatology #Ixekizumab #PROSPIRIT #RealWorldEvidence #InflammatoryDisease #Biologics #bDMARDs #tsDMARDs #IL17 #MedEd #HCPeducation #DermRheum #PatientCentredCare #ClinicalPractice #Podcast #Vodcast

Episode supported by and IME Grant from Eli Lilly.

ABOUT Dr. Chih-ho Hong, MD, FRCPC

Dermatologist, Vancouver, BC

Dr. Hong is a board-certified dermatologist working in Greater Vancouver BC, Canada. He runs a busy office-based dermatology clinic with a focus on clinical research. He is a Clinical Associate Professor in the Department of Dermatology and Skin Sciences and teaches at St. Paul’s Hospital in Vancouver, where he is active staff. Dr. Hong is the past head of the BC Section of Dermatology, the current Economics representative for Dermatology at the BCMA, and is the past chair of the Education Committee of the Canadian Dermatology Association. He is also a past examiner in Dermatology for the Royal College of Physicians of Canada residency qualification examination.

He is currently the Canadian representative to SPIN (The Skin Inflammation and Psoriasis International Network) – spindermatology.org

Dr. Hong is active in clinical practice and dermatology research. His main clinical areas of interest are psoriasis and eczema. He has been an investigator in over 150 trials of treatments in dermatology and has over 50 peer reviewed publications. He has lectured locally, nationally, and internationally on dermatology treatments and has been an invited speaker at international dermatology congresses.

ABOUT Dr. May Kazem, MD, FRCPC

Rheumatologist, Vancouver, BC

Dr. Mikameh “May” Kazem is a Canadian rheumatologist based in Vancouver, BC. She holds an undergraduate degree in biotechnology and a Master’s in Health Administration. She completed her Internal Medicine residency at the University of British Columbia, followed by Rheumatology fellowship training at the Schulich School of Medicine at Western University.

Dr. Kazem practices general rheumatology in Vancouver and her areas of interest include management of patients with various inflammatory rheumatologic disorders and complex osteoporosis. She is also actively involved in medical education and patient advocacy, to promote awareness, knowledge-sharing, and improved care for individuals living with rheumatic conditions.

📻www.skinandjoints.ca

✉️info@skinandjoints.ca

📻www.skinandjoints.ca

✉️info@skinandjoints.ca

View Details

🎙️✨ Melinda Knows Best at AAD Denver: Hands Down, Chronic Hand Eczema Is Getting a New Playbook 🖐️

Live from AAD 2026 in Denver 🏔️, a podcast favorite, Melinda Knows Best returns with Dr. Melinda Gooderham for a true post-game analysis🏀 of new chronic hand eczema data — and yes, this one is all about helping hands get back to doing what hands do best: opening jars 🥜, buttoning shirts 👔, holding coffee cups ☕, and generally not letting everyday life feel just like a clinical endpoint.

In this episode, we break down new pooled post-hoc data evaluating delgocitinib cream versus vehicle in adults with moderate-to-severe chronic hand eczema, with a practical twist: does prior systemic therapy exposure matter for patient success, especially when it comes to pain and itch? 🤔

We dive into:

• Does this data push delgocitinib earlier in the treatment algorithm for Melinda?
• What are the biggest critiques or caveats a dermatologist should keep in mind when looking at this data?
• Who is the real-world patient you would think about tomorrow after seeing this poster

Well the chronic hand eczema treatment ladder may not be a one-way escalator anymore. 🪜🔄

Dr. Gooderham brings the real-world lens 👩‍⚕️: patients do not just want almost clear skin on a study scale — they want to work, cook, dress, sleep, and live without painful, itchy, fissured hands getting in the way.

Because when it comes to chronic hand eczema, sometimes the most meaningful outcome is being able to open the peanut butter jar without negotiating with your skin first. 🥜😅

Learning objectives 📚
By the end of this episode, listeners will be able to:

1. Summarize new AAD 2026 data evaluating delgocitinib cream in moderate-to-severe chronic hand eczema based on prior systemic therapy exposure.
2. Compare response patterns in systemic-naïve versus systemic-experienced patients.
3. Discuss the real-world clinical relevance of early itch and pain improvement in chronic hand eczema.
4. Identify key caveats of the analysis, including its post-hoc design, subgroup size, and 16-week timeframe.
5. Consider how delgocitinib may fit into evolving treatment algorithms for chronic hand eczema.

SkinAndJointsPodcast #MelindaKnowsBest #AAD2026 #ChronicHandEczema #HandEczema #EczemaCare #Dermatology #DermatologyPodcast #Delgocitinib #MedicalEducation #HCPeducation #DermTwitter #AADDenver #SkinScience #TopicalTherapy #RealWorldDermatology #IGA #HESD #itch #pain

Episode supported by and IME Grant from LEO Pharma

ABOUT Dr.Melinda Gooderham, MD, FRCPC ( Dermatology)

Toronto, ON

Melinda Gooderham MD MSc FRCPC Dr. Gooderham is a Dermatologist and Medical Director at the SKiN Centre for Dermatology and an Investigator with Probity Medical Research. She is an Assistant Professor at Queens University and a Consultant Physician at the Peterborough Regional Health Centre. She is a fellow of the Royal College of Physicians and Surgeons of Canada.

Dr. Gooderham has been the principal investigator for over 200 clinical trials and she practices with a focus on inflammatory diseases of the skin. She also contributes to several peer-reviewed dermatology publications as an associate editor, reviewer, and has been an author of 205 articles. She enjoys lecturing to global audiences on new therapies for skin diseases.

📻www.skinandjoints.ca

✉️info@skinandjoints.ca

📻www.skinandjoints.ca

✉️info@skinandjoints.ca

View Details

🎙️✨ Isotretinoin + Clascoterone: Acne’s New Power Couple?

When acne gets severe, isotretinoin usually enters the chat as the big gun.💥
But what happens when you pair it with topical clascoterone — the anti-androgen sidekick targeting the sebaceous gland from another angle?

In this episode, we break down new real-world data from a multi-centre retrospective study comparing oral isotretinoin monotherapy versus combination isotretinoin + topical clascoterone for severe acne vulgaris and what the implications are for clinic.

And yes — the combo arm brought some serious main-character energy.

Our expert guests unpack what this could mean in clinic:
✨ faster clearance
✨ improved tolerability
✨ hormonal acne considerations
✨ patient adherence realities
✨ the ever-important goal of preventing scars before they happen

Because in acne care, almost clear is nice… but clear-clear is the assignment. ✅

This conversation dives into the practical side: When should clascoterone be added? Which patients may benefit most? How do we keep regimens simple for younger patients already juggling isotretinoin, labs, moisturizers, sunscreen, and TikTok skincare detox?

Learning objectives:
✅ Review emerging data comparing isotretinoin monotherapy with isotretinoin plus topical clascoterone in severe acne vulgaris
✅ Discuss the potential clinical relevance of combination therapy for clearance, tolerability, and patient experience
✅ Explore practical approaches to integrating clascoterone into isotretinoin treatment plans
✅ Consider real-world limitations of retrospective data, including confounders, dosing variation, skincare use, and patient selection
✅ Reframe acne treatment goals beyond lesion counts to include scarring prevention, satisfaction, and long-term disease control

🎧 AAD 2026 coverage from the Mile High City. Special thanks Dr. Mohannad Abu-Hilal.

SkinAndJointsPodcast #AAD2026 #Dermatology #Acne #AcneVulgaris #Isotretinoin #Clascoterone #Winlevi #DermTwitter #MedEd #DermatologyEducation #SevereAcne #AcneScarring #SkinHealth #ClinicalDermatology #Vodcast #Podcast #HealthcareEducation

ABOUT Dr. Renée A. Beach MD FRCPC DABD Dermatologist | Toronto, ON

Dr. Renée A. Beach is a dermatologist practicing in Toronto for more than 10 years. She earned her medical doctor (MD) degree from McMaster University, followed by Dermatology residency at the University of Ottawa (FRCPC).

As an adjunct assistant professor at the University of Toronto, she teaches trainees in the Undergraduate MD program as well as postgraduate dermatology residents and has collaborated with them on various peer-reviewed publications. She is a trusted, regularly sought-after authority across media outlets and is the on-air dermatologist for CTVs The Social and Your Morning. On social media, she is active on Instagram (@dermabeach).

At her private office, DermAtelier on Avenue, she sees patients for medical and cosmetic treatments with the goal of delivering dermatologic excellence to patients of all skin tones and types

About Dr. Irina Oroz, MD FRCPC DABD Dermatologist | Saskatoon, SK

Dr. Irina Oroz is a fellow of the Royal College of Physicians and Surgeons of Canada in Dermatology, a Diplomate of the American Board of Dermatology, and Assistant Clinical Professor of Dermatology at the University of Saskatchewan.

Currently she practices medical, surgical and cosmetic dermatology at Oroz Dermatology in Saskatoon. Her areas of interest lie in skin cancer, acne and psoriasis.

Dr. Oroz completed her medical degree at the University of Saskatchewan, prior to undertaking a five-year dermatology residency program at the University of Saskatchewan and University of Alberta. Her interest in the diagnosis and management of skin disease has been enhanced with elective training in USA, Australia and across Canada, with specialized training in Skin Cancer at the Royal Alexandra Hospital in Brisbane Australia, as well as medical education research in Edmonton.

Active in the medical community, Dr. Oroz is one of the founding members, as well as the current treasurer of the Saskatchewan Dermatology Association.

Supported by an IME Grant from SUN Pharma.

📻www.skinandjoints.ca

✉️info@skinandjoints.ca

View Details

🎙️✨ New Acne Data Just Dropped — and We’re Bringing the Post-Game Analysis from AAD 2026! 🏀

Live from Denver — the Mile High City — the Skin and Joints Podcast is breaking down new 52-week real-world acne data exploring the impact of clascoterone 1% on sebum reduction, acne improvement, tolerability, and what it actually means in day-to-day dermatology practice.

Because let’s be honest: in acne care, it’s not just about lesion counts. Patients care about oiliness, shine, pores, irritation, post-inflammatory marks, and whether their treatment routine feels like a science experiment before bed.

In this episode, Dr. Renée A. Beach and Dr. Irina Oroz (and a mystery guest co-host ;)) join the conversation to unpack the clinical relevance of the data — and why “treat-to-happy” might just be the endpoint patients really care about.

We also get into the practical side:
✅How do you layer clascoterone with retinoids?
✅What does sebum reduction actually mean in clinic?
✅Is “zero irritation” too good to be true — or reflective of real-world experience?
✅And most importantly… is it pronounced sebometer or sebumeter?

From male acne patients who now have a topical anti-androgen option, to patients who have tried everything, to those who need a tolerable long-term acne strategy — this episode explores where the data meets the real world.

Learning Objectives:
✅ Review new 52-week data on clascoterone 1% and sebum reduction in acne
✅ Discuss the clinical relevance of sebum, shine, oiliness, and patient-reported treatment success
✅ Evaluate long-term acne outcomes including IGA success, inflammatory and non-inflammatory lesion reduction, and tolerability
✅ Explore practical strategies for layering clascoterone with retinoids, benzoyl peroxide, and combo topical therapies
✅ Identify patient profiles who may benefit from topical anti-androgen therapy in real-world practice

ABOUT Dr. Renée A. Beach MD FRCPC DABD Dermatologist | Toronto, ON

Dr. Renée A. Beach is a dermatologist practicing in Toronto for more than 10 years. She earned her medical doctor (MD) degree from McMaster University, followed by Dermatology residency at the University of Ottawa (FRCPC).

As an adjunct assistant professor at the University of Toronto, she teaches trainees in the Undergraduate MD program as well as postgraduate dermatology residents and has collaborated with them on various peer-reviewed publications. She is a trusted, regularly sought-after authority across media outlets and is the on-air dermatologist for CTVs The Social and Your Morning. On social media, she is active on Instagram (@dermabeach).

At her private office, DermAtelier on Avenue, she sees patients for medical and cosmetic treatments with the goal of delivering dermatologic excellence to patients of all skin tones and types

About Dr. Irina Oroz, MD FRCPC DABD Dermatologist | Saskatoon, SK

Dr. Irina Oroz is a fellow of the Royal College of Physicians and Surgeons of Canada in Dermatology, a Diplomate of the American Board of Dermatology, and Assistant Clinical Professor of Dermatology at the University of Saskatchewan.

Currently she practices medical, surgical and cosmetic dermatology at Oroz Dermatology in Saskatoon. Her areas of interest lie in skin cancer, acne and psoriasis.

Dr. Oroz completed her medical degree at the University of Saskatchewan, prior to undertaking a five-year dermatology residency program at the University of Saskatchewan and University of Alberta. Her interest in the diagnosis and management of skin disease has been enhanced with elective training in USA, Australia and across Canada, with specialized training in Skin Cancer at the Royal Alexandra Hospital in Brisbane Australia, as well as medical education research in Edmonton.

Active in the medical community, Dr. Oroz is one of the founding members, as well as the current treasurer of the Saskatchewan Dermatology Association.

Supported by an IME Grant from SUN Pharma.

📻www.skinandjoints.ca

✉️info@skinandjoints.ca

View Details

🎙️ Age, Risk, and the JAK Factor: A 6-Year Safety Deep Dive- Part 2

Guests: Dr. Marissa Joseph and Dr. Fiona Lovegrove
Location: 📍 AAD 2026

We’re back with Part 2 of our atopic dermatitis double-header with Dr. Marissa Joseph and Dr. Fiona Lovegrove from AAD 2026 in Denver—and this time, we’re getting into the data that always enters the chat when JAK inhibitors in Atopic Dermatitis are mentioned: long-term safety.

Our expert faculty unpack fresh 6-year safety data on upadacitinib in moderate-to-severe atopic dermatitis—looking beyond efficacy and into the real-world clinical questions dermatologists face every day:

🧩 Who is the right patient?
⚖️ How do we balance real world risk vs benefit?
👵 Does anything change when a patient is over 65? Or is it about how risk is really framed?
💉 Where does zoster vaccination fit into the treatment conversation?

📊 And how do we contextualize MACE, VTE, malignancy, infections, and herpes zoster without turning nuance into noise?

Because let’s be honest: when it comes to JAK inhibitors, the safety conversation doesn’t just knock politely—it pulls up a chair. 🪑

This episode dives into how long-term data can help clinicians move beyond blanket “yes/no” thinking and toward more individualized decision-making: age, comorbidity stacking, dose, baseline risk, quality of life, disease severity, and patient preference all matter.

The big takeaway? Decisions in the gray zone—and that’s exactly where expert interpretation matters most.

🎯 Learning Objectives:
By the end of this episode, listeners will be able to:

1. Discuss the clinical relevance of long-term safety data for upadacitinib in moderate-to-severe atopic dermatitis.
2. Identify key safety considerations, including herpes zoster, serious infections, MACE, VTE, and malignancy.
3. Describe how age, comorbidities, dose selection, and baseline patient risk influence treatment decisions with oral JAK inhibitors.
4. Explain the role of shared decision-making and risk-benefit communication when treating adolescents, adults, and older patients with AD.
5. Recognize practical considerations around zoster vaccination and routine immunization when initiating JAK inhibitor therapy.

🎧 Tune in for a practical, nuanced, and slightly puppy-interrupted breakdown of what this data actually means for your clinic.

SkinAndJointsPodcast #AAD2026 #AtopicDermatitis #Dermatology #JAKInhibitors #Upadacitinib #Rinvoq #EczemaCare #DermTwitter #MedEd #HCPeducation #DermatologyPodcast #Vodcast #ClinicalPearls #SharedDecisionMaking #SkinScience #ADTreatment

REFERENCE:

Long-Term 6-Year Safety of Upadacitinib in Moderate-to-Severe Atopic Dermatitis Across Ages: Results From Three Phase 3 Studies

ABOUT Dr. Marissa Joseph MD FRCPC TORONTO, ON

DERMATOLOGIST AND PEDIATRICIAN

Dr. Marissa Joseph is an Associate Professor at the University of Toronto and the Medical Director of the Ricky Kanee Schachter Dermatology Centre at Women’s College Hospital. She also practices at The Hospital for Sick Children (SickKids), where she cares for children with complex skin disease in both clinic and inpatient settings and leads a pediatric laser program.

Her clinical work spans general adult, pediatric, and surgical dermatology. Internationally recognized for her expertise in pediatric dermatology, inflammatory skin disorders, and equity, diversity, and inclusion in dermatologic care, Dr. Joseph has authored book chapters and numerous peer-reviewed publications. She has also been honoured for excellence in teaching at the University of Toronto.

Her vision for the field is both simple and ambitious: equitable, high-quality dermatologic care for everyone.

ABOUT Dr. Fiona Lovegrove MD FRCPC LONDON, ON

DERMATOLOGIST

Dr. Fiona Lovegrove is a board-certified dermatologist and founder of Lovegrove Dermatology in London, Ontario. She earned her MD and PhD at the University of Toronto, where she also completed her dermatology residency. A Fellow of the Royal College of Physicians and Surgeons of Canada, she holds an academic appointment as Adjunct Professor at the Schulich School of Medicine & Dentistry.

Her clinical expertise includes psoriasis, eczema, skin cancer, and complex diseases such as bullous pemphigoid. Actively engaged in research and clinical trials, she has contributed to publications, conferences, national and global advisory boards and is a GRAPPA member. Dr. Lovegrove is committed to providing patient-centered, evidence-based dermatology care.

Supported by an IME Grant from ABBVIE..

📻www.skinandjoints.ca

✉️info@skinandjoints.ca

View Details

🎙️ If They Get There, Do They Stay There? A 140-Week AD Data Dive — Part 1 of a 2-Part Double Header

Guests: Dr. Marissa Joseph and Dr. Fiona Lovegrove
Location: 📍 AAD 2026

We came to Denver for AAD 2026, adjusted to the altitude, caught our breath — barely — and dove straight into the data.

In Part 1 of this two-part atopic dermatitis double header, Dr. Marissa Joseph and Dr. Fiona Lovegrove join us live from the Mile High City to break down fresh new clinical data in moderate-to-severe atopic dermatitis, with a focus on long-term maintenance of stringent patient-reported outcomes with upadacitinib from the Measure Up 1 and Measure Up 2 studies.

Because patients do not walk into clinic asking if their EASI score improved by 70%.
They ask:

• “Will I sleep?”
  “Will the itch stop?”
  “Can I focus at work or school?”
  “Can I stop thinking about my eczema every single day?”

Our conversation gets into the so what behind the numbers —what this data implies for your real world patient decisions, why durability matters, why week 16 response may help guide long-term expectations, and why patient-reported outcomes are moving from nice-to-have to true treatment targets in atopic dermatitis.

We also explore the challenge of measuring multiple domains in practice, and why aiming high does not mean treating partial responders as failures. How do our experts frame better sleep, less itch, and fewer daily disease interruptions for these partial responders?

Think of this as your compact AAD post-game analysis — but instead of Shaq and the scoreboard, we’re breaking down itch, sleep, emotional burden, dose optimization, and the future of treat-to-target AD care.

Learning Objectives:
By the end of this episode, listeners will be able to:

1. Describe the clinical relevance of long-term patient-reported outcome data in moderate-to-severe atopic dermatitis.
2. Discuss how itch, sleep, emotional burden, and daily functioning can inform treatment success beyond skin clearance alone.
3. Interpret the significance of sustained responses from week 16 through longer-term follow-up in the Measure Up 1 and 2 studies.
4. Identify practical considerations and limitations when incorporating stringent PRO targets into real-world dermatology practice.
5. Apply key insights from AAD 2026 data to therapeutic decision making, patient counselling, expectation-setting, and shared decision-making in AD care.

Skin and Joints Podcast — where we bring the science, the clinical translation, and just enough altitude-related commentary to keep things interesting.

Part 2 is already warming up in the bullpen.

REFERENCES:

Long-Term Maintenance of Stringent Patient-Reported Outcomes With Upadacitinib in Moderate-to-Severe Atopic Dermatitis: 140-Week Results From the Measure Up 1 and 2 Phase 3 Studies

SkinAndJointsPodcast #AAD2026 #AtopicDermatitis #EczemaCare #Dermatology #PatientReportedOutcomes #JAKInhibitors #Upadacitinib #MeasureUp #DermatologyEducation #MedicalEducation #HCPeducation #TreatToTarget #InflammatorySkinDisease #ClinicalData #DermTwitter #MedEd #Vodcast #PodcastEpisode #AADDenver #JAK #JAKinhibitor

ABOUT Dr. Marissa Joseph MD FRCPC TORONTO, ON

DERMATOLOGIST AND PEDIATRICIAN

Dr. Marissa Joseph is an Associate Professor at the University of Toronto and the Medical Director of the Ricky Kanee Schachter Dermatology Centre at Women’s College Hospital. She also practices at The Hospital for Sick Children (SickKids), where she cares for children with complex skin disease in both clinic and inpatient settings and leads a pediatric laser program.

Her clinical work spans general adult, pediatric, and surgical dermatology. Internationally recognized for her expertise in pediatric dermatology, inflammatory skin disorders, and equity, diversity, and inclusion in dermatologic care, Dr. Joseph has authored book chapters and numerous peer-reviewed publications. She has also been honoured for excellence in teaching at the University of Toronto.

Her vision for the field is both simple and ambitious: equitable, high-quality dermatologic care for everyone.

ABOUT Dr. Fiona Lovegrove MD FRCPC LONDON, ON

DERMATOLOGIST

Dr. Fiona Lovegrove is a board-certified dermatologist and founder of Lovegrove Dermatology in London, Ontario. She earned her MD and PhD at the University of Toronto, where she also completed her dermatology residency. A Fellow of the Royal College of Physicians and Surgeons of Canada, she holds an academic appointment as Adjunct Professor at the Schulich School of Medicine & Dentistry.

Her clinical expertise includes psoriasis, eczema, skin cancer, and complex diseases such as bullous pemphigoid. Actively engaged in research and clinical trials, she has contributed to publications, conferences, national and global advisory boards and is a GRAPPA member. Dr. Lovegrove is committed to providing patient-centered, evidence-based dermatology care.

Supported by an IME Grant from ABBVIE..

📻www.skinandjoints.ca

✉️info@skinandjoints.ca

View Details

🎙️ World Psoriasis Day Special

This special World Psoriasis Day episode of The Skin and Joints Podcast shines a light on the evolving psoriasis journey—from the first plaque to total skin clearance. Dermatologist Dr. Jessica Asgarpour, now back in her sunny hometown of Calgary, joins us for an honest, hopeful conversation about how far psoriasis care has come—and where it’s headed next.

From coal tar and cumbersome creams to once-every-12-week biologic injections, Dr. Asgarpour unpacks the “treatment ladder” and what really determines when to climb it. Together they explore:

Why World Psoriasis Day (Oct 29) matters for awareness, stigma reduction, and timely re-referral

How to recognize when a patient is undertreated and ready for escalation

The topical-to-systemic continuum—including steroid-free innovations, orals vs. biologics, and the occasional role for IV therapy

Real-world barriers in access and adherence—from referral deserts to needle phobia

Matching therapy to patient lifestyle, comorbidities, and comfort level (“the clinic playbook”)

Why dermatologists today can say, confidently, that there is hope for every patient

It’s part myth-busting, part motivation—a must-listen whether you’re a clinician optimizing care or a patient ready to revisit your treatment options.

🎯 Learning ObjectivesAfter listening to this episode, participants will be able to:

• Describe the modern therapeutic ladder for psoriasis, from topicals and orals to biologics and infusions.
• Identify clinical and quality-of-life criteria that signal the need for treatment escalation.
• Discuss common barriers leading to undertreatment and strategies to enhance patient access and adherence.
• Compare classes of biologic agents (TNF-α, IL-17, IL-23, IL-12/23) and their practical considerations in real-world care.
• Empower patients with evidence-based reassurance about safety, efficacy, and long-term outcomes of advanced therapies.

🩵 World Psoriasis Day is more than awareness—it’s a call to action for clear skin, renewed confidence, and collaborative care.

WorldPsoriasisDay #SkinAndJointsPodcast #PsoriasisAwareness #Dermatology #Biologics #PatientJourney #ClearSkinAhead

Supported by SUN Pharma.

ABOUT Dr. Jessica Asgarpour Dermatologist, Calgary, ABBoard-certified in both Canada and the U.S., Dr. Asgarpour completed medical school at the Cumming School of Medicine and her Dermatology residency at the University of Alberta. She practices medical, surgical, and cosmetic dermatology with a special interest in hidradenitis suppurativa and deroofing surgeries, as well as acne, psoriasis, eczema, skin cancer, and women’s health. She is currently working at the Skin Health and Wellness Centre in Calgary. She is a lecturer at the University of Toronto, a courtesy clinical associate at Women’s College Hospital, and is an active investigator for ongoing clinical trials in inflammatory diseases. She is a board member on the Canadian Hidradenitis Suppurativa foundation.

📻www.skinandjoints.ca

✉️info@skinandjoints.ca

📻www.skinandjoints.ca

✉️info@skinandjoints.ca

View Details

Acne in Paris: Croissants, Comedones & Cutting-Edge Care at EADV 2025

Guests: Dr. Chloe Ward & Dr. Natalie Cunningham
Location: 📍 EADV 2025, Paris 🇫🇷

From café chatter to late-breaker abstracts, this fresh field report stitches together breaking new data and what matters for acne care today.

Our two Canadian derm Faculty dynamos, Dr. Chloe Ward and Dr. Natalie Cunningham, join us live from EADV 2025 to decode acne in the TikTok age. We swap “Dr. Google” for real talk on psychosocial fallout (filters, FOMO, and 4 a.m. routines), sanity-check the diet myths, and map where AI actually helps in assessment—think consistent severity tracking and smarter primary-care triage—without replacing clinical eyes (especially in richer skin tones).

Drs. Ward and Cunningham unpack multimodal regimens patients can actually tolerate, topical androgen-receptor blockade at the sebaceous unit, and smarter maintenance so scars don’t steal the show.

We dig into pigment beyond classic PIH (hello, primary melanogenesis), when energy devices earn a seat (including a 1726-nm sebaceous-targeting laser), why most at-home red light is a detour, and the rare moments biologics enter the chat for overlap/refractory cases.

Throughout: practical pearls and fresh evidence

Learning Objectives

After this episode, participants will be able to:

1. 🧠 Assess psychosocial burden in acne (sleep 💤, stress 😰, social media behaviors 📱) and integrate into severity and treatment decisions 🩺.
2. 🥗 Debunk prevalent myths (“diet cures acne” ❌) with balanced, evidence-based counseling 📖 that acknowledges diet/stress/hormones as contributors, not sole causes ⚖️.
3. 🧴 Design patient-centered, multimodal regimens that optimize efficacy ✅ and tolerability 🤝—leveraging combination therapy 🔗.
4. 🧬 Explain mechanisms (incl. topical androgen-receptor blockade at the sebaceous gland) and position them in stepwise care from induction 🚀 to maintenance 🔁.
5. 🎨 Differentiate pigment pathways (PIH vs. emerging primary melanogenesis) and tailor strategies for all skin tones 🌈 with rigorous photoprotection 🧢🕶️.
6. 🤖 Use AI judiciously for documentation 📝 and triage 🏥; recognize limitations in diverse skin tones 🌍 and keep the patient’s lived experience central ❤️.
7. 🛡️ Prevent scars proactively by identifying scar-risk patients early ⏱️ and escalating appropriately (e.g., isotretinoin candidacy) 🎯.
8. 🔦 Outline the role of energy-based devices (including the 1726-nm sebaceous-targeting laser) in reducing inflammation 🔥, erythema 🌺, and remodeling 🧱—and why most at-home red-light devices fall short 🚫🔴.
9. 🧬 Spot the edge cases where biologics or overlap-syndrome thinking may be appropriate 🧩, and outline key research gaps to watch 🔭 (hormonal pathways, AI validation, long-term maintenance).

Perfect for

• Dermatologists, primary-care clinicians, pharmacists, nurses, and any HCP who fields “I saw this on TikTok…” and wants practical, patient-first to translate Paris-level science into Monday-morning care.

ABOUT Dr Natalie Cunningham, MD FRCPC HALIFAX, NS

Dr. Cunningham is a co-founder of Maritime Dermatology and was born and raised in Halifax, Nova Scotia. Her roots are in Yarmouth, Nova Scotia and Vienna, Austria. She completed a Bachelor of Science in Neuroscience, Medical School and Dermatology Residency, serving as chief resident, at Dalhousie University. She passed her Royal College examination in 2017. She has been active in medical education and is assistant professor in the department of medicine at Dalhousie medical school. She sees patients of all ages and has a pediatric dermatology clinic at the IWK where she also supervises medical students and residents. She is active in research and has publications in high impact scientific journals and is the research director at Maritime Dermatology.

ABOUT Dr. Chloé Ward, MD, FRCP(C), DABD OTTAWA, ON

Chloé Ward, MD, FRCP(C), DABD is a board-certified dermatologist working alongside our team of plastic surgeons at The Ottawa Clinic. She specializes in cutaneous laser surgery and helps patients with a wide range of cosmetic and medical skin care needs.

ABOUT Dr Natalie Cunningham, MD FRCPC HALIFAX, NS

Dr. Cunningham is a co-founder of Maritime Dermatology and was born and raised in Halifax, Nova Scotia. Her roots are in Yarmouth, Nova Scotia and Vienna, Austria. She completed a Bachelor of Science in Neuroscience, Medical School and Dermatology Residency, serving as chief resident, at Dalhousie University. She passed her Royal College examination in 2017. She has been active in medical education and is assistant professor in the department of medicine at Dalhousie medical school. She sees patients of all ages and has a pediatric dermatology clinic at the IWK where she also supervises medical students and residents. She is active in research and has publications in high impact scientific journals and is the research director at Maritime Dermatology.

ABOUT Dr. Chloé Ward, MD, FRCP(C), DABD OTTAWA, ON

Chloé Ward, MD, FRCP(C), DABD is a board-certified dermatologist working alongside our team of plastic surgeons at The Ottawa Clinic. She specializes in cutaneous laser surgery and helps patients with a wide range of cosmetic and medical skin care needs.

Supported by an IME Grant from SUN Pharma.

📻www.skinandjoints.ca

✉️info@skinandjoints.ca

View Details

Acne in Paris: Croissants, Comedones & Cutting-Edge Care at EADV 2025

Guests: Dr. Chloe Ward & Dr. Natalie Cunningham
Location: 📍 EADV 2025, Paris 🇫🇷

From café chatter to late-breaker abstracts, this fresh field report stitches together breaking new data and what matters for acne care today.

Our two Canadian derm Faculty dynamos, Dr. Chloe Ward and Dr. Natalie Cunningham, join us live from EADV 2025 to decode acne in the TikTok age. We swap “Dr. Google” for real talk on psychosocial fallout (filters, FOMO, and 4 a.m. routines), sanity-check the diet myths, and map where AI actually helps in assessment—think consistent severity tracking and smarter primary-care triage—without replacing clinical eyes (especially in richer skin tones).

Drs. Ward and Cunningham unpack multimodal regimens patients can actually tolerate, topical androgen-receptor blockade at the sebaceous unit, and smarter maintenance so scars don’t steal the show.

We dig into pigment beyond classic PIH (hello, primary melanogenesis), when energy devices earn a seat (including a 1726-nm sebaceous-targeting laser), why most at-home red light is a detour, and the rare moments biologics enter the chat for overlap/refractory cases.

Throughout: practical pearls and fresh evidence

Learning Objectives

After this episode, participants will be able to:

1. 🧠 Assess psychosocial burden in acne (sleep 💤, stress 😰, social media behaviors 📱) and integrate into severity and treatment decisions 🩺.
2. 🥗 Debunk prevalent myths (“diet cures acne” ❌) with balanced, evidence-based counseling 📖 that acknowledges diet/stress/hormones as contributors, not sole causes ⚖️.
3. 🧴 Design patient-centered, multimodal regimens that optimize efficacy ✅ and tolerability 🤝—leveraging combination therapy 🔗.
4. 🧬 Explain mechanisms (incl. topical androgen-receptor blockade at the sebaceous gland) and position them in stepwise care from induction 🚀 to maintenance 🔁.
5. 🎨 Differentiate pigment pathways (PIH vs. emerging primary melanogenesis) and tailor strategies for all skin tones 🌈 with rigorous photoprotection 🧢🕶️.
6. 🤖 Use AI judiciously for documentation 📝 and triage 🏥; recognize limitations in diverse skin tones 🌍 and keep the patient’s lived experience central ❤️.
7. 🛡️ Prevent scars proactively by identifying scar-risk patients early ⏱️ and escalating appropriately (e.g., isotretinoin candidacy) 🎯.
8. 🔦 Outline the role of energy-based devices (including the 1726-nm sebaceous-targeting laser) in reducing inflammation 🔥, erythema 🌺, and remodeling 🧱—and why most at-home red-light devices fall short 🚫🔴.
9. 🧬 Spot the edge cases where biologics or overlap-syndrome thinking may be appropriate 🧩, and outline key research gaps to watch 🔭 (hormonal pathways, AI validation, long-term maintenance).

Perfect for

• Dermatologists, primary-care clinicians, pharmacists, nurses, and any HCP who fields “I saw this on TikTok…” and wants practical, patient-first to translate Paris-level science into Monday-morning care.

ABOUT Dr Natalie Cunningham, MD FRCPC HALIFAX, NS

Dr. Cunningham is a co-founder of Maritime Dermatology and was born and raised in Halifax, Nova Scotia. Her roots are in Yarmouth, Nova Scotia and Vienna, Austria. She completed a Bachelor of Science in Neuroscience, Medical School and Dermatology Residency, serving as chief resident, at Dalhousie University. She passed her Royal College examination in 2017. She has been active in medical education and is assistant professor in the department of medicine at Dalhousie medical school. She sees patients of all ages and has a pediatric dermatology clinic at the IWK where she also supervises medical students and residents. She is active in research and has publications in high impact scientific journals and is the research director at Maritime Dermatology.

ABOUT Dr. Chloé Ward, MD, FRCP(C), DABD OTTAWA, ON

Chloé Ward, MD, FRCP(C), DABD is a board-certified dermatologist working alongside our team of plastic surgeons at The Ottawa Clinic. She specializes in cutaneous laser surgery and helps patients with a wide range of cosmetic and medical skin care needs.

ABOUT Dr Natalie Cunningham, MD FRCPC HALIFAX, NS

Dr. Cunningham is a co-founder of Maritime Dermatology and was born and raised in Halifax, Nova Scotia. Her roots are in Yarmouth, Nova Scotia and Vienna, Austria. She completed a Bachelor of Science in Neuroscience, Medical School and Dermatology Residency, serving as chief resident, at Dalhousie University. She passed her Royal College examination in 2017. She has been active in medical education and is assistant professor in the department of medicine at Dalhousie medical school. She sees patients of all ages and has a pediatric dermatology clinic at the IWK where she also supervises medical students and residents. She is active in research and has publications in high impact scientific journals and is the research director at Maritime Dermatology.

ABOUT Dr. Chloé Ward, MD, FRCP(C), DABD OTTAWA, ON

Chloé Ward, MD, FRCP(C), DABD is a board-certified dermatologist working alongside our team of plastic surgeons at The Ottawa Clinic. She specializes in cutaneous laser surgery and helps patients with a wide range of cosmetic and medical skin care needs.

Supported by an IME Grant from SUN Pharma.

📻www.skinandjoints.ca

✉️info@skinandjoints.ca

View Details

Paris Pop-Up: Hands Down the Most Fun You’ll Have Learning About Chronic Hand Eczema Late Breaker Edition

Chronic Hand Eczema in Focus: DELTA-Teen efficacy & pooled safety of topical pan-JAK

Episode Tasting Menu 🍽️:
Jet-lag ✈️, steak-frites , and NEW science : we unpack fresh adolescent data for a topical pan-JAK cream in chronic hand eczema (CHE) and a pooled safety package that’s so uneventful it’s…beautiful 😌. (Melinda’s words: “Boring is good.”)

Fresh from EADV Paris 🗼🇫🇷, the team breaks down two late-breaking updates on CHE:

1. DELTA-Teen — a randomized (3:1) 16-week trial of a topical pan-JAK inhibitor (delgocitinib cream) in adolescents (12–17) with moderate–severe CHE. 📊
2. Pooled safety analysis across five trials (Phase 2b/3; 16-week regular use + up to 52-week as-needed). 🛡️📈

What’s on the tasting menu :
• EADV in Paris — highlights with a dash of Melinda’s Paris story 🥐📸
• Current adolescent CHE care — steroid limits & non-steroidal gaps
• DELTA-Teen unpacked — design, endpoints, results, onset, adherence impact
• Safety deep-dive — pooled 5-trial analysis, 52-week PRN, counseling talking points
• Practice pearls — payer metrics (IGA-CHE), cross-setting messaging, fast-tracking from primary care
• Wrap — off-label nuance, what to tell parents/teens, what to watch for next

We dive into where a non-steroidal topical JAK can fit for adolescents—an area with gaps given steroid hesitancy and tolerability issues with other non-steroidals 🧩.
Plus, a practical workflow map 🗺️: primary care triage → dermatology fast-track → pharmacy counseling (steroid fears, adherence benefits from rapid itch relief) → documentation (expect IGA-CHE to be required by payers). Importantly, efficacy signals span CHE subtypes (atopic, irritant, allergic) ✅—supporting broad real-world relevance 🌍.

Learning objectives 🎯:

1. Describe the DELTA-Teen trial design for adolescent CHE, including primary (IGA-CHE TS) and key secondary endpoints (HECSI-90, HESD itch/pain).
2. Interpret week-16 efficacy results and differentiate early patient-reported benefits from statistical-significance timing (e.g., week-12 separation)—and weave this into adherence counseling ⏳.
3. Summarize pooled safety across five trials (16-week regular use + up to 52-week PRN): common AEs, no increased AE rates vs vehicle, and implications of minimal systemic absorption & no boxed warning for topical delgocitinib 🛡️📉.
4. Identify gaps in adolescent CHE management (steroid limitations, tolerability of other non-steroidals) and position topical pan-JAK inhibitors appropriately—acknowledging off-label use where applicable 🧭.
5. Apply a care-pathway playbook (primary care → dermatology → pharmacy counseling → payer documentation) and document outcomes likely required for access (e.g., IGA-CHE scoring) across CHE subtypes 📋✅.

Practical pearls (AKA Clinic Cheat Codes) :
• Expect early itch relief that can boost adherence; set expectations about week-12 statistical separation ⏱️🙌.
• Use IGA-CHE in documentation; keep HECSI-90/HESD in mind for research/quality initiatives 📝🔍.
• Safety talking points: AEs comparable to vehicle; long-term PRN data up to 52 weeks; discuss the no boxed warning context vs class concerns 🛡️🗣️.
• Reinforce steroid-sparing options to address teen/parent anxieties about skin thinning 🧴.
• Subtype-agnostic efficacy supports practical use while you sort mixed etiologies 🧪🔄.

—
Notes ⚠️🗒️: Adolescent use discussed here reflects off-label prescribing in many regions pending any label extension. Always consult local product labeling and guidance.

SkinAndJointsPodcast #ChronicHandEczema #CHE #EADV2025 #Paris #Dermatology #DELTATeen #Delgocitinib #JAKInhibitor #TopicalJAK #AdolescentDerm #PediatricDerm #ItchRelief #SteroidSparing #ClinicalTrials #RealWorldEvidence #IGACHE #HECSI90 #HESD #PracticePearls #DermPharmacy #MedEd #HCPs #EvidenceBasedDerm

SUPPORTED BY AN IME GRANT FROM LEO PHARMA

ABOUT Dr.Melinda Gooderham, MD, FRCPC ( Dermatology)

Toronto, ON

Melinda Gooderham MD MSc FRCPC Dr. Gooderham is a Dermatologist and Medical Director at the SKiN Centre for Dermatology and an Investigator with Probity Medical Research. She is an Assistant Professor at Queens University and a Consultant Physician at the Peterborough Regional Health Centre. She is a fellow of the Royal College of Physicians and Surgeons of Canada.

Dr. Gooderham has been the principal investigator for over 200 clinical trials and she practices with a focus on inflammatory diseases of the skin. She also contributes to several peer-reviewed dermatology publications as an associate editor, reviewer, and has been an author of 205 articles. She enjoys lecturing to global audiences on new therapies for skin diseases.

📻www.skinandjoints.ca

✉️info@skinandjoints.ca

📻www.skinandjoints.ca

✉️info@skinandjoints.ca

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

View Details

🎙️ Our PsO Playbook: Brothers on the Fairway, Biologics Experts in the Clinic ⛳️🧬✨

What happens when two Ontario derms swap the golf course for the Skin and Joints studio?

You get a rapid-fire, real-world deep dive into bimekizumab for plaque psoriasis—complete with candid golf confessions, myth-busting on intra-class switching, and a candidiasis reality check you can actually use.

Dr. Ron Vender (80 rounds a season 🙌) and Dr. Jensen Yeung (proud caddy and data devotee) unpack their 16-week, multicentre retrospective review of adults with moderate to severe PsO who’d already tangoed with other IL-17 inhibitors.

Spoiler: 86 % hit IGA 0/1 and PASI 90, while 63 % nailed PASI 100. Not bad for so-called “tough” patients.

Expect quick-hit pearls on why dual IL-17 A + F blockade matters, how to frame the switch and treatment class conversation in 30 seconds, and why starting with your heaviest hitter first-line might be a good real world strategy️‍♀️💡

🎯 Learning Objectives Decode the Data 📊
Translate 16-week real-world outcomes (IGA 0/1, PASI 90/100) into day-to-day decision-making for IL-17–experienced psoriasis patients. * Master the Switch 🔄
Compare primary vs secondary non-responders—and justify when intra-class IL-17 switching still makes clinical (and payer) sense. * Counsel with Confidence 🗣️
Craft a 30-60-second convo to prep patients to set realistic skin clearance expectations. * Rethink the Ladder 🪜
Debate first-line versus “last-resort” positioning the current IL-17 vs IL-23 landscape. * Plan for Durability 📅
Identify unanswered questions—1-year persistence, multi-failure cohorts—and how ongoing real-world follow-up could reshape treatment algorithms.*

🔔 Hit play, level up your treatment playbook, and maybe even shave a few strokes off your psoriasis management game. #SkinAndJointsPodcast #PsoriasisPearls 🩺

EXCLUSIVE TO THE SKIN AND JOINTS PODCAST

About Dr. Ron Vender MD, FRCPCDermatologist | Hamilton
Dr. Ron Vender is a Dermatologist who currently practices in Hamilton. He is the founder and director of Dermatrials Research Incorporated and Venderm Innovations in Psoriasis. He has participated as principal investigator in over 100 clinical trials. He is Associate Clinical Professor at McMaster University in the Department of Medicine, Division of Dermatology. Dr. Vender serves on the editorial board of the Journal of Cutaneous Medicine and Surgery reviewer for the JEADV, JAAD, and BJD. He is one of eight Canadians elected to the International Psoriasis Council, a member of the Canadian Professors of Dermatology and the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis. He represents Canada on several global educational steering committees as well as international advisory boards. He has published over 100 peer-reviewed manuscripts and has had posters, abstracts and lectures presented internationally.

About Dr.Jensen Yeung MD, FRCPCDermatologist | Toronto Dr. Jensen Yeung obtained a B.Sc. (Honours) and MD from McMaster University in 2001. In the same year, he began his dermatology residency training at the University of Toronto. During his residency training, he spent 6 months in Australia, New York, and Boston gaining clinical experience and acquiring the newest knowledge in the field of melanoma and dermoscopy from leading experts. In 2005, he was selected by the residency program as the co-chief resident for the year. Having obtained his board certification from the Royal College of Physicians and Surgeons of Canada in 2006, he joined the Faculty of Dermatology at the University of Toronto, where he ran teaching clinics at both Women’s College Hospital and the Sunnybrook Health Sciences Centre. In 2007, he was promoted to the position of medical director for the RKS Dermatology Program at Women’s College Hospital, where he ran a melanoma, psoriasis, and General Dermatology clinic. In 2013, he switched from RKS to PERC and took on the new role as the medical director of PERC (phototherapy education and research centre) where he runs weekly psoriasis/phototherapy clinic.

In 2014, he and Dr. Dana Jerome started a monthly combined psoriasis/psoriatic arthritis clinic at PERC. In 2011, he joined Dr. Kim Papp’s research facility in Waterloo and has participated in over 200 phase 1 to 4 clinical trials. He has also supervised and mentored many research students and residents, which has led to around 180 peer-reviewed publications. He is an associate editor at JCMS and Canadian Dermatology Today. He has received a number of teaching awards including the best resident teacher award in 2005, the 2008 Women’s College Hospital Department of Medicine Postgraduate Teaching Award, the 2009 University of Toronto Dermatology Postgraduate Program Staff Teaching Award, and the 2023 University of Toronto Department of Medicine Award for Excellence in Postgraduate Teaching.

📻www.skinandjoints.ca

✉️info@skinandjoints.ca

📻www.skinandjoints.ca

✉️info@skinandjoints.ca

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

View Details

🎙️ Before the Referral to Dr. Abdulla: Filling Your Acne 🛒 ‘Shopping Cart’—Rapid-Fire Ingredients & Real-World Care Considerations (Part 3 of 3)

Episode description

While your patient sits on a six-month wait-list for dermatology, their acne isn’t taking a holiday.

In the finale of our ingredient deep-dive mini-series, Dr. Sonya Abdulla add to the bulging cart: neo-glucosamine 🧴, glycerin 💧, niacinamide ✨, probiotics 🦠, peptides 🧬, and the aisle heroes—salicylic acid, benzoyl peroxide, and retiinol

Dr. Abdulla also tackles a practice gap too many overlook: the act of referral is not a management plan.

Tune in for bite-sized, practical scripts for product layering ➡️🧖‍♀️➡️🌞 and a myth-busting look at the microbiome 🤯

Powered by a rapid-fire Q&A, and (yes) a self-checkout beep 🔊, this episode hands you an expert toolkit 🧰 to keep acne care moving—because ⏱️ timing is everything.

Learning objectives

⏩ – Identify two evidence-based prescription or OTC therapies to start while patients await referral.

🧪 – Compare how neo-glucosamine, glycerin, niacinamide, salicylic acid, benzoyl peroxide & retinol hit the four pillars of acne pathophysiology.

🔍 – Summarize current evidence (and limits) for probiotics & peptides in acne care, guiding realistic patient expectations.

🤝 – List practical tips and resources that keep pharmacists, GPs & dermatologists co-aligned along the acne journey.

SkinAndJointsPodcast #AcneCare #DermTips #PrimaryCare #PharmacyPearls #SkinBarrier #IngredientDeepDive #StartLowGoSlow #DermEducation #Neutrogena #AcneAisleMiniSeries #SkinAndJointsPodcast #PharmToDerm 🛍️💡

Made possible with the support of Kenvue Neutrogena

Opinions are for educational purposes only and do not replace individualized medical advice.

ABOUT Dr. Sonya Abdulla

Dermatologist, TORONTO, ON

Dr. Abdulla is a board-certified dermatologist in Canada and the USA and has a blended medical and aesthetic dermatology practice at Dermatology on Bloor in Toronto. She earned her degree from the University of Ottawa, where she was awarded the Dr. André Peloquin Award for excellence in patient care. She completed additional Fellowship training in Dermatologic Laser Surgery and Aesthetic Medicine at the University of Toronto.

Dr. Abdulla is an active member of the Canadian Dermatology Association, American Academy of Dermatology, American Society of Dermatologic Surgery, European Academy of Dermatology and Venereology, Ontario Medical Association, and Canadian Medical Association. Additionally, she is a published author with numerous articles in peer-reviewed scientific journals.

📻www.skinandjoints.ca

✉️info@skinandjoints.ca

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

View Details

🎙️ Skin & Joints Podcast — Acne Aisle Adventure with Dr. Sonya Abdulla (Part 2 of 3) 🎙️

Dr. Sonya Abdulla is back at the mic, and her shopping cart is starting to look like it needs four-wheel drive. This second instalment rockets from benzoyl-peroxide to sulfur’s glow-up (no more rotten-egg vibes), detours into niacinamide’s barrier-boosting superpowers, and lands on why retinol deserves a nightly standing ovation. 🛒💥🧴

Learning Objectives 📚✨

By the end of Part 2, listeners will be able to:

1. Dose & Dispense Like a Pro
   • Choose between OTC benzoyl-peroxide and retinol strengths that maximize efficacy while minimizing irritation.
2. 🧼 Spot-Treat Smarter
   • Compare sulfur vs. niacinamide vs. hydrocolloid patches for on-demand blemish triage and know when each option is optimally introduced
3. 🔍 Master the Mixology
   • o Sequence AM/PM regimens so retinoids and peroxides play nice, and decode proprietary formulas when % labels ghost you.
4. 🕵️‍♀️ Escalate with Confidence
   • Recognize red-flags that warrant prescription-strength upgrades or derm referral. 🚑

🔍 Ingredient Sneak Peek — What’s Rolling onto the Conveyor Belt:

• Benzoyl Peroxide: The OG bacteria-slayer
• Sulfur: Acne care’s retro revival
• Niacinamide: The Swiss-army vitamin
• Retinol / Retinaldehyde: Night-shift gene whisperers that keep new breakouts from ever RSVPing.
• Hydrocolloid Patches: Tiny panic rooms for pimples

Catch the full low-down (percentages, pro hacks, and combo tricks) in the episode—your shopping cart will never be the same. 🎧🛒💥

AcneAisleMiniSeries #SkinAndJointsPodcast #PharmToDerm 🛍️💡

Made possible with the support of Kenvue Neutrogena

ABOUT Dr. Sonya Abdulla

Dermatologist, TORONTO, ON

Dr. Abdulla is a board-certified dermatologist in Canada and the USA and has a blended medical and aesthetic dermatology practice at Dermatology on Bloor in Toronto. She earned her degree from the University of Ottawa, where she was awarded the Dr. André Peloquin Award for excellence in patient care. She completed additional Fellowship training in Dermatologic Laser Surgery and Aesthetic Medicine at the University of Toronto.

Dr. Abdulla is an active member of the Canadian Dermatology Association, American Academy of Dermatology, American Society of Dermatologic Surgery, European Academy of Dermatology and Venereology, Ontario Medical Association, and Canadian Medical Association. Additionally, she is a published author with numerous articles in peer-reviewed scientific journals.

Made possible with the support of Kenvue Neutrogena

📻www.skinandjoints.ca

✉️info@skinandjoints.ca

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

View Details

🛒 Skin & Joints Podcast — Acne Aisle Adventure (Part 1 of 3) 🛒
Ready to turn the drug‑store shelf into your acne‑fighting playground? In this episode host‑with‑the‑most Erin Sahota tags in Toronto derm dynamo Dr. Sonia Abdulla for a cart‑cramming romp through OTC land. From prairie roots to downtown Toronto chic, Dr. A spills secrets on why salicylic acid is the Beyoncé of beta‑hydroxy acids, how to stop patients from “more‑is‑more” exfoliation crimes, and where pharmacists now fit in the prescription‑plus‑product relay race. Expect real‑talk on field therapy vs. spot shots, evidence‑based label sleuthing, and the brand‑new “Dr. Abdulla’s Shopping Cart” lightning round—because nothing says skin‑science like a checkout beep. 🎧✨

Learning ObjectivesBy the end of Part 1, listeners will be able to:

Decode the Acne Aisle: List the must‑know OTC actives (salicylic acid, benzoyl peroxide, retinoids, azelaic acid) and match them to cleanser, leave‑on, and spot‑treatment roles.

Coach Like a Pro: Craft patient counseling that sets realistic timelines (2–12 weeks), emphasizes whole‑field application, and prevents over‑zealous scrubbing sabotage.

Sync the Derm‑Pharm Duo: Describe how expanded pharmacist prescribing for mild acne can bridge access gaps and how consistent messaging keeps patients on track.

Build a Tiered Toolkit: Assemble product “menus” at multiple price points—because evidence‑based care shouldn’t hinge on a wallet size.

Grab your earbuds, your metaphorical basket, and part‑two‑worthy curiosity—the checkout line is just getting started! #SkinAndJointsPodcast #AcneUnlocked #PharmToDerm 🛒🧴💥

ABOUT Dr. Sonya Abdulla

Dr. Abdulla is a board-certified dermatologist in Canada and the USA and has a blended medical and aesthetic dermatology practice at Dermatology on Bloor in Toronto. She earned her degree from the University of Ottawa, where she was awarded the Dr. André Peloquin Award for excellence in patient care. She completed additional Fellowship training in Dermatologic Laser Surgery and Aesthetic Medicine at the University of Toronto.

Dr. Abdulla is an active member of the Canadian Dermatology Association, American Academy of Dermatology, American Society of Dermatologic Surgery, European Academy of Dermatology and Venereology, Ontario Medical Association, and Canadian Medical Association. Additionally, she is a published author with numerous articles in peer-reviewed scientific journals.

Made possible with the support of Kenvue Neutrogena

📻www.skinandjoints.ca

✉️info@skinandjoints.ca

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

View Details

🎙️ Part 2 – Safety First 🛡️✨

Still basking in Orlando sun, the crew zooms from efficacy fireworks to the serious stuff: a massive 2,500-patient-year integrated safety update on abrocitinib. Dr. Loo runs the numbers so you don’t have to:

• Four-and-a-half years of data, ~1,600 patients, ages 18–39 📊
• No signal for VTE, MACE, or new malignancies despite the boxed-warning hype 🚫❤️‍🩹
• Main watch-out: shingles (herpes zoster) pops more in adults than teens

Dr. Liu’s playbook:

• Benefit → then risk. The speedy itch-relief first, mention nausea/headache next, finish with Black-Box context (RA ≠ AD, pan vs selective JAK).
• Vaccinate, don’t vacillate. Shingrix before, during, or after start—flexibility wins.
• Lab light-touch. CBC, LFTs, creatinine at baseline & month 1, then q6mo.
• Dose dance. 200 mg for “put-out-the-fire” severe cases; 100 mg for teens, 65+ or comorbidity-heavy adults—with room to escalate.

🎯 Learning Objectives Summarize long-term safety signals of abrocitinib in moderate–severe AD and contrast them with boxed-warning concerns. * Apply* age- and risk-stratified dosing in shared decision-making for JAK initiation or escalation.

SkinAndJointsPodcast #AAD2025 #JAKSafety #Abrocitinib #EczemaCare #DermEd #ItchRelief #MedTwitter 🎧

About Dr Wei Jing Loo, BSc (Med), MBBS, MRCP (UK), FRCP(c)Dermatologist | London, ON

Dr Wei Jing Loo is the owner and Medical Director of DermEffects, a cutting edge dermatology centre located in London, Ontario. Dr Loo completed medical school in 1997 with an honours degree from the University of New South Wales in Sydney, Australia. She trained in Internal Medicine and obtained membership in the Royal College of Physicians in the United Kingdom in 1999. She completed her dermatology residency training in Cambridge, United Kingdom and obtained her Certificate of Specialist Training in Dermatology in 2005. She is board certified in Canada and a fellow of the Royal College of Physicians and Surgeons of Canada. She is a member of the Canadian Dermatology Association and American Academy of Dermatology.

Dr. Loo is at the forefront of the dynamic field of dermatology, serving as an associate investigator for Probity Medical Research. Dr. Loo is an Adjunct Professor at Western University in Ontario. She enjoys teaching and has published her work in many peer-reviewed journals

📻www.skinandjoints.ca

✉️info@skinandjoints.ca

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

View Details

🎙️PART 1: From Dupilumab to Abrocitinib🩺✨

Sun-kissed Orlando sets the stage as we talk all things eczema from dupilumab to abrocitinib—after squeezing in a little Disney magic, of course.

Listen to fresh poster data on switching stubborn AD patients from dupilumab to abrocitinib and debate whether to hit hard with 200 mg or start slow at 100 mg. Rapid EASI-90 gains, itch-free nights, and a “flat-line” durability curve you’ll actually love?

Along the way you’ll hear:

• The secret sauce for counseling risk-averse AD patients who’ve already weathered methotrexate and cyclosporine.
• Why comorbid alopecia or vitiligo might tip you toward a JAK-first strategy.

🎯 Learning Objectives Identify the clinical profile of AD patients who fail or can’t tolerate dupilumab and may benefit from switching to a JAK inhibitor. * Compare real-world efficacy & speed of response between abrocitinib 100 mg vs 200 mg, and craft pragmatic dose-titration plans. * Integrate* patient-reported outcomes (itch, DLQI) and comorbidity considerations into shared decision-making for advanced AD therapy.

SkinAndJointsPodcast #AAD2025 #AtopicDermatitis #EczemaCare #JAKinhibitors #Dupilumab #Abrocitinib #DermTwitter #MedEd #Podcast 🎧

SUPPORTED BY AN IME GRANT FROM PFIZER.

About Dr Wei Jing Loo, BSc (Med), MBBS, MRCP (UK), FRCP(c)Dermatologist | London, ONDr Wei Jing Loo is the owner and Medical Director of DermEffects, a cutting edge dermatology centre located in London, Ontario. Dr Loo completed medical school in 1997 with an honours degree from the University of New South Wales in Sydney, Australia. She trained in Internal Medicine and obtained membership in the Royal College of Physicians in the United Kingdom in 1999. She completed her dermatology residency training in Cambridge, United Kingdom and obtained her Certificate of Specialist Training in Dermatology in 2005. She is board certified in Canada and a fellow of the Royal College of Physicians and Surgeons of Canada. She is a member of the Canadian Dermatology Association and American Academy of Dermatology. Dr. Loo is at the forefront of the dynamic field of dermatology, serving as an associate investigator for Probity Medical Research. Dr. Loo is an Adjunct Professor at Western University in Ontario. She enjoys teaching and has published her work in many peer-reviewed journals

📻www.skinandjoints.ca

✉️info@skinandjoints.ca

📻www.skinandjoints.ca

✉️info@skinandjoints.ca

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

View Details

Episode: Do I start at 15 or jump straight to 30? Key Questions Answered:

• What’s the translational takeaway for dermatologists?🩺
• Do these findings reassure you about dose escalation or reduction?🤔
• 15 mg vs. 30 mg-clinic conundrum solved🏷️

🌴☀️ Sunshine, palm trees, and late-breaking dermatology data!

🎙️💡 In this special live episode of the Skin and Joints Podcast, from the AAD 2025 in sunny Orlando, Florida, we breakdown the FLEX UP late breaking trial results for upadacitinib for moderate to severe atopic dermatitis with with two leading Canadian dermatologists: Dr. Melinda Gooderham and Dr. Angela Law!

They also share their ultimate “conference flexes”

We go beyond EASI, spotlighting itch control 🤲, quality of life, and real-world relevance 🏥 for all those asking, “So what does this mean practically?

Together, our experts explore how this flexible dosing study answers a longstanding question:

• Should you start patients on the 15 mg or 30 mg dose, and can you switch between them for better results?

Hear how this late-breaking data might recalibrate your go-to prescribing assessment and whether it’s time to tweak your approach.

The discussion pokes at the trial’s design, why Week 12 and 24 were selected, the importance of itch reduction, and safety data.

Dr. Gooderham and Dr. Law also weigh in on how these findings might—or might not—revolutionize current clinical practice.

Learning Objectives1. FLEX UP Trial Design & Rationale * Grasp how the study was structured to evaluate flexible dosing of upadacitinib at 15 mg and 30 mg. 2. Clinical Efficacy Measures * Understand the role of EASI 90, NRS, and quality-of-life metrics in gauging patient outcomes. 3. Real-World Implications * Examine how FLEX UP data supports practical dosing choices—starting big or small—and equips you to address patient questions about switching doses. 4. Safety & Tolerability * Summarize the key safety findings (including VTE, serious infections, and zoster) and how they align with existing JAK-inhibitor data. 5. Future Directions * Recognize the need for longer-term follow-up and additional analyses to further refine flexible dosing strategies and patient selection.

🌞 Grab a comfy pair of sneakers 👟 and a protein bar 🍫 because we’re tackling front-line, day-to-day dilemmas in AD management—once and for all! Expect wit, warmth, and wisdom in this fast-paced chat, complete with palm trees, protein bars, and plenty of pro tips.

ABOUT DR. MELINDA GOODERHAM

Dermatologist, Peterborough, ON

Dr. Melinda Gooderham is a well-established dermatologist who serves as medical director at the SKiN Centre for Dermatology and the principal investigator for the SKiN Research Centre. Dr. Gooderham received her MD from the University of Western Ontario in 1999 and then completed her Dermatology residency at the University of Toronto in 2004. Before training in medicine, Dr. Gooderham obtained a Bachelor of Science degree from Queen’s University in Kingston in 1992 and a Master of Science degree from the University of Guelph in 1995. Dr. Gooderham is an Assistant Professor at Queens University and works as a Consultant Physician at the Peterborough Regional Health Centre (PRHC). A fellow of the Royal College of Physicians and Surgeons of Canada, she has investigated over 200 clinical trials focusing on inflammatory skin diseases, including psoriasis and atopic dermatitis. Beyond clinical practice, Dr. Gooderham actively contributes to dermatology publications as an author, reviewer, and associate editor, with authorship of over 200 articles. Her passion for education extends to global audiences through engaging lectures on innovative therapies for skin diseases.

About DR. ANGELA LAW MD, FRCPCDermatologist | VANCOUVER, BCDr. Angela Law is a board certified Dermatologist in both Canada and the United States. She completed her dermatology residency in a joint program at the University of Saskatchewan and Dalhousie University. She is a Clinical Instructor in the Department of Dermatology and Skin Science at UBC, regularly teaching medical students and residents, and runs the Urgent Dermatology Clinic at Mount Saint Joseph’s Hospital. She also has an active dermatology practice in downtown Vancouver.

Dr. Law also runs the Vulvar Dermatology Clinic at Mount Saint Joseph’s Hospital which is an innovative clinic with a focus on Women’s Health within Providence Health Care.

Episode supported by Abbvie.

📻www.skinandjoints.ca

✉️info@skinandjoints.ca

📻www.skinandjoints.ca

✉️info@skinandjoints.ca

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

View Details

🙌 Hands Down at AAD 2025: Delgocitinib and the “Super-Responder” Story 🌴🎧

🐶✨ Puppies in the hall, Snoop after dark, and a late-breaker that might change how you treat chronic hand eczema on Monday. In this AAD 2025 mini-episode of our “Melinda Knows Best” series, Dr. Melinda Gooderham unpacks a fresh subgroup analysis from the DELTA 1/2/3 program in chronic hand eczema (CHE)—what a “super responder” actually is, how long clearance can last off-therapy, and where a non-steroidal topical like delgocitinib could fit for real patients with real lives (and real world adherence). 🖐️🧴

Why queue this up? 🔥 Because it’s rare to get practice-ready signals for CHE: about half of patients hit at least one deep patient-reported threshold by Week 16, and—here’s the eye-opener—after stopping therapy at Week 16, ~⅓ were still clear/almost clear at 8 weeks and ~15% at 12 weeks. 📊⏱️

🎯 What you’ll learn:

1. 🧭Define “super responder” in CHE via three lenses:
2. 📝Read the right scales fast: quick-hit use of HESD, HECSI, and IGA-CHE—and how to translate them into patient-friendly goals.
3. ⏳Set expectations on durability: what “clear/almost clear” really means (that IGA-CHE bar is high) and how to discuss planned pauses without fueling steroid-withdrawal anxiety.
4. 🧴Position a topical, non-steroidal JAK inhibitor thoughtfully: where a topical, non-steroidal JAK inhibitor can slot alongside—or instead of—steroids/phototherapy in moderate–severe CHE, especially for adherence-sensitive hands.
5. 🔁Bridge trials to the clinic rooms: a simple CHE workflow (start → measure → decide → pause → rescue → re-start) anchored to PROs and signs you can track in under 60 seconds.

🔊 Teaser sound bites

• “Not all ‘super responders’ are the same—PROs, consistency, and maintenance tell different parts of the story.” 🎯
• “Clear/almost clear on IGA-CHE is a stringent bar—set it, explain it, and celebrate it.” ✅

🎙️ Hit play for late-breaker highlights🌴😅

AAD2025 #Dermatology #ChronicHandEczema #CHE #Delgocitinib #TopicalJAK #JAKInhibitors #EczemaCare #HECSI #HESD #IGACHE #PROs #LateBreaker #EvidenceBased #HCP #Derms #GPs #SkinAndJointsPodcast #MelindaKnowsBest #Orlando

ABOUT Dr.Melinda Gooderham, MD, FRCPC ( Dermatology)

Toronto, ON

Melinda Gooderham MD MSc FRCPC Dr. Gooderham is a Dermatologist and Medical Director at the SKiN Centre for Dermatology and an Investigator with Probity Medical Research. She is an Assistant Professor at Queens University and a Consultant Physician at the Peterborough Regional Health Centre. She is a fellow of the Royal College of Physicians and Surgeons of Canada.

Dr. Gooderham has been the principal investigator for over 200 clinical trials and she practices with a focus on inflammatory diseases of the skin. She also contributes to several peer-reviewed dermatology publications as an associate editor, reviewer, and has been an author of 205 articles. She enjoys lecturing to global audiences on new therapies for skin diseases.

📻www.skinandjoints.ca

✉️info@skinandjoints.ca

📻www.skinandjoints.ca

✉️info@skinandjoints.ca

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

View Details

Lights, laughter, and lasers on sebum?! 🤔 Absolutely!

Join us for our first-ever Skin and Joints Podcast episode live at Fall Clinical 2024 in sunny Las Vegas.

🎰 We’re unveiling our new segment “Cross-Border Talk,” featuring Dr. Zoe Diana Dreyloos (reformed mechanical engineer ✈️ from North Carolina) and Dr. Andrei Medlitsa US-based dermatologist (hello, North Carolina!) and a Canadian colleague (brrr, Calgary!) trade professional pearls and unique perspectives on acne care.

Expect runway-ready insights on:

• The big reveal of Clascoterone cream’s impact on sebum production (yep, they used a “sebum meter!”)
• Brand-new data showing significant improvements in both inflammatory and non-inflammatory acne lesions
• The “golden ticket” to fine dining in Vegas, plus confessions of flight fantasies (hint: not all high-flying action happens at the blackjack table)

If you’re tired of your patients asking, “Doc, how do I zap this shine?”—this is the episode for you. Because (despite the famous saying) what happens in Vegas definitely won’t stay in Vegas this time. Tune in for the scoop on everything from sebum science to top-secret bunker restaurants. 🍸

Episode Learning Objectives

1. Understand the central role of sebum production in acne pathogenesis and how it shapes therapeutic strategies.
2. Evaluate the newly released 12-week clinical data on Clascoterone cream 1%—with measured impact on both inflammatory and non-inflammatory lesions.
3. Discuss the safety and tolerability profile of Clascoterone, including real-world patient adherence considerations.
4. Translate the study’s findings into everyday practice, identifying which acne patients might benefit most from sebum-targeted therapy.
5. Explore future research directions, including combination approaches, longer-term outcomes, and potential applications in severe acne or pore-size reduction.
6. Understand the pivotal role of sebum production in acne pathogenesis and how it shapes therapeutic decisions.
7. Examine the newest 12-week clinical data on Clascoterone cream 1%—including its documented impact on both inflammatory and non-inflammatory acne lesions.
8. Apply practical tips for integrating Clascoterone into real-world regimens, tackling oily skin head-on with confidence.

Get ready to rethink your acne game plan…

Get ready for an antioxidant masterclass 🤓✨— that’ll have you completely rethinking your recommendations!

ABOUT Dr. Zoe Diana Draelos, MD, FAAD

DERMATOLOGIST, HIGH POINT, NORTH CAROLINA

Zoe Diana Draelos, MD, is a research and clinical board-certified dermatologist and a Fellow of the American Academy of Dermatology. She is in solo private practice in High Point, North Carolina, and a Consulting Professor of Dermatology at Duke University. In 1988, she founded Dermatology Consulting Services, PLLC, to initiate and perform research in aging skin, acne, rosacea, psoriasis, atopic dermatitis, actinic keratoses, eczema, and aesthetic procedures in the cosmetic, OTC drug, and pharmaceutical arenas. Prior to pursuing a medical career, Dr. Draelos completed an undergraduate degree in Mechanical Engineering and was elected a Rhodes Scholar. A member of Sigma Xi research honorary and Alpha Omega Alpha medical honorary, she is author of 14 books including Cosmetics in Dermatology and Hair Cosmetics. She is the editor of Cosmetic Dermatology: Products and Procedures (third edition) and Cosmeceuticals (fourth edition) with translations into 7 languages. She has contributed chapters to 44 textbooks, written 173 posters, served as the principal investigator on 982 studies, written 650 published papers, served on or contributed to 38 journal editorial boards, functioned as the editor-in-chief of the Journal of Cosmetic Dermatology for 10 years, and was a past member of the Board of Directors of the American Academy of Dermatology and the American Society for Dermatologic Surgery. She was elected Vice-President of the American Academy of Dermatology. She is recognized as a pioneer in cosmetic dermatology and received a lifetime achievement award from Health Beauty America for her research and the 2008 DermArts award for her contributions to dermatology. In 2010, she received the Albert Kligman Innovation Award and in 2016 she was awarded a Presidential Citation from the American Academy of Dermatology for her research contributions to advance the specialty. She received the prestigious Maison deNavarre award from the Society of Cosmetic Chemists for her contributions to the art and science of cosmetics in 2017. In 2019, she was the inaugural recipient of the Florence Wall Award from the Society of Cosmetics Chemists naming her as the most influential women in cosmetic science.

ABOUT Dr. Andrei Metelitsa, MD, FRCPC, FAAD

DERMATOLOGIST, CALGARY, AB

Dr. Metelitsa is a Board-Certified Dermatologist in both Canada and United States and is currently a Clinical Professor at the University of Calgary's Faculty of Medicine. He graduated from medical school at the University of Alberta, Canada at the age of 23. He further received a 5-year dermatology training at the University of Alberta. After completing his residency, Dr. Metelitsa pursued an additional 1-year fellowship training in Lasers and Cosmetic Surgery in Boston, Massachusetts at SkinCare Physicians under the direction of world-renowned faculty from Harvard and Yale. Dr Metelitsa’s Special Interests include: Botox and Dysport injections, Restylane and Juvederm Injections (filler), CO2 Laser Rejuvenation, Excel V Laser, Skin Cancer, Psoriasis. Dr. Metelitsa is also a primary investigator for clinical trial for new and novel dermatology conditions at Beacon Dermatology.

SUPPORTED BY SUN PHARMA

📻www.skinandjoints.ca

✉️info@skinandjoints.ca

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

View Details

Hold onto your antioxidants—this episode of the podcast is a full-court press on free radicals!

When it comes to the science of antioxidants and topical formulations, we have the right person-dermatologist Dr. Mark Lupin debuts as a faculty expert on the podcast to practically decipher what you NEED to know

Also debuting on the podcast, but as a guest co-host, is dermatologist Dr. Vincent Richer who's ready to fire up the hot seat with pharmacist Aaron Sihota to ask the tough questions.

Don’t miss our RAPID FIRE round where we break down must-know ingredients faster than you can say ‘free radical!’ 🚀🦸

We dust off your old sunscreen routine and show you why slathering on antioxidants might just be your skin’s new secret weapon. Tune in for a fast-paced conversation that hops effortlessly from clinic chairs to concert halls, apples to ferulic acid, and vitamin C to conjugated retinol. Here, myths get busted, fancy science terms get decoded, and you’ll finally learn the ABCs of a top-tier skincare regimen—no sunscreen-shy patients or lost winter gloves required. ☀️🧴🍏

Trust us, this episode is your on-demand playbook reference for practice! 🎧📖

Learning Objectives:

1. Antioxidant Fundamentals: Understand how environmental aggressors cause oxidative stress on the skin and how antioxidants serve as powerful defenders. The latest science on how these mighty molecules supercharge your broad-spectrum sunscreen and reduce UV-induced damage?🌞🔬 ‍🍃
2. Key Ingredients in formulations: Identify evidence-based antioxidant ingredients, learn why they’re paired together, and explore optimal formulation concentrations and pH levels for maximum skin benefits. 🍏🔬
3. Critical Evaluation of Research: Gain tools and strategies to discern credible studies from marketing fluff, ensuring more informed clinical recommendations. 📚🔎
4. Integration into Practice: Discover practical tips for incorporating antioxidants into morning routines, combining them effectively with sunscreens, and managing patient expectations. ⏰✔️
5. Future Directions in Dermatology: Explore the promising frontier of antioxidant research, including their potential to complement medical interventions and the call for standardized validation measures. 🔭🚀

Get ready for an antioxidant masterclass 🤓✨— that’ll have you completely rethinking your recommendations!

ABOUT DR.MARK LUPIN MD FRCPC DABD

VICTORIA, BC

Dr. Lupin is a Board-certified Dermatologist, Founder in 1998 of Cosmedica Laser Centre in Victoria, British Columbia and Chief Clinical Officer of MedSpa Partners Inc.He has degrees in Mathematics, Music and Medicine having studied at the University of Toronto, University of British Columbia, Dalhousie University, Indiana University and the University of Southern California. He has special interests in photodermatology and laser medicine, having studied under Professor John Hawk at St John’s Institute of Dermatology, London, England. He is active with research and education, has additional subspecialty training in Neurology and is past President of the Canadian Laser Aesthetic Surgery Society.

As a concert violinist, Dr Lupin has performed as soloist at Carnegie Hall, New York and with major orchestras around the world. He is Concertmaster of the World Doctors Orchestra (WDO), performing most recently in Australia at the Sydney Opera House, with all proceeds donated to charities. His research interests extend to space medicine and fluid dynamics where he has been active with mathematical modeling for space tools and has developed several patent pending energy efficient devices.

ABOUT Dr. Vincent Richer MD FRCPC

VANCOUVER, BC

Dr Vincent Richer practices cosmetic dermatology at Pacific Derm Atelier in Vancouver and holds a position as Clinical Assistant Professor at the University of British Columbia’s Department of Dermatology and Skin Science. He trained at Université de Montréal in Medicine and Dermatology and completed a fellowship in Photobiology and Cutaneous Laser Surgery at UBC. He is involved as a subinvestigator in cosmetic clinical trials, has published 35+ peer reviewed scientific articles and is active in undergraduate, graduate and continuing medical education.

EPISODE SUPPORTED BY SKINCEUTICALS AND SKINBETTER SCIENCE.

📻www.skinandjoints.ca

✉️info@skinandjoints.ca

📻www.skinandjoints.ca

✉️info@skinandjoints.ca

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

View Details

Unlocking the Secrets of Clear Skin (and Soggy Shoes) in Amsterdam! 🌧️👟✨

Ready to revolutionize your approach to atopic dermatitis? 🤔

Join us on the latest episode of the Skin and Joints podcast, live from the EADV in Amsterdam! 🇳🇱

Dr. Marissa Joseph and Dr. Max Sauder, braved the Dutch downpours to bring you exclusive insights into lebrikizumab—the new kid on the block that's making waves 🌊 in eczema treatment.

Discover how this IL-13 inhibitor is changing the game 🎯 with its long-term efficacy, flexible dosing schedules, and impressive safety profile. 📊 We'll dive deep into the ADJOIN study's three-year data, discuss where lebrikizumab fits into the current treatment landscape for their respective practices 🩺, and explore how it could be a game-changer for your patients..

🗺️Get a taste of our guests' Amsterdam adventures—from waterlogged wanderings 🚶‍♀️🌧️ to culinary delights 🍽️ Plus, find out why Max might be shopping for a princess dress 👗 before the next conference 🏰🎢

🎙️ Tune in and get ready to see atopic dermatitis treatment in a whole new light! 💡

Learning Objectives:

1. Understand the mechanism of action of lebrikizumab in treating atopic dermatitis, focusing on its role as an IL-13 inhibitor 🧬.
2. Analyze the long-term efficacy and safety data from the ADjoin study, emphasizing the durability of lebrikizumab over a three-year period 📈.
3. Compare the dosing regimens (biweekly vs. monthly) of lebrikizumab and their implications for patient adherence and treatment outcomes 📆.
4. Evaluate how lebrikizumab fits into current clinical practice for atopic dermatitis, considering patient preferences and the spectrum of available therapies 🩺.
5. Recognize the importance of expanding therapeutic options in atopic dermatitis management and how to personalized patient care 🎯.

ABOUT DR.MARISSA JOSEPH

Dermatologist, Toronto, ON

Marissa Joseph, MSc, MD, FRCPC ( Pediatrics), FRCPC ( Dermatology)

Dr. Marissa Joseph is a board certified Pediatrician and Dermatologist after completing Pediatric training at the Hospital For Sick Children, following with a Dermatology residency at the University of Toronto. She completed a MSc in Community Health at the Dalla Lana School of Public Health.

Dr. Joseph is full time academic faculty at the Unee Schachter Dermatology Centre at Women's College Hospital. She also works at the Hospital For Sick Children where she manages children with complex dermatologic disease in outpatient and inpatient settings, as well as a pediatric laser treatment program. Dr. Joseph enjoys her diverse practice in general adult, pediatric and surgical dermatology. Her clinical and research interests include inflammatory skin disorders such as psoriasis, atopic dermatitis, and hidradenitis suppurativersity of Toronto. She has received and has been nominated for teaching awards in both undergraduate and postgraduate medical education. Dr. Joseph is the Medical Director of the Ricky Kaniva; genodermatoses, and equity, diversity and inclusivity.

About Dr.Maxwell Sauder MD, FRCPCDermatologist | Toronto Dr. Maxwell Sauder is a board-certified dermatologist with additional fellowship training. He earned his Doctor of Medicine at McMaster University and completed a residency in dermatology at The University of Ottawa. He completed fellowship training in Cutaneous Oncology at Harvard Medical School. He is a former instructor in dermatology at Harvard Medical School.

Dr. Sauder is currently an assistant professor at the University of Toronto. He is an onco-dermatologist at Princess Margaret Cancer Centre. He also practices at Toronto Dermatology Centre where he is the research director and the director of the Pigmented Lesion Clinic.

Well published in numerous peer-reviewed journals, Dr. Sauder has also authored several book chapters, been referenced on www.uptodate.com, and has won numerous awards including the Partner’s President Prize at Harvard and the Royal College’s Detweiler Fellowship Award. His publications have covered topics such as eczema, patient education, aesthetic dermatology, sun safety, psoriasis, biologics, adverse drug reactions, hemangiomas, contact dermatitis, cutaneous oncology, and a host of complex medical dermatology conditions.

Epsode supported by an Independent Medical Educational Grant from Lilly.

📻www.skinandjoints.ca

✉️info@skinandjoints.ca

📻www.skinandjoints.ca

✉️info@skinandjoints.ca

View Details

🚴‍♀️ Biking and the Battle Against Itch! 🎙️

Live from the charming canals of Amsterdam at the EADV 2024 meeting, we sit down with the ever-energetic Dr. Perla Lansang from Toronto!

🍁 She's ditched cabs and metros to embrace the Dutch biking culture, even bringing her own bike across the pond! 🚲🌍 From navigating streets with more bikes than people 😲 to packing rain ponchos for unpredictable weather ☔, Dr. Lansang shares her love for the city.

🍽️ She's on a mission to find the best delectable mini Dutch pancakes topped with butter and powdered sugar 🥞✨. And while we couldn't coax the secret behind her infamous kale smoothie 🥬🥤, we dive into something even more exciting.

We explore late breaking fresh new data presented at EADV on nemolizumab, the new therapeutic targeting IL-31 that's set to revolutionize atopic dermatitis treatment! What does this new 56-week data from an interim analysis of the phase III ARCADIA long-term extension study mean for your patients?

🧪🔥 Discover how this game-changing drug offers rapid itch relief—some patients feel better in just days! 😮🧖‍♂️

We'll unpack nemolizumab’s long-term efficacy and safety in atopic dermatitis, discuss the stellar safety profile, and delve into how it is poised to transform patient care by improving sleep 😴 and overall quality of life 🌟.

This episode is packed with laughs 😂, insightful clinical pearls 🩺, and a sprinkle of Dutch delight! 🎧🌷

Learning Objectives:

1. Understand the pivotal role of IL-31 in atopic dermatitis and why nemolizumab's targeting of this cytokine is a breakthrough.
2. Review the design, key findings, and clinical significance of the Arcadia 1 and 2 long-term extension data up to 56 weeks.
3. Discuss the rapid efficacy and excellent safety profile of nemolizumab and its impact on itch relief, clearance and patient adherence.
4. Evaluate the clinical implications of integrating nemolizumab into practice and its potential to transform atopic dermatitis management.

ABOUT Dr. Perla Lansang, MD, FRCPC ( Dermatology)

Toronto, ON

Dr. Perla Lansang is a full-time staff dermatologist and associate professor in the Division of Dermatology, University of Toronto where she is the Division Head of Dermatology at Sunnybrook Health Sciences Centre. She is also cross appointed at the Section of Paediatric Dermatology at the Hospital for Sick Children, and the Division of Obstetric Medicine at Sunnybrook Health Sciences Centre.

She completed her medical school and dermatology residency at the University of the Philippines-Philippine General Hospital. Having done fellowships in paediatric dermatology at The Hospital for Sick Children and in advanced medical dermatology at Sunnybrook Health Sciences Centre, Dr. Lansang’s practice is a mixture of pediatric, adolescent, and adult dermatology, with a special focus on psoriasis, atopic dermatitis, cutaneous lymphoma, pregnancy dermatoses, and general medical dermatology. She has a special interest in immune-mediated skin diseases and has extensive clinical and research experience in many areas of immunodermatology.

📻www.skinandjoints.ca

✉️info@skinandjoints.ca

📻www.skinandjoints.ca

✉️info@skinandjoints.ca

View Details

🎙 Amsterdam Stories, Delta Force & A Game-Changing Topical for Chronic Hand Eczema

🎉✨ Melinda Knows Best is BACK! 🚀💥

This time, Dr. Gooderham brings us a heavyweight showdown 🥊 between a new topical superhero 🦸‍♀️ and the reigning oral champ 💊 in the battle against Chronic Hand Eczema! reporting live from the European Academy of Dermatology and Venereology (EADV) Congress in the beautiful city of Amsterdam! 🇳🇱✨

In this special episode, we’re diving into the Delta Force Trial – a bold study comparing topical delgocitinib to oral alitretinoin for chronic hand eczema 💊🧴

👀 Dr. Gooderham spills the beans on impressive results, rapid relief, and how this new treatment is about to change the game for dermatologists and patients alike. 🎉

Oh, and don’t worry, we didn’t forget to ask about her Amsterdam adventures! 🌍 Did she run into some famous faces at dinner? 🍽️👀 Tune in for the scoop!

💡 Melinda Knows Best will keep you at the cutting edge of CHE breakthroughs. 👩‍⚕️✨

🎯 Learning Objectives:

1. Explore the Delta Force Trial Findings: Understand the significance of the Delta Force trial comparing topical delgocitinib to oral alitretinoin for chronic hand eczema. 🧴💊
2. Evaluate the Efficacy of Topicals vs Orals for chronic hand eczema: Learn about the early onset of symptom relief with delgocitinib, including i reductions in HEXI scores and patient quality of life improvements. ⏱️📉
3. Identify Key Real-World Implications: Discuss how this new topical treatment can shift the landscape for clinicians and patients, offering rapid, safe relief without the headaches (literally!) of oral therapies. 💡
4. Dive into secondary endpoints, including itch and pain relief, and how this data compares to other major clinical trials in hand eczema treatment. 📊🔬

ABOUT Dr.Melinda Gooderham, MD, FRCPC ( Dermatology)

Toronto, ON

Melinda Gooderham MD MSc FRCPC Dr. Gooderham is a Dermatologist and Medical Director at the SKiN Centre for Dermatology and an Investigator with Probity Medical Research. She is an Assistant Professor at Queens University and a Consultant Physician at the Peterborough Regional Health Centre. She is a fellow of the Royal College of Physicians and Surgeons of Canada.

Dr. Gooderham has been the principal investigator for over 200 clinical trials and she practices with a focus on inflammatory diseases of the skin. She also contributes to several peer-reviewed dermatology publications as an associate editor, reviewer, and has been an author of 205 articles. She enjoys lecturing to global audiences on new therapies for skin diseases.

📻www.skinandjoints.ca

✉️info@skinandjoints.ca

📻www.skinandjoints.ca

✉️info@skinandjoints.ca

View Details

🎙️ Skin Joins Podcast Wrap-Up: Sunny Stories & Cool Pools 🌞

We welcome back Dr. Michele Ramien, who graced our podcast last July from the sunny World Congress of Dermatology in Singapore. 🌏 Fast forward, she reflects on dermatology innovation from vibrant city of San Diego! 🌴

Dr. Ramien shares a delightful (and chilly) San Diego story about renting a house wit, a freezing-cold pool, and a group of eager people determined to swim🏊‍♂️❄️

We deep dive into the exciting highlights from the American Academy of Dermatology conference. Dr. Ramien, attending AAD for the first time in a while, reveals fascinating pearls and🩺✨ innovative treatments including the potential for disease remission in young patients, as well as fresh new insights on melasma and post-inflammatory hyperpigmentation in Asian skin 🌟

Dr. Ramien also touches on the importance of adapting treatments for different skin types and the promising future of pediatric dermatology. 👶💡

Learning Objectives:

1. 🌍 Understand the global advancements in dermatology from the AAD conference.
2. 🧴 Learn about innovative treatments for atopic dermatitis, including pediatric applications.
3. 🎨 Explore the management of melasma and post-inflammatory hyperpigmentation in diverse skin types.
4. 🧒 Discover the potential for disease remission in young patients with early and targeted treatments.

Tune in for a blend of personal stories, professional insights, and a sneak peek into the future of dermatological treatments. 📚🔍

Stay tuned, stay informed, and as always, keep your skin happy 🌟🧴

Supported by an IME Grant from Pfizer

ABOUT Dr. Michele L. Ramien

Pediatric Dermatologist | Calgary

Dr. Michele Ramien is an academic dermatologist based at the Alberta Children’s Hospital, in the foothills of the Rocky Mountains in Calgary, Canada. She has both pediatric and general medical dermatology practices, with a focus on teaching and mentoring the next generations and research interests in eczema management, patient education, and severe cutaneous reactions in children.

Dr. Ramien enjoys volunteer leadership positions as a way to meet colleagues across the country, like-minded and not, who believe that a small group of thoughtful, committed individuals can change and improve dermatology and delivery of care in Canada.

📻www.skinandjoints.ca

✉️info@skinandjoints.ca

View Details

🎙️ More than Skin Deep Insights with Dr. Lauren Lam!🎙️

👩‍⚕️💬 As we get close to wrapping up our coverage of AAD 2024, get ready as we welcome back Dr. Lauren Lam. We dive deep into her recent experience at the AAD in sunny San Diego. 🌞🏖️

Learning Objectives:

1. 🧠 Understand the practical applications of translational medicine in dermatology, particularly in treating chronic skin conditions.
2. 🛠️ Identify key clinical pearls and advancements in dermatology that can be immediately implemented in practice to improve patient care.

What’s on the agenda for this mini-podcast drop?

1. 🌟 San Diego Stories: From bar hopping in a Japanese-themed spot 🌸🍹 to pelican watching at the pier 🦩📸, Lauren shares her unique experiences and the vibrant cultural mix that San Diego offers.
2. 🔍 Translational Medicine Takeaways: Discover how the latest advancements in bench-to-bedside research are transforming dermatological practices. 🧬🩺
3. 💡 Clinical Pearls Galore:
4. Hidradenitis Suppurativa Insights: Understand why de-roofing is essential even with biologics 🩹🔬.
5. Alopecia Areata Breakthroughs: Learn about the impact of JAK inhibitors 🧑‍🦲➡️🧑‍🦰.
6. Pyoderma Gangrenosum Progress: Hear about the promising results of IL-36 inhibitors in treating this challenging condition 💉🌟.

Join us for a lively episode that blends professional insights with personal anecdotes, and don't miss out on the laughter and wisdom Dr. Lam brings to the table 🎧✨

ABOUT Dr. Lauren Lam

Dermatologist | Calgary

Dr. Lauren Lam is a Canadian & American board-certified dermatologist. She is a native Calgarian who completed her medical school training at the University of Calgary & her dermatology residency at the University of Alberta. Since graduating, Dr. Lam has become a Clinical Lecturer with the University of Alberta. Her particular passions in dermatology are acne & hidradenitis suppurativa deroofings. In addition to her regular practice, she volunteers on overseas medical trips. Her passion for providing care for under-served populations has taken her to Nunavut & rural Fiji. Outside of medicine, Dr. Lam is a proud aunt to 4 dogs, culinary enthusiast & international explorer.

📻www.skinandjoints.ca

✉️info@skinandjoints.ca

View Details

🎙️ My CASMO (Canadian Skin Management in Oncology) Playbook: Part 2🎙️

Description:

In Part 2, dermooncologist Dr. Max Sauder returns to delve deeper into the CASMO algorithm. We navigate the complexities of managing severe cutaneous reactions in patients undergoing radiation. From identifying critical symptoms that necessitate urgent care to understanding the nuances of radiation dermatitis stages and risk factors, this episode is packed with expert insights and practical advice. We focus on 2 specific areas:

1. Assessment and Severity Evaluation: Guidance on evaluating the severity of skin toxicities, incorporating case studies to illustrate practical approaches.
2. Management Protocols: Exploration of practical management strategies and specific interventions for common skin toxicities, drawing on literature evidence and expert consensus.

Learning Objectives:

Identify Critical Symptoms:

• Recognize severe cutaneous adverse reactions and understand when urgent care is necessary based on symptoms like fever, skin pain, blisters, mucous membrane involvement, and abnormal labs. 🚨

Understand Radiation Dermatitis:

• Differentiate between acute and chronic radiation dermatitis.
• Learn the grading systems (CTCAE and RTOG) and their simplified applications in the CASMO algorithm. 📊

How to Manage Radiation Dermatitis:

• Implement effective treatment strategies for both dry and moist desquamation.
• Understand the role of topical steroids and topical over-the-counter dos and don’ts💊

Recognize Risk Factors:

• Identify the factors that increase the risk of radiation dermatitis, considering the cancer type, radiation modality, and regimen. 🧬
• Learn to manage photosensitivity reactions, particularly with targeted therapies.
• Explore strategies to ensure patient adherence to prescribed skincare and sun protection protocols, emphasizing the importance of these measures in minimizing treatment interruptions. 🛡️

Photosensitivity Reactions:

• Understand the importance of proactive sun protection and the role of topical treatments. ☀️

Promote Adherence:

• Explore strategies to ensure patient adherence to prescribed skincare and sun protection protocols, emphasizing the importance of these measures in minimizing treatment interruptions. 🛡️

Episode Highlights:

• Danger Zone: Learn to identify those serious skin reactions that need urgent care, stat! 🌡️
• Radiation Dermatitis Deep Dive: Understand the stages and treatment of radiation dermatitis without getting lost in the weeds. 📋
• Risk Factors Unmasked: Get to know the usual suspects behind radiation dermatitis. 🔬
• Photosensitivity Savvy: Protect patients from those sneaky photosensitivity reactions with top-notch tips. 🌞
• Adherence Hacks: Keep patients sticking to their skincare and sun protection routines like glue. 🔄

Join us for a discussion perfect for a quick listen on your commute or work out🎧

REFERENCES AND FURTHER RESOURCES:

1. The role of skin care in oncology patients: STL-Supp-SkinCareOnc-v2-correction.pdf (skintherapyletter.com)

2. Canadian general algorithm (cleanse, moisturize, protect):Canadian Skin Management in Oncology (CaSMO) Algorithm for Patients with Oncology Treatment-Related Skin Toxicities (skintherapyletter.com)

3. Canadian radiotherapy algorithm:Canadian Skin Management in Oncology Group (Casmo) Algorithm for the Prevention and Management of Acute Radiation Dermatitis (skintherapyletter.com)

4. Canadian immunotherapy algorithm: CaSMO Management of Cutaneous Toxicities Associated with Immune Checkpoint Inhibitors: A Practical Primer (skintherapyletter.com)

5. Canadian hormonal therapy algorithm: Casmo Algorithm for Management of Hormonal Therapy-Related Cutaneous Adverse Effects in Oncology Patients (skintherapyletter.com)

6. Canadian targeted therapy algorithm:Casmo Prevention and Management of Four Common Cutaneous Toxicities Associated with Targeted Cancer Therapies: Papulopustular Eruption, Xerosis, Paronychia, and Hand-Foot Skin Reaction (skintherapyletter.com)

About Dr.Maxwell Sauder MD, FRCPCDermatologist | Toronto Dr. Maxwell Sauder is a board-certified dermatologist with additional fellowship training. He earned his Doctor of Medicine at McMaster University and completed a residency in dermatology at The University of Ottawa. He completed fellowship training in Cutaneous Oncology at Harvard Medical School. He is a former instructor in dermatology at Harvard Medical School.

Dr. Sauder is currently an assistant professor at the University of Toronto. He is an onco-dermatologist at Princess Margaret Cancer Centre. He also practices at Toronto Dermatology Centre where he is the research director and the director of the Pigmented Lesion Clinic.

Well published in numerous peer-reviewed journals, Dr. Sauder has also authored several book chapters, been referenced on www.uptodate.com, and has won numerous awards including the Partner’s President Prize at Harvard and the Royal College’s Detweiler Fellowship Award. His publications have covered topics such as eczema, patient education, aesthetic dermatology, sun safety, psoriasis, biologics, adverse drug reactions, hemangiomas, contact dermatitis, cutaneous oncology, and a host of complex medical dermatology conditions.

📻www.skinandjoints.ca

✉️info@skinandjoints.ca

📻www.skinandjoints.ca

✉️info@skinandjoints.ca

View Details

🌞🎧Dermatologist Dr.Max Sauder joins us and navigates us through the complexities of modern dermatological care💡

🎙️ My CASMO (Canadian Skin Management in Oncology) Playbook: Part 1🎙️

Get ready for a laugh and learn session as Dr. Jessica Asgarpour takes the co-hosting hot seat! This episode, we’re diving headfirst into the CASMO project with dermo-oncologist Dr. Max Sauder. We’ll decode the CASMO algorithm, tackle the nitty-gritty of managing skin toxicities, and even uncover Dr. Sauder's secret summer plans. Buckle up! 🎢

We're peeling back the layers of the CASMO project, an innovative approach to managing skin toxicities in cancer treatment. Can certain skin toxicities be prevented in patients? Is there a proactive skincare regimen that can be recommended?

1. Introduction to CaSMO and Skin Toxicities in Cancer Treatment: Overview of the significance of managing skin toxicities, introducing the CaSMO algorithm's development and objectives.
2. Prevention Strategies: Detailed discussion on general skincare measures recommended by CaSMO, including the rationale behind the use of cleansers and moisturizers to maintain skin hydration and integrity.

Episode Learning Objectives:

1. Understand the CASMO algorithm and its role in managing skin toxicities associated with cancer treatments.
2. Recognize the importance of a multidisciplinary approach in improving patient outcomes.
3. Identify practical proactive strategies for preventing and managing skin toxicities.
4. Learn about the impact of skin toxicities on patients' quality of life and how to address these issues.
5. Explore the role of various healthcare providers, including oncologists, nurses, and pharmacists, in supporting patients through their cancer journey.

Press play for a dose of dermatological delight 🎙️✨

Episode supported by an IME Grant from LA ROCHE POSAY

REFERENCES AND FURTHER RESOURCES:

1. The role of skin care in oncology patients: STL-Supp-SkinCareOnc-v2-correction.pdf (skintherapyletter.com)

2. Canadian general algorithm (cleanse, moisturize, protect):Canadian Skin Management in Oncology (CaSMO) Algorithm for Patients with Oncology Treatment-Related Skin Toxicities (skintherapyletter.com)

3. Canadian radiotherapy algorithm:Canadian Skin Management in Oncology Group (Casmo) Algorithm for the Prevention and Management of Acute Radiation Dermatitis (skintherapyletter.com)

4. Canadian immunotherapy algorithm: CaSMO Management of Cutaneous Toxicities Associated with Immune Checkpoint Inhibitors: A Practical Primer (skintherapyletter.com)

5. Canadian hormonal therapy algorithm: Casmo Algorithm for Management of Hormonal Therapy-Related Cutaneous Adverse Effects in Oncology Patients (skintherapyletter.com)

6. Canadian targeted therapy algorithm:Casmo Prevention and Management of Four Common Cutaneous Toxicities Associated with Targeted Cancer Therapies: Papulopustular Eruption, Xerosis, Paronychia, and Hand-Foot Skin Reaction (skintherapyletter.com)

About Dr.Maxwell Sauder MD, FRCPCDermatologist | Toronto Dr. Maxwell Sauder is a board-certified dermatologist with additional fellowship training. He earned his Doctor of Medicine at McMaster University and completed a residency in dermatology at The University of Ottawa. He completed fellowship training in Cutaneous Oncology at Harvard Medical School. He is a former instructor in dermatology at Harvard Medical School.

Dr. Sauder is currently an assistant professor at the University of Toronto. He is an onco-dermatologist at Princess Margaret Cancer Centre. He also practices at Toronto Dermatology Centre where he is the research director and the director of the Pigmented Lesion Clinic.

Well published in numerous peer-reviewed journals, Dr. Sauder has also authored several book chapters, been referenced on www.uptodate.com, and has won numerous awards including the Partner’s President Prize at Harvard and the Royal College’s Detweiler Fellowship Award. His publications have covered topics such as eczema, patient education, aesthetic dermatology, sun safety, psoriasis, biologics, adverse drug reactions, hemangiomas, contact dermatitis, cutaneous oncology, and a host of complex medical dermatology conditions.

📻www.skinandjoints.ca

✉️info@skinandjoints.ca

📻www.skinandjoints.ca

✉️info@skinandjoints.ca

View Details

🎙️ Melinda Knows Best at the AAD! 🌟

We’ve got a special LATEBREAKER episode for you, continuing our coverage from the American Academy of Dermatology in San Diego!

👟💡 Pro Tip: Don't miss Dr. Gooderham’s advice on navigating massive convention centers in style and comfort!

We dive into the highly anticipated Delta 3 study, shedding light on long-term safety and efficacy of Delgocitinib cream for Chronic Hand Eczema.

• Subjects who completed the 16-week treatment period in one of the parent trials DELTA 1 and DELTA 2 were treated with twice daily delgocitinib cream as needed to control their chronic hand eczema for 36 weeks.

Practical Tips for Dermatology Practices 🏥💼

• Adapting treatment plans for chronic hand eczema.
• Benefits of as-needed treatment approaches for better patient outcomes.

Dr. Gooderham’s Conference Adventures 🛫👩‍⚕️👨‍⚕️

• Dr. Gooderham also shares her intriguing encounters from Toronto to San Diego, including a surprise meeting with April Armstrong and an old friend from med school. 🛫

Episode Learning Objectives:

1. Understand the primary and secondary endpoints of the Delta 3 study and its implications for treating chronic hand eczema.
2. Learn about the safety profile of Delgocitinib cream and its significance in long-term treatment plans.
3. Gain insights into real-world application of delgocitinib and patient adherence strategies for topical treatments

Lace up those sneakers, grab a protein bar, and join us for a walk through the latest dermatological advancements! 🥾🍫

🎙️ Melinda Knows Best at the AAD – where expert insights meet real-world application (pun intended)📍📍

Episode supported by an IME Grant from LEO Pharma

ABOUT Dr.Melinda Gooderham, MD, FRCPC ( Dermatology)

Dermatologist | Toronto

Toronto, ON

Melinda Gooderham MD MSc FRCPC Dr. Gooderham is a Dermatologist and Medical Director at the SKiN Centre for Dermatology and an Investigator with Probity Medical Research. She is an Assistant Professor at Queens University and a Consultant Physician at the Peterborough Regional Health Centre. She is a fellow of the Royal College of Physicians and Surgeons of Canada.

Dr. Gooderham has been the principal investigator for over 200 clinical trials and she practices with a focus on inflammatory diseases of the skin. She also contributes to several peer-reviewed dermatology publications as an associate editor, reviewer, and has been an author of 205 articles. She enjoys lecturing to global audiences on new therapies for skin diseases.

References

1. Gooderham M. Long-term safety and efficacy of delgocitinib cream for up to 36 weeks in adults with chronic hand eczema: results of the phase 3 open-label extension DELTA 3 trial. Presented at: 2024 American Academy of Dermatology Annual Meeting; March 8-12, 2024; San Diego, CA.

📻www.skinandjoints.ca

✉️info@skinandjoints.ca

View Details

🎙️🌞 Tight Spaces & Hair-Raising Breakthroughs – Live from AAD San Diego! 🎙️🌴

Join Skin and Joints Podcast AAD Guest Faculty and Vancouver based dermatologist, Dr,Diana Diao, as she navigates the cramped quarters of a historic boutique hotel in the Gaslamp Quarter—tiny rooms, weird noises, and all! 🏨😅

Dr. Diao explore groundbreaking sessions on alopecia areata, revealing innovative treatments and valuable clinical insights that are shaping the future of dermatology.

🌟💊Don't miss out on Dr. Diao's top clinical takeaways that could revolutionize treatment approaches for dermatologists everywhere. Whether it's systemic therapies for extensive scalp involvement or tailored treatments for unique patient profiles, this episode is packed with insights that promise to enhance patient care.

💬 Tune in, transform your approach with pearls that could change your practice overnight!

🎧✨ #SkinJointsPodcast #DermatologyInDepth

Learning Objectives:

1. Gain Insight into New Treatments for Alopecia Areata: Learn about the latest advancements and clinical trials discussed at AAD, including newly approved treatments and their application in real world practice.
2. Appreciate the Psychosocial Aspects of Dermatological Conditions: Recognize the significant emotional and social challenges faced by patients with alopecia areata and the importance of addressing these in real world practice.
3. Implement Clinical Pearls in Practice: Discover actionable tips and strategies that can be immediately applied to improve patient outcomes.

#SkinAndJointsPodcast #DermatologyDeepDive #SanDiegoSun
Episode supported by an IME Grant from Pfizer and Bausch Health.

ABOUT DR. DIANA DIAO FRCPC, FAAD

Dermatologist | Vancouver, BCDr. Diana Diao is a Dermatologist and a Clinical Instructor in the Department of Dermatology and Skin Science at the University of British Columbia. She is a consultant dermatologist at both Vancouver General Hospital and St. Paul’s Hospital. Dr. Diao practices medical and procedural dermatology, with a special interest in using energy-based modalities such as lasers to treat a variety of skin conditions.

Dr. Diao completed both her Medical Doctorate degree and dermatology residency training at the University of British Columbia, and is a Fellow of the Royal College of Physicians and Surgeons of Canada. Dr. Diao is a mother, a published author, and has presented her work at conferences such as the World Congress of Dermatology and the American Academy of Dermatology meetings. Dr. Diao is also fluent in Mandarin.

📻www.skinandjoints.ca

✉️info@skinandjoints.ca

View Details

🎙️🌞 An AAD 2024 Coles Notes Deep Dive – Welcome to a potpourri episode of the Skin and Joints Podcast, streaming from the vibrant city of San Diego.

Join us as we sit down with Guest Faculty dermatologist expert the much-anticipated Dr. Mark Kirchhoff, whose voice is as deep and profound as his insights into dermatology. 🎤💬

Medical Innovations Uncovered:

• Key Sessions from AAD: We traverse the entire meeting with key insights into s🎙️🌞 An AAD 2024 Coles Notes Deep Dive – Welcome to a potpourri episode of the Skin and Joints Podcast, streaming from the vibrant city of San Diego.

Join us as we sit down with Guest Faculty dermatologist expert the much-anticipated Dr. Mark Kirchhoff, whose voice is as deep and profound as his insights into dermatology. 🎤💬

Medical Innovations Uncovered:

• Key Sessions from AAD: We traverse the entire meeting with key insights into significant advancements, focusing on HS, AD, PsO and AA.

• Late Breaker Highlights: An overview of the most cutting-edge studies presented, including potential new therapies and their implications for future treatment protocols including rethinking long term disease remission to the exploration of new and novel therapeutic targets.

Learning Objectives:

• Delve into Dermatological Innovations: Get the latest updates on groundbreaking treatments for HS, AA, AD and PsO as well as other skin conditions from the AAD meeting. 🔬💡
• Discuss Future Directions in Dermatology: Examine the potential shifts in treatment approaches and how they align with current patient needs and future therapeutic strategies. 🌟

Dr. Kirchhoff also reflects on the changing landscape of medical conferences influenced by social media and digital dissemination of knowledge

Join us for a blend of professional insights and personal anecdotes that promise to educate and entertain. Tune in to catch Dr. Kirchhoff’s voice and vision for the future of dermatology! 📚🎧

#SkinAndJointsPodcast #DermatologyDeepDive #SanDiegoSun

Episode supported by an IME Grant from Pfizer and Bausch Health.

ABOUT DR. MARK KIRCHHOF,MD, PHD, FRCPC, FAAD

Dermatologist | Ottawa, ONDr. Mark Kirchhof is the Division Head of Dermatology in the Faculty of Medicine at the University of Ottawa and The Ottawa Hospital. After receiving his Bachelor of Science in molecular biology from McMaster University, Dr. Kirchhof completed his medical degree and PhD at Western University in London, Ontario. His PhD research involved studies of the signalling pathways important to immune system regulation. He then went on to complete his dermatology residency at the University of British Columbia in Vancouver, British Columbia.

Until August 2017, Dr. Kirchhof was the Education Director at Queen’s University in Kingston, Ontario, where he coordinated and led undergraduate, post-graduate and continuing medical education activities. He has published over 40 peer-reviewed papers and maintains a keen interest in clinical and bench-to-bedside research. He has been invited to speak at local, national and international meetings. His clinical interests are varied and he sees both pediatric and adult patients.ignificant advancements, focusing on HS, AD, PsO and AA.

• Late Breaker Highlights: An overview of the most cutting-edge studies presented, including potential new therapies and their implications for future treatment protocols including rethinking long term disease remission to the exploration of new and novel therapeutic targets.

Learning Objectives:

• Delve into Dermatological Innovations: Get the latest updates on groundbreaking treatments for HS, AA, AD and PsO as well as other skin conditions from the AAD meeting. 🔬💡
• Discuss Future Directions in Dermatology: Examine the potential shifts in treatment approaches and how they align with current patient needs and future therapeutic strategies. 🌟

Dr. Kirchhoff also reflects on the changing landscape of medical conferences influenced by social media and digital dissemination of knowledge

Join us for a blend of professional insights and personal anecdotes that promise to educate and entertain. Tune in to catch Dr. Kirchhoff’s voice and vision for the future of dermatology! 📚🎧

#SkinAndJointsPodcast #DermatologyDeepDive #SanDiegoSun

Episode supported by an IME Grant from Pfizer and Bausch Health.

ABOUT DR. MARK KIRCHHOF,MD, PHD, FRCPC, FAAD

Dermatologist | Ottawa, ONDr. Mark Kirchhof is the Division Head of Dermatology in the Faculty of Medicine at the University of Ottawa and The Ottawa Hospital. After receiving his Bachelor of Science in molecular biology from McMaster University, Dr. Kirchhof completed his medical degree and PhD at Western University in London, Ontario. His PhD research involved studies of the signalling pathways important to immune system regulation. He then went on to complete his dermatology residency at the University of British Columbia in Vancouver, British Columbia.

Until August 2017, Dr. Kirchhof was the Education Director at Queen’s University in Kingston, Ontario, where he coordinated and led undergraduate, post-graduate and continuing medical education activities. He has published over 40 peer-reviewed papers and maintains a keen interest in clinical and bench-to-bedside research. He has been invited to speak at local, national and international meetings. His clinical interests are varied and he sees both pediatric and adult patients.

📻www.skinandjoints.ca

✉️info@skinandjoints.ca

View Details

🌍✨ Welcome to a US-Canada Acne Dialogue Where we Unpack the Art of Acne Treatment Customization and Master Practical Clinical Pearls.🎙️🍁🇺🇸

🌉🔬Skin and Joints Podcast Faculty Dermatologist duo, Dr.Linda Stein Gold and Dr. Mimi Tran, converge to unravel a MasterClass on the latest in acne management, distilled straight from the AAD with a focus on defining the role and place of a new topical hormonal anti-androgen agent and why all isotretinoin options are not the same 🌞

🎯Learning Objectives:

1. Advances in Acne Care Innovation: Gain practical insights into the newly released AAD acne guidelines, how they should be used for the patient in front of you, straight from one of the Faculty members that helped create it! Dr.Stein Gold deep dives into the critical balance between guideline recommendations and the nuanced needs of individual patients, highlighting the importance of cost considerations, treatment efficacy, and the patient-practitioner partnership in dermatology.
2. Dive into the world of new acne therapies, including the groundbreaking topical androgen receptor blocker and its role in reducing sebum production. A leap forward in topical acne treatment! 🆕💡
3. Beyond the Surface: Learn about the significance of vehicle design in topical medications — a crucial factor for efficacy, tolerability, and patient satisfaction. It's not just what's inside that counts, but how it's delivered. 🚚💊
4. The Isotretinoin Evolution: Explore the latest advancements in isotretinoin formulations that promise enhanced absorption without the need for fatty meals, paving the way for more effective and flexible treatment options. 🍽️➡️💧
5. Empowering Patients: Embrace the power of visual progress tracking with baseline and follow-up photographs, fostering patient engagement and adherence. A picture is worth a thousand words, especially in acne treatment! 📸📈

🌟 Stay tuned

HealthcareCrossroads #AcneInnovation #USCanadaConnection 🎧💬

EPISODE Supported by SUN Pharma

Dr.Linda F Stein Gold, MD, FAADDermatologist, Detroit, MI

Linda Stein Gold, MD, is Director of Dermatology Clinical Research at Henry Ford Health System in Detroit, Michigan, as well as Division Head of Dermatology at Henry Ford Health System in West Bloomfield, Michigan.

Dr. Stein Gold earned her undergraduate degree at the Wharton School of the University of Pennsylvania and her medical degree from the University Of Pennsylvania School Of Medicine in Philadelphia and completed her residency in dermatology at Henry Ford Hospital in Detroit.

Dr. Stein Gold is very active in clinical research on a variety of dermatologic conditions, including the treatment of chronic plaque-type psoriasis, actinic keratosis, atopic dermatitis, acne vulgaris, seborrheic dermatitis, and rosacea. She has published articles in journals such as the Journal of the American Academy of Dermatology, Cutis, the Journal of Drugs in Dermatology among others. She is a frequent national and international lecturer on acne, rosacea, psoriasis, actinic keratosis, alopecia, viral infections, atopic dermatitis, and fungal infections, at grand rounds and medical society meetings. She is also the treasurer of the National Acne and Rosacea Society and a member of the National Psoriasis Foundation Medical Board.

Dr. Mimi Tran MD, FRCPCDermatologist, Winnipeg, MB

Dr Mimi Tran is a dual board-certified Dermatologist in Canada and the USA. After graduating from medical school at the University of Calgary, she pursued a rigorous Dermatology residency at the University of British Columbia. She has trained in centres across Canada. With her extensive experience from practicing in Vancouver, Dr Tran decided to bring her exceptional skills and expertise back to her hometown of Winnipeg. Dr. Tran practices in both Medical and Cosmetic Dermatology. She has a particular interest in Skin Cancer, Acne, Eczema, Psoriasis, as well as Cosmetic Dermatology.

📻www.skinandjoints.ca

✉️info@skinandjoints.ca

View Details

🌞🎙️ Live from AAD 2024 in San Diego!🎙️🌞

We're bringing you the freshest insights straight from the sun-kissed halls of the AAD 2024 conference in San Diego. 🌴✨ With the iconic Hard Rock Hotel glittering in the back, we dive deep into the world of acne - and oh boy, do we have some groundbreaking news for you! 🧴💥

🤩 Joining us are our guest Faculty tag team from Toronto who share their pearls of wisdom under the California sun. We're buzzing about the latest in acne attack plans, especially the shiny new AAD guidelines dropped like a hot potato at the end of January. 📜🔍

🧪 From the comforting confirmation of our daily dermatological dos to the intriguing nods towards affordability and access - this episode is packed! 🎉 We navigate through the sea of sessions to spotlight the crème de la crème on acne management. 🚀

1. Understand the 2024 Acne Guidelines: Gain a comprehensive understanding of the new AD acne guidelines released in January 2024, including their recommendations for the management of acne with topical antibiotics, retinoids, benzoyl peroxides, and the strategic use of oral therapies .
2. Discuss the Impact of Drug Pricing: Delve into the discussion around how drug pricing influences the listing of therapies as first, second, or third line in the guidelines, and consider the implications of this from both U.S. and Canadian perspectives.
3. Consider New and Emerging Therapies: Identify and evaluate new and emerging therapies in acne treatment, including the anticipation of new triple combination therapies and the introduction of clascotarone, highlighting their alignment with guideline recommendations for combination therapies
4. Address the BPO Controversy:And just when you thought it couldn't get more exciting, we unboxed the potential of emerging therapies and dived into the benzene buzz surrounding benzoyl peroxide and how to counsel patients on these issues.

Here's to clearer skies and even clearer skin ahead! 🌈👩‍⚕️👨‍⚕️ #AAD2024 #AcneAwareness #DermatologyDeepDive

EPISODE Supported by BAUSCH Health.

About Dr. Sam Hanna, FAAD, DABDDermatologist, Toronto, ON

Dr. Sam Hanna is at the forefront of innovation in cosmetic dermatology and is passionate about improving patient skin health with laser treatments, light treatments, and injectable solutions. Dr. Hanna specializes in achieving natural-looking outcomes by way of a holistic approach to cosmetic medicine. A board certified dermatologist and recognized expert in the use of cosmetic injectables including fillers, neuromodulators and sodium deoxycholate, Dr. Hanna is regularly called upon to share his expertise with physician colleagues in lectures and hands-on-training courses. He also lectures on a variety of issues such as dermatology workforce and skin disease treatments.

Dr. Hanna is the Medical Director at Dermatology On Bloor as well as a Diplomate of the American Board of Dermatology. He travels the world sharing his expertise and insights with the global medical and dermatology community.

Dr. Hanna was one of the first Dermatologists in Canada who was trained and certified to offer the Vacuum-Assisted Cellulite Band Release procedure for treatment of cellulite on the thighs and buttocks.

An active clinical trialist, Dr. Hanna has served as a principal investigator for numerous cosmetic & medical clinical trials with Probity Medical Research.

About Dr.Jessica Asgarpour, MD, FRCPC Dermatologist | Toronto, ON

Dr. Jessica Asgarpour is a Canadian and American board-certified dermatologist.She practices medical, surgical and cosmetic dermatology with a special interest in hidradenitis suppurativa, eczema, acne, psoriasis, and women’s health. She is currently working at Canadian Dermatology Centre and is also a clinical associate at Women’s College Hospital. She is a lecturer at University of Toronto and an active sub-investigator for ongoing clinical trials.

📻www.skinandjoints.ca

✉️info@skinandjoints.ca

📻www.skinandjoints.ca

✉️info@skinandjoints.ca

View Details

🌞🔍 Photoprotection in Skin of Colour: The Role of Visible Light and New Perspectives on Sun Protection

Episode Sneak Peek:

• 🤔 Debunking Myths: Think all skin reacts the same under the sun? Think again! We’re tackling 3 big misconceptions about photodamage across the Fitzpatrick Skin Types.

Hot Seat Confessions: Our panel of dermatologist experts faces the heat 🔥, answering burning questions:

• Is photodamage consistent across all skin colors?
• Can melanin alone ward off the sun’s advances?
• Do broad-spectrum sunscreens offer the ultimate armor against all sunlight villains?

🌿💡Antioxidants: The Hype or Hero? We dissect the buzz around antioxidants in sunscreens – are they just a marketing myth or a must-have in your skincare arsenal?

🌞🧴 And yes, don’t forget your sunscreen, no matter your shade!

Episode Learning Objectives

• Identify and correct misconceptions regarding the significance of photoprotection across different populations with a focus on darker skin phenotypes.
• Understand the detrimental effects of visible light on skin health.
• Explore the function of Reactive Oxygen Species (ROS) and antioxidants in sunscreen formulations.
• Apply tailored photoprotection regimens for individuals of all Fitzpatrick Skin Types (FSTs)

SkinAndJointsPodcast #ShadesOfBrown #BeyondLabels #SunProtectionForAll

EPISODE Supported by EUCERIN.

About Dr.Tasneem F. Mohammad, MD FAAD

Dermatologist, Detroit, MI

Tasneem F. Mohammad, MD FAAD is a Staff Physician in the Henry Ford Health System Department of Dermatology in Detroit, MI where she also completed her residency training and a photomedicine and pigmentation research fellowship. Her clinical and research interests include photomedicine, vitiligo, and pigmentary disorders. She has served on various committees for the Global Vitiligo Foundation, Skin of Color Society, and American Academy of Dermatology.

About Dr. Jennifer Beecker MD, FRCPC, CCFP(EM), DABD

Dermatologist, Ottawa, ON

Dr. Jennifer Beecker is a Royal College-certified dermatologist who is fully trained and certified in three separate medical specialties: Dermatology, Emergency Medicine and Family Medicine. In addition, she has earned American board-certification as a dermatologist by the American Board of Dermatology. Dr. Beecker is an active Staff Dermatologist at The Ottawa Hospital and Assistant Professor at the University of Ottawa. The range of conditions in which Dr. Beecker holds expertise includes medical dermatology, skin cancer, as well as cosmetic dermatology.

Dr. Beecker is a national expert in skin cancer detection and prevention. Dr. Beecker founded the Melanoma and Pigmented Lesion Clinic at The Ottawa Hospital academic teaching centre. She is the only dermatologist in Canada using this specialized equipment at a teaching hospital. Dr. Beecker trains medical residents and medical students in this clinic, as well as in general dermatology clinics. She is also Vice-Chair of the Dermatology Examination Committee at the Royal College of Physicians and Surgeons of Canada, which sets and conducts the exam for dermatology residents graduating and attempting to obtain Canadian certification as a dermatologist.

As Research Director for the Division of Dermatology at The Ottawa Hospital and a Clinical Investigator in the Clinical Epidemiology Program at the Ottawa Hospital Research Institute (OHRI), Dr. Beecker conducts and supervises many research studies, and has multiple publications in the medical literature. She is invited to lecture about dermatology locally, nationally, and internationally, and is frequently interviewed by the media, especially on topics such as sun protection and skin cancer. In 2020, Dr. Beecker was awarded the prestigious “President’s Cup Award” by the Canadian Dermatology Association for the second time having also received this award in 2016. She is now President Elect of the Canadian Dermatology Association.

📻www.skinandjoints.ca

✉️info@skinandjoints.ca

📻www.skinandjoints.ca

✉️info@skinandjoints.ca

View Details

🎙️✨ Dive into Part 2 of the Skin and Joints Podcast with Dr.Max Sauder: PsO and the Art of Decision Making with Dr.Maxwell Sauder where we delve into the groundbreaking reSURFACE 1 and reSURFACE 2 Trials on Tildrakizumab in PsO exploring the Efficacy and Safety of Tildrakizumab in Older Patients: Pooled Analyses of Two Randomized Phase III Clinical Trials (reSURFACE 1 and reSURFACE 2) Through 244 weeks.

Dr. Sauder takes us through a deep dive into the study's findings, highlighting the similar improvement rates in skin lesions and disease-related quality of life among younger and older patients alike.

PART 2 explores:

• The Dr.Sauder Method: why this treatment stands out in Dr. Sauder's arsenal against psoriasis, not just for the elderly but across all ages and how he makes real world decisions in clinic
• From a mechanistic perspective, do we have an idea as to what is going on? As a form of precision medicine, we also explore a study that aimed to investigate the specific patient population that would derive the greatest benefit from tildrakizumab, as well as the mechanism of action and efficacy of tildrakizumab in reducing the occurrence of psoriatic arthritis (PsA).
• This study also examined the quantity and role of regulatory T cells (Tregs) and T helper 17 cells both pre- and post-treatment-what do you need to know?

Episode supported by an IME Grant from SUN Pharma

About Dr.Maxwell Sauder MD, FRCPCDermatologist | Toronto Dr. Maxwell Sauder is a board-certified dermatologist with additional fellowship training. He earned his Doctor of Medicine at McMaster University and completed a residency in dermatology at The University of Ottawa. He completed fellowship training in Cutaneous Oncology at Harvard Medical School. He is a former instructor in dermatology at Harvard Medical School.

Dr. Sauder is currently an assistant professor at the University of Toronto. He is an onco-dermatologist at Princess Margaret Cancer Centre. He also practices at Toronto Dermatology Centre where he is the research director and the director of the Pigmented Lesion Clinic.

Well published in numerous peer-reviewed journals, Dr. Sauder has also authored several book chapters, been referenced on www.uptodate.com, and has won numerous awards including the Partner’s President Prize at Harvard and the Royal College’s Detweiler Fellowship Award. His publications have covered topics such as eczema, patient education, aesthetic dermatology, sun safety, psoriasis, biologics, adverse drug reactions, hemangiomas, contact dermatitis, cutaneous oncology, and a host of complex medical dermatology conditions.

📻www.skinandjoints.ca

✉️info@skinandjoints.ca

📻www.skinandjoints.ca

✉️info@skinandjoints.ca

View Details

🌞🎧Dermatologist Dr.Max Sauder joins us and navigates us through the complexities of modern dermatological care💡

🎧In PART I, we dive into a discussion on the unique challenges of treating psoriasis in elderly patients, exploring the delicate balance of therapy selection amidst comorbidities and the scarcity of evidence-based guidelines for our older patients 🧓🔬

Although biologics seem to be relatively safe, this limited evidence-based management could trigger treatment reluctance to prescribe (newer) biologics in older patients for fear of lower efficacy or tolerabilityC

Curious to hear about clinical secrets today when it comes to managing PsO in elderly patients?

Hear specifically a unique means of how Dr.Sauder frames his therapy selection with Tildrakizumab and clinical outcomes that arise from this in his clinic.

Episode Learning Objectives

• Understand key considerations of treating elderly patients with moderate to severe PsO
• Describe how to incorporate evidence in utilizing Tildrakizumab for PsO in elderly patients
• Discuss implications of these findings and translate into real world clinical decision making

Episode supported by an IME Grant from SUN Pharma

About Dr.Maxwell Sauder MD, FRCPCDermatologist | Toronto Dr. Maxwell Sauder is a board-certified dermatologist with additional fellowship training. He earned his Doctor of Medicine at McMaster University and completed a residency in dermatology at The University of Ottawa. He completed fellowship training in Cutaneous Oncology at Harvard Medical School. He is a former instructor in dermatology at Harvard Medical School.

Dr. Sauder is currently an assistant professor at the University of Toronto. He is an onco-dermatologist at Princess Margaret Cancer Centre. He also practices at Toronto Dermatology Centre where he is the research director and the director of the Pigmented Lesion Clinic.

Well published in numerous peer-reviewed journals, Dr. Sauder has also authored several book chapters, been referenced on www.uptodate.com, and has won numerous awards including the Partner’s President Prize at Harvard and the Royal College’s Detweiler Fellowship Award. His publications have covered topics such as eczema, patient education, aesthetic dermatology, sun safety, psoriasis, biologics, adverse drug reactions, hemangiomas, contact dermatitis, cutaneous oncology, and a host of complex medical dermatology conditions.

📻www.skinandjoints.ca

✉️info@skinandjoints.ca

📻www.skinandjoints.ca

✉️info@skinandjoints.ca

View Details

🔍Welcome back to Part 2 of our dialogue with Skin and Joint Podcast EADV Ambassador, Dr.Melinda Gooderham, where we delve deep into the groundbreaking advancements in treating chronic hand eczema, featuring the innovative pivotal trials and their implications for care.
Are we entering a new era for care for our patients with chronic hand eczema?

Making her guest hosting debut on the Podcast, Dr. Jessica Asgarpour joins us for PART 2.

🆕Key Highlights we take a look at in PART 2:

Exploring New Agents in Chronic Hand Eczema Treatment (Efficacy Perspectives and Quality of Life Measures):

• Dr. Gooderham offers an in-depth analysis of delgocitinib cream, a new topical for CHE.
• Delta 1 and Delta 2 trials focus on efficacy and safety
  • Outcomes in terms of the Hand Eczema Area and Severity Index (HEXI) and DLQI scores.

Safety Profile of Topical JAK inhibitors:

• Patient Adherence and Formulation Challenges
• The role of delgocitinib as a non-steroidal option in treating hand eczema.
• Discussion on the evolving landscape of dermatological treatments and patient access to new therapies

Episode supported by an IME Grant from LEO Pharma

ABOUT Dr.Melinda Gooderham, MD, FRCPC ( Dermatology)

Toronto, ON

Melinda Gooderham MD MSc FRCPC Dr. Gooderham is a Dermatologist and Medical Director at the SKiN Centre for Dermatology and an Investigator with Probity Medical Research. She is an Assistant Professor at Queens University and a Consultant Physician at the Peterborough Regional Health Centre. She is a fellow of the Royal College of Physicians and Surgeons of Canada.

Dr. Gooderham has been the principal investigator for over 200 clinical trials and she practices with a focus on inflammatory diseases of the skin. She also contributes to several peer-reviewed dermatology publications as an associate editor, reviewer, and has been an author of 205 articles. She enjoys lecturing to global audiences on new therapies for skin diseases.

About Dr.Jessica Asgarpour, MD, FRCPCDermatologist | Toronto Dr. Jessica Asgarpour is a Canadian and American board-certified dermatologist. She completed her medical school at the Cumming School of Medicine, in Calgary, Alberta, where she was born and raised. She went on to the University of Alberta for her residency training in dermatology, where she acted as co-chief resident from 2019-2020, and was awarded the Dr. Andrew Lin Dermatology Scholar award. She has also been awarded multiple scholarships to conferences to keep her up-to-date with the ever changing medical literature.

She has published in many peer-reviewed journals, and practices medicine with this same evidence-based approach. She practices medical, surgical and cosmetic dermatology. When she is not practicing dermatology, she enjoys keeping active and loves to run, spin and hike.

📻www.skinandjoints.ca

✉️info@skinandjoints.ca

📻www.skinandjoints.ca

✉️info@skinandjoints.ca

View Details

🐻Got lost in a labyrinth, found a bear, and almost became a rock star! 🐻⛏️

This week’s drop on the Skin and Joints Podcast PART 1 is a wild ride - from mistaking a geology conference for a dermatology one, to navigating Messe’s maze-like corridors. Ever wondered if ‘Messe’ stands for ‘mess’ or ‘maze’?

Join Dr. Melinda Gooderham, our Skin and Joints Podcast EADV Ambassador, as we uncover the hilarious journey at the EADV Berlin.

Making her guest hosting debut on the Podcast, Dr. Jessica Asgarpour joins us to share tales from her world travels and EADV.

Spoiler alert: it involves accidental geology lectures and statue selfies! 🗺️

Tune in for an episode that’s more twisty than our conference’s hallways:

• EADV 2023 Conference Debrief: Dr. Melinda Gooderham shares her unique insights from the EADV conference in Berlin, adding a layer of global expertise to the conversation.
• Cultural and Culinary Delights: From the historic streets of Berlin to the culinary adventures, the podcast paints a vivid picture of the experiences beyond the conference halls
• Chronic Hand Eczema (CHE) Insights: An enlightening conversation about CHE, a troublesome condition affecting many, characterized by itchiness, pain, and a significant impact on quality of life. A deep dive into the existing approaches to managing CHE, outlining their limitations and the need for more effective, long-term solutions.
• Breaking News from EADV: A new tool in the toolkit-delgocitinib's promising results in the DELTA 1 and 2 trials for CHE.

Other PART 1 Highlights of the Episode:

• Four-Year Triumph with tralokinumab, data on Nemolizumab for treating pruritus in atopic dermatitis, psoriasis breakthroughs - oral peptides and more, foam home advantage for scalp and body psoriasis and weighty matters in psoriasis treatment

Episode supported by an IME Grant from LEO Pharma

ABOUT Dr.Melinda Gooderham, MD, FRCPC ( Dermatology)

Toronto, ON

Melinda Gooderham MD MSc FRCPC Dr. Gooderham is a Dermatologist and Medical Director at the SKiN Centre for Dermatology and an Investigator with Probity Medical Research. She is an Assistant Professor at Queens University and a Consultant Physician at the Peterborough Regional Health Centre. She is a fellow of the Royal College of Physicians and Surgeons of Canada.

Dr. Gooderham has been the principal investigator for over 200 clinical trials and she practices with a focus on inflammatory diseases of the skin. She also contributes to several peer-reviewed dermatology publications as an associate editor, reviewer, and has been an author of 205 articles. She enjoys lecturing to global audiences on new therapies for skin diseases.

About Dr.Jessica Asgarpour, MD, FRCPCDermatologist | Toronto Dr. Jessica Asgarpour is a Canadian and American board-certified dermatologist. She completed her medical school at the Cumming School of Medicine, in Calgary, Alberta, where she was born and raised. She went on to the University of Alberta for her residency training in dermatology, where she acted as co-chief resident from 2019-2020, and was awarded the Dr. Andrew Lin Dermatology Scholar award. She has also been awarded multiple scholarships to conferences to keep her up-to-date with the ever changing medical literature.

She has published in many peer-reviewed journals, and practices medicine with this same evidence-based approach. She practices medical, surgical and cosmetic dermatology. When she is not practicing dermatology, she enjoys keeping active and loves to run, spin and hike.

📻www.skinandjoints.ca

✉️info@skinandjoints.ca

📻www.skinandjoints.ca

✉️info@skinandjoints.ca

View Details

🎙️🎙️ Dr. Lauren Lam joins us LIVE from the World Congress of Dermatology in Singapore! Dive into our Crazy Rich Asians-style adventures, unpack the future of AI in dermatology, and get the inside scoop on the latest was we think about HS (hidradenitis suppurtiva) 💡

• Dive into Dr. Lam's Singaporean escapades! 🇸🇬
• What's the next big thing for HS treatment? 🧐
• How might AI revolutionize medical writing? ✍️
• Bonus: Have you heard of the Triple Threat yet?

From mirage-like mansions to cutting-edge derm findings, join us for a roller coaster of insights, anecdotes and unscripted, unfiltered (maybe somewhat savage) moments.

Let Dr. Lam lead you through an unforgettable journey at the crossroads of dermatology, tech, and an unforgettable experience 🌟

EPISODE Supported by Pfizer.

ABOUT Dr. Lauren Lam BScH, MD, FRCPC Medical, Surgical & Cosmetic Dermatologist Calgary,AB

Clinical Lecturer | Division of Dermatology, Department of Medicine | University of Alberta

Dr. Lam is a Canadian board-certified dermatologist. She completed her medical school training at the University of Calgary & her dermatology residency at the University of Alberta. Since graduating, Dr. Lam has become a Clinical Lecturer with the University of Alberta. Her particular passions in dermatology are acne & hidradenitis suppurativa deroofings.

In addition to her regular practice, she volunteers on overseas medical trips. Her passion for providing care for under-served populations has taken her to Nunavut & rural Fiji. Outside of medicine, Dr. Lam is a proud aunt to 4 dogs, culinary enthusiast & international explorer.

📻www.skinandjoints.ca

✉️info@skinandjoints.ca

📻www.skinandjoints.ca

✉️info@skinandjoints.ca

View Details

🎙️🍫 Our Convo with Dr.Jerry TAN on Acne, Sun, Shades of Brown, and Identity 🌞🎨

🎙✈️ From a surprise detour in Toronto to runway rendezvous at the world’s best shopping airport. Join us for Dr. Jerry Tan’s deep dive into what's new in the world of acne

🌍✨Skin and Joints Podcast Dermatologist expert Dr.Jerry Tan untangles the intricate threads of identity. What do we say when someone asks about our ethnicity or race in an ever-mixed global landscape??🎨 Sick of the phototype jargon? Dive into a refreshing conversation where we shift from shades of grey to exploring every shade of brown 🎨

🌞🧴 And yes, don’t forget your sunscreen, no matter your shade!

SkinAndJointsPodcast #WorldCongressOfDermatology #ShadesOfBrown #BeyondLabels #SunProtectionForAll

P.S. Spoiler Alert: Jet engines might be involved. 📍✈️😉

EPISODE Supported by BAUSCH HEALTH.

About Dr. Jerry Tan

Dermatologist, Windsor, ON

Dr. Tan received his medical degree from Queen’s University in Kingston, Ontario and trained in internal medicine at the University of Toronto and in dermatology at University of British Columbia and University of Michigan. His general dermatology and aesthetic dermatology practices are in Windsor Ontario Canada. He conducts clinical trials research at Windsor Clinical Research, a clinical trials site in dermatology. Aside from industry grants, he has received research funding from the Canadian Dermatology Foundation and the National Institutes of Health Research.

Research focus includes acne, acne scars and rosacea. Additional interests include outcome measurements and informed shared decision making in dermatology.

Dr. Tan chairs the working group on clinical practice guidelines of the Canadian Dermatology Association, the rosacea international consensus group (ROSCO) and the acne core outcomes research network (ACORN). He has been an associate editor of the Journal of the American Academy of Dermatology and the British Journal of Dermatology. Over the past 3 decades, Dr. Tan has authored/co-authored more than 100 peer-reviewed publications.

📻www.skinandjoints.ca

✉️info@skinandjoints.ca

📻www.skinandjoints.ca

✉️info@skinandjoints.ca

View Details

🛍️ Mall Maze Misadventures in Singapore 🛍️

🚨🔄Skin and Joints PodcastFaculty Dr. Melinda Gooderham: Dermatologist by day, unintentional mall explorer by... also day. 😂

Circling for hours, getting acquainted with that same pesky roundabout, and yet always ending up at square one – all within a stone’s throw of her hotel.

Could it be strategic design? 🤔 Or perhaps the universe’s way of reminding us that not all shortcuts turn out short. Or maybe just the irresistible allure of Singapore’s shopping havens? 🌆A chic linen suit, anyone? 🌸👗

🎙️ Tune in to hear Dr.Gooderham’s Singapore Story only on the Skin and Joints PodcastLive from the 25th World Congress of Dermatology in Singapore.

Episode supported by an IME Grant from Pfizer

MallMisadventures#SingaporeStories#DermatologyDiaries#WCD🌏🎧

ABOUT Dr.Melinda Gooderham, MD, FRCPC ( Dermatology)

Toronto, ON

Melinda Gooderham MD MSc FRCPC Dr. Gooderham is a Dermatologist and Medical Director at the SKiN Centre for Dermatology and an Investigator with Probity Medical Research. She is an Assistant Professor at Queens University and a Consultant Physician at the Peterborough Regional Health Centre. She is a fellow of the Royal College of Physicians and Surgeons of Canada.

Dr. Gooderham has been the principal investigator for over 200 clinical trials and she practices with a focus on inflammatory diseases of the skin. She also contributes to several peer-reviewed dermatology publications as an associate editor, reviewer, and has been an author of 205 articles. She enjoys lecturing to global audiences on new therapies for skin diseases.

📻www.skinandjoints.ca

✉️info@skinandjoints.ca

View Details

🔊🎧 🎙️ Missing Efficiency in Your Dermatology Clinic: A Dive into Lean Sigma Six with Dr. Perry Grewal PART 1🔊🎧

Dr.Perry Grewal drops in to join us on the Skin and Joints Podcast.

💅🍿🎥Summer’s hot, but you know what’s hotter? The latest buzz about the new Barbie movie. If Barbie taught us anything, it's to be unexpected. And the Skin and Joints podcast? Well, it’s right on brand. Hear Dr.Grewal's take.

Dr.Perry Grewal chat's about a novel real world project he lead utilizing Lean Sigma Six - heard of it? This technique, popular in the automotive industry, might just be the salve for healthcare hitches! Can it be applied to a dermatology practice? Let's find out!

In a world where workflows matter, where seconds count, and inefficiencies lurk behind every corner... 🎵 dun dun DUN 🎵... Get ready for an in-depth episode like no other.

If you've ever been held hostage by wait times or struggled with workflow in your clinic, this episode is your antidote.

In PART 1 we deep dive:

• Reflections on balancing medical practice and patient care with the business side
• An inside scoop on the objective behind analyzing a dermatologist's workflow and practice.
• Tackling wait times, staff efficiency, and fax machine fiascos!

DermTalks #EfficiencyInHealthcare #PharmacyLife #LeanSigmaSixHealth #DermWorkflow #MedicineMeetsManagement #BehindTheStethoscope #HealthcareDeepDive #PatientCareFirst #PracticePerfect #SkinAndSystems #DoctorDiaries #ClinicCheckup #HealthcareHacks #PracticeReflections #FromThePharmacyToTheClinic #OptimizedOutcomes #DermDeepDive

Only on the Skin and Joints Podcast !

▶️Episode supported by Novartis.

ABOUT Dr. Parbeer S. Grewal MD FRCPC FAAD

Medical Director of Rejuvenation Dermatology and Aesthetics Downtown Edmonton

Associate Clinical Professor, University of Alberta, Division of Dermatology

Dr. Grewal is an Associate Clinical Professor within the Faculty of Medicine, Division of Dermatology, at the University of Alberta. He is the Medical Director of Dermatology and Clinical Research Trials at Rejuvenation Dermatology and Aesthetics Downtown Edmonton. He is also a consulting physician for the University of Alberta Hospital, the Royal Alexandra Hospital, the Grey Nuns Hospital, and the Misericordia Hospital. Dr. Grewal has participated in over 80 clinical research trials and has published many journal articles and book chapters in Dermatology.

View Details

🔊🎧 🎙️ What's New in PsO TX: My Real World Experience with Bimekizumab 🔊🎧

🎙️🩺🔍 Age-defying Dr.Marni Wiseman journeys with us through 22 years in #dermatology, spilling the secrets of revolutionary treatments and today's #psoriasis patient journeys.

🔊🎧 From the evolution of 1st gen biologic therapy to the latest data around Bimekizumab and it's role, we dive into a fresh discussion about Dr.Wiseman's secret sauce when it comes to treating plaque #psoriasis.

🔊🎧Hear about her initial approach to biologic naïve patients to determine suitability for biologic therapy.

Don't let PART 1 be skin deep; dive right in! 🎙️🩺🔍

In PART 1 we explore:

• Bimekizumab, a new addition to the IL-17 inhibitor family, a humanized IgG1 antibody that binds both IL-17A and IL-17F.
• Clinical trial insights: Significant and clinically meaningful improvements over various comparators in pivotal studies such as BE VIVID, BE READY, BE SURE, and more. We look at efficacy when compared to other biologics like placebo, ustekinumab, adalimumab, and secukinumab
• Does real-world practice experience align with clinical trials? IL 17 inhibitors, especially bimekizumab, are associated with fungal infections or oral candidiasis: what you need to know about management and if it really is an issue in practice

🎙️Spoiler alert: Not all IL-17 inhibitors are created equal! And if you're itching (pun intended) to learn about that one Bimekizumab side effect everyone's talking about and the real world experience, tune in!

DermTalks #Derm #MedicineMeetsManagement #BehindTheStethoscope #HealthcareDeepDive #PatientCareFirst #PracticePerfect #SkinAndSystems #DoctorDiaries #ClinicCheckup #HealthcareHacks #OptimizedOutcomes #DermDeepDive

Only on the Skin and Joints Podcast !

▶️Episode supported by UCB.

ABOUT Dr.Marni Wiseman MD FRCPC

Dr. Marni Wiseman began her Dermatology practice in Winnipeg, Manitoba in 2001. In addition to her teaching responsibilities as an Associate Professor and Section Head of Dermatology in the Faculty of Medicine at the University of Manitoba, Dr. Wiseman is the Medical Director of SKiNWISE DERMATOLOGY where she is involved in a general dermatology practice.

Dr. Wiseman’s areas of interest include psoriasis, atopic dermatitis, hidradenitis suppurativa, acne, and aesthetic dermatology. She actively participates in clinical trials through Wiseman Dermatology Research, where she has participated in over a hundred clinical trials. Dr. Wiseman is a frequent supervisor and mentor for medical students and residents. She has extensively published in areas of inflammatory skin disease, photodermatosis, and cutaneous malignancy.

Her community commitments are extensive and include involvement with the Canadian Dermatology Association as Provincial Director of the National Sun Awareness Program. She is an editor of the Journal of Cutaneous Medicine and Surgery, and was the chair of the Skin Cancer Disease Site Group at CancerCare Manitoba for 15 years. Dr. Wiseman does regular outreach skin cancer screening clinics in rural locations of Manitoba, has been featured in many news stories, and regularly presents at meetings and congresses nationally and internationally.

View Details

🔊🎧 🎙️ Missing Efficiency in Your Dermatology Clinic: A Dive into Lean Sigma Six with Dr. Perry Grewal PART 1🔊🎧

Dr.Perry Grewal drops in to join us on the Skin and Joints Podcast.

💅🍿🎥Summer’s hot, but you know what’s hotter? The latest buzz about the new Barbie movie. If Barbie taught us anything, it's to be unexpected. And the Skin and Joints podcast? Well, it’s right on brand. Hear Dr.Grewal's take.

Dr.Perry Grewal chat's about a novel real world project he lead utilizing Lean Sigma Six - heard of it? This technique, popular in the automotive industry, might just be the salve for healthcare hitches! Can it be applied to a dermatology practice? Let's find out!

In a world where workflows matter, where seconds count, and inefficiencies lurk behind every corner... 🎵 dun dun DUN 🎵... Get ready for an in-depth episode like no other.

If you've ever been held hostage by wait times or struggled with workflow in your clinic, this episode is your antidote.

In PART 1 we deep dive:

• Reflections on balancing medical practice and patient care with the business side
• An inside scoop on the objective behind analyzing a dermatologist's workflow and practice.
• Tackling wait times, staff efficiency, and fax machine fiascos!

DermTalks #EfficiencyInHealthcare #PharmacyLife #LeanSigmaSixHealth #DermWorkflow #MedicineMeetsManagement #BehindTheStethoscope #HealthcareDeepDive #PatientCareFirst #PracticePerfect #SkinAndSystems #DoctorDiaries #ClinicCheckup #HealthcareHacks #PracticeReflections #FromThePharmacyToTheClinic #OptimizedOutcomes #DermDeepDive

Only on the Skin and Joints Podcast !

▶️Episode supported by Novartis.

ABOUT Dr. Parbeer S. Grewal MD FRCPC FAAD

Medical Director of Rejuvenation Dermatology and Aesthetics Downtown Edmonton

Associate Clinical Professor, University of Alberta, Division of Dermatology

Dr. Grewal is an Associate Clinical Professor within the Faculty of Medicine, Division of Dermatology, at the University of Alberta. He is the Medical Director of Dermatology and Clinical Research Trials at Rejuvenation Dermatology and Aesthetics Downtown Edmonton. He is also a consulting physician for the University of Alberta Hospital, the Royal Alexandra Hospital, the Grey Nuns Hospital, and the Misericordia Hospital. Dr. Grewal has participated in over 80 clinical research trials and has published many journal articles and book chapters in Dermatology.

View Details

🎧 BEDTIME STORIES WITH DR.DUTZ.

🎧 "Island Adventures & Lupus Revelations"

🎙️ 🎙️Ever wondered how a tiny island in Singapore shaped its skyline? Or what it's like to bike through a mangrove swamp in the middle of nowhere? How about the breakthroughs in the world of dermatology?

🎧🚴Dive deep into the tropical and historical allure of Singapore's hidden gem, Lau Uben, where city stones tell as Dr. Dutz shares his extraordinary adventures in Singapore's forgotten islands and the latest in dermatological research as we pedal into the intricate world of Lupus and breakthroughs on the horizon. 🚲💉

What's inside:

• Dr. Dutz's thrilling off-the-rail escapade to a lesser-known Singaporean island. 🏝️
• Juicy nuggets from the World Congress: from skin surprises to systemic lupus treatments: what’s new?
• A tease of a revolutionary non-antibody treatment that's turning heads: get the latest buzz on an oral IL-23 inhibitor. Game-changer? 🚀

Plus, you won’t believe which delicious Singaporean experience eluded Dr. Dutz's palate.

🎧🚀🍜Pack your curiosity (and maybe a snack) - this episode is a rollercoaster of discovery, history, and cutting-edge medicine!

🌌Tune in. Get enlightened. And maybe a bit of entertainment

SkinAndJointsPodcast #DrDutzAdventures #SingaporeTales #BedtimeStoriesWithDrDutz

Episode supported by an IME from Pfizer.

View Details

Buckle up, globetrotters! 🌏✈️ Journey with our guest, Dr.Michele Ramien, as she hopscotches across continents, from the chilly climes of Calgary to the bustling streets of Singapore.

But this isn’t just any travel tale—it’s a dermatological world tour with a twist!

We delve into a peculiar case of the stubborn palmoplantar keratoderma and how a woodworking tool might just be the dermatologist’s unexpected sidekick! 🛠️ But that’s not where the story ends. Dive in to discover a groundbreaking treatment path. There’s a new player in town. Get ready to be skin-spired!

Trust us, you won’t want to miss a minute. Ready to go full circle?

Only on the Skin and Joints Podcast

DermAroundTheWorld #TravelTalesWithATwist #wcd #dermatology #rheumatology🌐🩺.

EPISODE Supported by Pfizer.

About Dr. Michele L. Ramien, FRCPC, FAAD

Dermatologist | Calgary, AB

Dr. Ramien graduated from McGill Medical School in 2008. She then completed Dermatology residency at the University of Toronto and University of Ottawa. Dr. Ramien has been board-certified in Dermatology by the Royal College of Physicians and Surgeons of Canada and the American Board of Dermatology since 2013, with Pediatric Dermatology certification since 2018.

In 2013-2014, she completed a Pediatric Dermatology fellowship at CHU Sainte-Justine, in Montréal, Québec funded by the University of Ottawa Fellowship for New Faculty and the Children’s Hospital of Eastern Ontario’s Popham Fellowship. Dr. Ramien is currently a Clinician-Investigator at the Alberta Children’s Hospital in Calgary, Alberta. Her practice is focused on clinical care of medically or dermatologically complex children.

📻www.skinandjoints.ca

✉️info@skinandjoints.ca

View Details

🎙 Live from Singapore, it's The Skin and Joints Podcast with Dr. Sonya Abdulla🌍

Dive into this tantalizing episode where Toronto meets the World Congress of Dermatology.

🎧🍁From the multicultural marvels of Singapore to groundbreaking skin-care revelations, get your dose of dermatology discoveries and some unexpected Singapore stories!

🧴💡 Can skin sensitivity be linked to hormonal phases? Ever heard of sarcosinic acid for acne? Will this be the next game-changer in acne treatment? And get ready because regenerative medicine might just change everything.

🧴🔍 Join us for a dermatological detective story, a touch of compounding chemistry, and a hint of skincare scent controversies. Tune in to hear all about it, and discover other sizzling dermatological updates too. Perfect for anyone wanting to be in-the-know, from the clinic to the cosmetics aisle.

#ClearSkinClearWay #DermatologyRevealed #CanadianDermatologyDeepDive

EPISODE Supported by L'Oreal Dermatological Beauty.

About Dr. Sonya Abdulla MD, FRCPC, FAAD

Dermatologist | Toronto, ON

Dr. Sonya Abdulla is a double board-certified dermatologist in Canada and the US. She completed additional Fellowship training in Dermatologic Laser Surgery and Aesthetic Medicine at the University of Toronto.

Dr. Abdulla has an active medical and cosmetic dermatology practice where she is involved in clinical research and teaching. Her clinical interests include acne, rosacea and psoriasis as well as minimally invasive aesthetic procedures including injectables, energy-based devices and laser surgery. Dr. Abdulla is a strong proponent of evidence-based skin care – her opinion and expertise serve as an invaluable resource for patients, peers and media.

📻www.skinandjoints.ca

✉️info@skinandjoints.ca

View Details

🎙Skin & Joints Podcast: Live from Singapore!🎙

Dive into today's episode as Dr. Monica Lee dazzles us with tales from the famed Raffles Hotel, the iconic (and mocktail version of) Singapore Sling, and that jaw-dropping Crazy Rich Asians set. 🍹🎬

• But the juice doesn’t end there! Ever heard of pre-bunking, nudging, or debunking? Discover how these crucial processes combat misinformation in the medical realm, ensuring you're always ahead in the true-fact game. 🚫🤥
• From the secrets of graceful aging across diverse cultures to nitty-gritty anatomical insights for those facial tweaks we all love, Dr. Lee serves a masterclass in understanding and respecting cultural differences in skincare and aesthetics. 🌏💄
• Dermatologists, skincare enthusiasts, and inquisitive minds, get ready for a roller coaster of knowledge, fun facts, and the essence of beauty from every corner of the globe.

Tune in now to be part of the buzz straight from the World Congress of Dermatology 2023. 🎉🎤

And... a little hint: for those battling the myths of atopic dermatitis, Dr. Lee's insights might just be the salve you needed. 🦠🩺

EPISODE Supported by L'Oreal Dermatological Beauty.

About Dr.Monica Li MD, FRCPC, FAAD

Dermatologist | Vancouver

Monica Li MD, FRCPC, FAAD is a double board-certified, fellowship-trained dermatologist in Canada and the United States, and a Clinical Instructor in the Department of Dermatology & Skin Science at the University of British Columbia. She practices in Vancouver and Surrey. Dr. Li is actively involved with the American Society for Dermatologic Surgery and American Society for Laser Medicine & Surgery, has been a spokesperson for the Canadian Dermatology Association, and is author of a number of book chapters and more than 15 peer-reviewed publications. She has been an invited speaker to many national and international conferences, including the most recent past World Congress of Dermatology in Milan. Dr. Li is a regular voice to local and national media on topics in both medical and cosmetic dermatology.

📻www.skinandjoints.ca

✉️info@skinandjoints.ca

View Details

Dr.Angela Law serves as a special correspondent to the Podcast in Singapore at WCD with the freshest scoops that may change the way you practice when it comes to Acne and Rosacea.

🎧 Whether you're a skincare savant or just skin-curious, join us on this enlightening WCD mini escapade. 🌟🔊

Dr.Law covers in this Skin and Joints Episode:

Acne Complexion Chronicles: Navigating acne & rosacea in skin of color isn’t a walk in the park. Beyond primary lesions, there’s the tricky terrain of pigmentation aftermath. Thanks to maestros like Dr.Andrew Alexis, we've got pointers the role of retinoids & azelaic acid against post-inflammatory hyperpigmentation. 🎨💡

Rosacea Revelations: We dive into the world of rosacea treatments and a groundbreaking study that introduces Paroxetine as a potential savior for flushing, Could serotonin 😇 be the key?

Derm Olympics Relay: From the charm of Milan 🍝👠 to the sizzle of Singapore 🌞🍹, the World Congress feels like the grand stage of Dermatology Olympics. On your marks for the next location - Guadalajara or Munich? 🏁🏛️

EPISODE Supported by Bausch Health.

About Dr.Angela Law, MD, FRCPC

Dermatologist | Vancouver

Dr.Angela Law is a dually certified dermatologist in Canada and the US. She completed her medical school training at the University of British Columbia and was accepted into the joint Dermatology program between the University of Saskatchewan and Dalhousie University. She opened SkinSense Dermatology in Saskatoon after residency and practiced medical and aesthetic dermatology for six years before moving back to Vancouver during the COVID pandemic.

She is a Clinical Instructor in the Department of Dermatology and Skin Sciences at UBC and sits on the Undergraduate Education Committee in Dermatology. She has a special interest in pediatric and adolescent dermatology but has been trained in all aspects of medical, surgical and cosmetic dermatology. She splits her time between her new medical clinic with a group of seasoned plastic surgeons at Clinic One Three Eight in downtown Vancouver, aesthetics at Dermapure and a Dermatology rapid access clinic at Mount St. Joseph’s Hospital through Providence Health.

📻www.skinandjoints.ca

✉️info@skinandjoints.ca

View Details

🎙️🩺Dr.Chih-ho Hong shares the intriguing shifts in the treatment landscape for #atopic #dermatitis and how #patient #access is shaping choice.

🌍The World Congress of #Dermatology isn’t just any conference – it really is the Olympics of #Dermatology, and Dr. Hong gives us a peek behind the curtains, tracing his journey from a fresh resident to a podium regular.

Tune in to learn, laugh, and leap into the world of global #AD trends, and hear Dr.Hong's #Singapore #Story 🌍🩺🥇

🎤 Only on the Skin and Joints Podcast

EPISODE Supported by an IME Grant from Pfizer

ABOUT DR.CHIH-HO HONG

🎧 Dr. Hong is a board certified dermatologist working in Greater Vancouver BC, Canada. He runs a busy office based dermatology clinic with a focus on clinical research. He is a Clinical Assistant Professor in the Department of Dermatology and Skin Sciences and teaches at St. Paul’s Hospital in Vancouver, where he is active staff. Dr. Hong is the past head of the BC Section of Dermatology, the current Economics representative for Dermatology at the BCMA, and is the past chair of the Education Committee of the Canadian Dermatology Association. He is also a past examiner in Dermatology for the Royal College of Physicians of Canada residency qualification examination.

Dr. Hong is active in clinical practice and dermatology research. His main clinical areas of interest are psoriasis and eczema. He has been an investigator in over 150 trials of treatments in dermatology and has over 50 peer reviewed publications. He has lectured locally, nationally, and internationally on dermatology treatments and has been an invited speaker at international dermatology congresses.

View Details

🎙️🌟 𝘽𝙞𝙤𝙨𝙞𝙢𝙞-𝙇𝙖𝙪𝙣𝙘𝙝: 𝘼 𝙏𝙖𝙡𝙚 𝙤𝙛 𝙎𝙠𝙞𝙣, 𝙅𝙤𝙞𝙣𝙩𝙨 𝙖𝙣𝙙 𝘽𝙤𝙡𝙙 𝘽𝙚𝙜𝙞𝙣𝙣𝙞𝙣𝙜𝙨 PART 2! 🌟🎙️

🚀#𝗢𝗻𝘁𝗮𝗿𝗶𝗼 𝗵𝗮𝘀 𝘁𝗮𝗸𝗲𝗻 𝗮 𝗺𝗮𝗷𝗼𝗿 𝘀𝘁𝗲𝗽 𝗳𝗼𝗿𝘄𝗮𝗿𝗱 𝗶𝗻 𝘁𝗵𝗲 𝘄𝗼𝗿𝗹𝗱 𝗼𝗳 #𝗯𝗶𝗼𝘀𝗶𝗺𝗶𝗹𝗮𝗿 𝘁𝗵𝗲𝗿𝗮𝗽𝗶𝗲𝘀 𝘄𝗶𝘁𝗵 𝘁𝗵𝗲 𝘀𝘁𝗮𝗿𝘁 𝗼𝗳 𝘁𝗵𝗲𝗶𝗿 𝘁𝗿𝗮𝗻𝘀𝗶𝘁𝗶𝗼𝗻 𝗽𝗲𝗿𝗶𝗼𝗱 & 𝘄𝗲'𝘃𝗲 𝗴𝗼𝘁 𝘁𝗵𝗲 𝗶𝗻𝘀𝗶𝗱𝗲 𝘀𝗰𝗼𝗼𝗽!

𝗢𝗻𝘁𝗮𝗿𝗶𝗼 𝗯𝗮𝘀𝗲𝗱 #rheumatologist, 𝗗𝗿.Carter Thorne 𝗹𝗼𝗼𝗸s 𝗶𝗻𝘁𝗼 𝘁𝗵𝗲 𝗳𝗮𝘀𝗰𝗶𝗻𝗮𝘁𝗶𝗻𝗴 𝘄𝗼𝗿𝗹𝗱 𝗼𝗳 𝗿𝗲𝗮𝗹-𝘄𝗼𝗿𝗹𝗱 𝗲𝘃𝗶𝗱𝗲𝗻𝗰𝗲 (RWE) 𝗳𝗼𝗿 𝗯𝗶𝗼𝘀𝗶𝗺𝗶𝗹𝗮𝗿 𝘁𝗵𝗲𝗿𝗮𝗽𝗶𝗲𝘀💉🔍𝗲𝗺𝗲𝗿𝗴𝗶𝗻𝗴 𝗥𝗪𝗘 transition 𝗱𝗮𝘁𝗮 𝘁𝗿𝗲𝗻𝗱𝘀, 𝗮𝗻𝗱 𝘁𝗵𝗲 𝘃𝗮𝗹𝘂𝗲 𝗶𝘁 𝗰𝗮𝗻 𝗵𝗮𝘃𝗲 𝗼𝗻 𝗷𝗼𝗶𝗻𝘁 & 𝘀𝗸𝗶𝗻 𝘁𝗿𝗲𝗮𝘁𝗺𝗲𝗻𝘁 𝗺𝗮𝗻𝗮𝗴𝗲𝗺𝗲𝗻𝘁 𝗱𝗲𝗰𝗶𝘀𝗶𝗼𝗻𝘀! 💪🤓
𝗙𝗶𝗻𝗱 𝗼𝘂𝘁 𝗵𝗼𝘄 𝘁𝗼 𝗯𝗲 𝗮 #𝗯𝗶𝗼𝘀𝗶𝗺𝗶𝗹𝗮𝗿 wizard 💼🏆 𝘄𝗶𝘁𝗵 𝗼𝘂𝗿 𝗲𝘀𝘀𝗲𝗻𝘁𝗶𝗮𝗹 𝗴𝘂𝗶𝗱𝗲 𝘁𝗼 𝗻𝗮𝘃𝗶𝗴𝗮𝘁𝗶𝗻𝗴 𝘁𝗵𝗶𝘀 𝗻𝗲𝘄 𝘁𝗲𝗿𝗿𝗮𝗶𝗻 𝗶𝗻 𝘆𝗼𝘂𝗿 𝗱𝗮𝘆-𝘁𝗼-𝗱𝗮𝘆 𝗽𝗿𝗮𝗰𝘁𝗶𝗰𝗲 🗺️👩‍⚕️👨‍⚕️

👨‍⚕️Dr.Thorne 𝙞𝙨 𝙞𝙣𝙫𝙤𝙡𝙫𝙚𝙙 𝙞𝙣 𝘾𝘼𝙏𝘾𝙃 (𝘾𝙖𝙣𝙖𝙙𝙞𝙖𝙣 𝙀𝙖𝙧𝙡𝙮 𝘼𝙧𝙩𝙝𝙧𝙞𝙩𝙞𝙨 𝘾𝙤𝙝𝙤𝙧𝙩), 𝙊𝘽𝙍𝙄 (𝙊𝙣𝙩𝙖𝙧𝙞𝙤 𝘽𝙚𝙨𝙩 𝙋𝙧𝙖𝙘𝙩𝙞𝙘𝙚𝙨 𝙍𝙚𝙨𝙚𝙖𝙧𝙘𝙝 𝙄𝙣𝙞𝙩𝙞𝙖𝙩𝙞𝙫𝙚) 𝙖𝙣𝙙 𝙖𝙩 𝙡𝙤𝙘𝙖𝙡, 𝙥𝙧𝙤𝙫𝙞𝙣𝙘𝙞𝙖𝙡 𝙖𝙣𝙙 𝙣𝙖𝙩𝙞𝙤𝙣𝙖𝙡 𝙢𝙤𝙙𝙚𝙡𝙨 𝙤𝙛 𝙘𝙖𝙧𝙚 𝙞𝙣𝙞𝙩𝙞𝙖𝙩𝙞𝙫𝙚𝙨.

🎧 🎉Dr. Thorne is an Assistant Professor at the University of Toronto, and is on the Consultant Staff at Southlake Regional Health Centre in Newmarket, Ontario where he was Chief of the Division of Rheumatology and Director of The Arthritis Program; the latter is a unique Inter-Professional care program established to optimize outcomes for people who have arthritis and other rheumatic disorders. He is sought for his expertise in developing Outcome Based clinical Programs, not only in Arthritis Care, but also Shared Care in a Comprehensive Musculoskeletal Program, Wound Management and NeuroRehab/Stroke Care.

He is active in Clinical Research as Principal Investigator with The Arthritis Program Research Group Inc. As part of a strategic interest in identifying ‘Best Practices’, he has established an Early Arthritis Clinic, collaborating with a national initiative, CATCH -of which he is a member of the Scientific Advisory Committee and Operations Director, and an Osteoporosis Intervention Clinic. He sits on the Steering and Scientific Committee of the Ontario Best Practices Research Initiative, a collaborative attempt among stakeholders to describe and disseminate outcomes and best practices, in the management of Rheumatoid Arthritis. He was an active Investigator and participant in the successful Canadian Rheumatology Research Consortium and served as Secretary-Treasurer, until its conclusion in 2014. He is a founding member of the Ontario Rheumatology Association and Past-President (2006-10). He is past President of the Canadian Rheumatology Association (2012-2014) and past Secretary-Treasurer (1996-2004). He is past Secretary-Treasurer of PANLAR, and has served on the Steering Committee of CARE, a European-based group interested in the non-pharmacologic management of arthritis. He was a member of the Rehab Committee of the American College of Rheumatology 2003-09 and served as Chair pf the Committee, till its dissolution.

He has been involved in improving care for those with arthritis through the above initiatives, and his work with CRA and ORA, in Best Practices identification and dissemination strategies, and development of Models of Care frameworks (ORA); and improving the health of the community, as a past member of the York Region District Health Council (DHC) and past-Chair of the amalgamated Simcoe-York DHC. Since the recent cancellation of TAP by Southlake, he has become energized in the establishment of a Not-for-Profit organization (Centre of Arthritis Excellence - CArE) to develop a community-based MSK program, the first of its kind supported by the Ontario Ministry of Health, as a Portal of MSK Care, utilizing an Inter-Professional MoC, opening September 2022.

Dr. Thorne has been recognized by his colleagues and peers, with the ORA Distinguished Rheumatologist Award (2010), the CRA Distinguished Rheumatologist Award (2015), and the Queen Elizabeth II Diamond Jubilee Medal (2012), and has been recognized as a Master of the American College of Rheumatology (2016), in Washington DC. And awarded Master CRA in

Episode Learning Objectives

In this podcast episode, we will explore the value of Real-World Evidence (RWE) in biosimilars for daily clinical practice decisions. Our discussion will be divided into two parts: the first part will focus on RWE, and the second part will center on the biosimilar switch experience.

By the end of this episode, listeners should be able to:

• Understand the concept of Real-World Evidence (RWE) in the biosimilar space and its significance for healthcare professionals.
• Recognize the benefits and advantages of RWE, such as switch data and varying patient demographics.
• Analyze the impact of RWE on therapeutic decision-making for inflammatory joint management.
• Differentiate between various types of RWE in the biosimilar space (e.g., registry CATCH cohort, data based on patient records, health economic research) and evaluate their credibility and methodology.
• Discuss the future of TNFA-i and RWE in clinical practice.
• Identify factors to consider when differentiating between biosimilars during a switch.
• Address potential pain points during the biosimilar switch process, such as managing patient expectations, mitigating the nocebo effect, and navigating access.
• Share insights and strategies for healthcare professionals to approach the biosimilar switch process effectively in their clinic and practice workflow

View Details

🔊🎧 DR.GOODERHAM AND DR.YADAV ARE BACK! BRACE YOUR EARS FOR #ROUND 2 PART 2 🎧🔊

💡💼🌐 Prepare for an enlightening dive as we continue to explore the intricacies of roflumilast NOW AVAILABLE! The last mini series sparked many questions from our HCP listeners.

🎧🔊 In PART 2, we delve into real-life scenarios from our dermatologist's dynamic-duo's perspective, discussing the management of patients with moderate AD and the trade-offs between cost, efficacy, and tolerability.

🎧🔊We then deep-dive on patient reported outcomes (PROs) and the tolerability of topical roflumilast. Listeners will gain insights into how both patients and investigators rated the tolerability, offering an intriguing perspective on the alignment of these ratings.

🩺🌊This episode also touches on the #real-world application of this therapy, its potential to increase adherence, and the implications for treatment outcomes. We finally question the generalizability of the trial results across different patient populations.

💡💼🌐Join us for this enlightening conversation that bridges the gap between clinical trials and practical frontline practice, and deepens our understanding of roflumilast in the AD armamentarium.

🗓️👂So, mark your calendars, grab your favorite beverage, and tune in!

SkinAndJointsPodcast #Dermatology #Psoriasis #Roflumilast #Healthcare #StayTuned #Podcast #Medicine #SkinHealth #PSO #PDE4inhibitor #innovationmattersOnly on the Skin and Joints Podcast !

SkinAndJointsPodcast #Dermatology #Psoriasis #Roflumilast #Healthcare #StayTuned #Podcast #Medicine #SkinHealth #PSO #PDE4inhibitor #innovationmatters

Only on the Skin and Joints Podcast !

▶️Episode supported by Arcutis.

ABOUT Dr.Melinda Gooderham, MD, FRCPC ( Dermatology)

Toronto, ON

Melinda Gooderham MD MSc FRCPC Dr. Gooderham is a Dermatologist and Medical Director at the SKiN Centre for Dermatology and an Investigator with Probity Medical Research. She is an Assistant Professor at Queens University and a Consultant Physician at the Peterborough Regional Health Centre. She is a fellow of the Royal College of Physicians and Surgeons of Canada.

Dr. Gooderham has been the principal investigator for over 200 clinical trials and she practices with a focus on inflammatory diseases of the skin. She also contributes to several peer-reviewed dermatology publications as an associate editor, reviewer, and has been an author of 205 articles. She enjoys lecturing to global audiences on new therapies for skin diseases.

ABOUT Dr. Geeta Yadav, MSc, MD, FRCPC ( Dermatology)

Toronto, ON

Dr. Geeta Yadav is an expert in both medical and cosmetic dermatology and founder of FACET Dermatology in Toronto. . A second-generation Canadian, her interest in under-serviced communities and treating BIPOC patients was inspired by her childhood travels to India. She holds a master’s degree in International Health from Johns Hopkins and completed her dermatology training at the University of Toronto, where she still teaches today. Dr. Yadav is a fellow of the Royal College of Physicians and Surgeons, the American Academy of Dermatology, and the European Academy of Dermatology and Venereology. She has a special interest in skin of color and has been quoted in numerous main stream publications including the New York Times, Wall Street Journal, Allure, Vanity Fair and Cosmopolitan.

When she’s not working, she volunteers as an Alumni Governor at the University of Toronto. She also loves running, dancing, and spending time with her husband and three young children.

▶️Episode supported by Arcutis.

View Details

🎙️🌟 𝘽𝙞𝙤𝙨𝙞𝙢𝙞-𝙇𝙖𝙪𝙣𝙘𝙝: 𝘼 𝙏𝙖𝙡𝙚 𝙤𝙛 𝙎𝙠𝙞𝙣, 𝙅𝙤𝙞𝙣𝙩𝙨 𝙖𝙣𝙙 𝘽𝙤𝙡𝙙 𝘽𝙚𝙜𝙞𝙣𝙣𝙞𝙣𝙜𝙨! 🌟🎙️

🚀#𝗢𝗻𝘁𝗮𝗿𝗶𝗼 𝗵𝗮𝘀 𝘁𝗮𝗸𝗲𝗻 𝗮 𝗺𝗮𝗷𝗼𝗿 𝘀𝘁𝗲𝗽 𝗳𝗼𝗿𝘄𝗮𝗿𝗱 𝗶𝗻 𝘁𝗵𝗲 𝘄𝗼𝗿𝗹𝗱 𝗼𝗳 #𝗯𝗶𝗼𝘀𝗶𝗺𝗶𝗹𝗮𝗿 𝘁𝗵𝗲𝗿𝗮𝗽𝗶𝗲𝘀 𝘄𝗶𝘁𝗵 𝘁𝗵𝗲 𝘀𝘁𝗮𝗿𝘁 𝗼𝗳 𝘁𝗵𝗲𝗶𝗿 𝘁𝗿𝗮𝗻𝘀𝗶𝘁𝗶𝗼𝗻 𝗽𝗲𝗿𝗶𝗼𝗱 & 𝘄𝗲'𝘃𝗲 𝗴𝗼𝘁 𝘁𝗵𝗲 𝗶𝗻𝘀𝗶𝗱𝗲 𝘀𝗰𝗼𝗼𝗽!

𝗢𝗻𝘁𝗮𝗿𝗶𝗼 𝗯𝗮𝘀𝗲𝗱 #rheumatologist, 𝗗𝗿.Carter Thorne 𝗹𝗼𝗼𝗸s 𝗶𝗻𝘁𝗼 𝘁𝗵𝗲 𝗳𝗮𝘀𝗰𝗶𝗻𝗮𝘁𝗶𝗻𝗴 𝘄𝗼𝗿𝗹𝗱 𝗼𝗳 𝗿𝗲𝗮𝗹-𝘄𝗼𝗿𝗹𝗱 𝗲𝘃𝗶𝗱𝗲𝗻𝗰𝗲 (RWE) 𝗳𝗼𝗿 𝗯𝗶𝗼𝘀𝗶𝗺𝗶𝗹𝗮𝗿 𝘁𝗵𝗲𝗿𝗮𝗽𝗶𝗲𝘀💉🔍𝗲𝗺𝗲𝗿𝗴𝗶𝗻𝗴 𝗥𝗪𝗘 transition 𝗱𝗮𝘁𝗮 𝘁𝗿𝗲𝗻𝗱𝘀, 𝗮𝗻𝗱 𝘁𝗵𝗲 𝘃𝗮𝗹𝘂𝗲 𝗶𝘁 𝗰𝗮𝗻 𝗵𝗮𝘃𝗲 𝗼𝗻 𝗷𝗼𝗶𝗻𝘁 & 𝘀𝗸𝗶𝗻 𝘁𝗿𝗲𝗮𝘁𝗺𝗲𝗻𝘁 𝗺𝗮𝗻𝗮𝗴𝗲𝗺𝗲𝗻𝘁 𝗱𝗲𝗰𝗶𝘀𝗶𝗼𝗻𝘀! 💪🤓
𝗙𝗶𝗻𝗱 𝗼𝘂𝘁 𝗵𝗼𝘄 𝘁𝗼 𝗯𝗲 𝗮 #𝗯𝗶𝗼𝘀𝗶𝗺𝗶𝗹𝗮𝗿 wizard 💼🏆 𝘄𝗶𝘁𝗵 𝗼𝘂𝗿 𝗲𝘀𝘀𝗲𝗻𝘁𝗶𝗮𝗹 𝗴𝘂𝗶𝗱𝗲 𝘁𝗼 𝗻𝗮𝘃𝗶𝗴𝗮𝘁𝗶𝗻𝗴 𝘁𝗵𝗶𝘀 𝗻𝗲𝘄 𝘁𝗲𝗿𝗿𝗮𝗶𝗻 𝗶𝗻 𝘆𝗼𝘂𝗿 𝗱𝗮𝘆-𝘁𝗼-𝗱𝗮𝘆 𝗽𝗿𝗮𝗰𝘁𝗶𝗰𝗲 🗺️👩‍⚕️👨‍⚕️

👨‍⚕️Dr.Thorne 𝙞𝙨 𝙞𝙣𝙫𝙤𝙡𝙫𝙚𝙙 𝙞𝙣 𝘾𝘼𝙏𝘾𝙃 (𝘾𝙖𝙣𝙖𝙙𝙞𝙖𝙣 𝙀𝙖𝙧𝙡𝙮 𝘼𝙧𝙩𝙝𝙧𝙞𝙩𝙞𝙨 𝘾𝙤𝙝𝙤𝙧𝙩), 𝙊𝘽𝙍𝙄 (𝙊𝙣𝙩𝙖𝙧𝙞𝙤 𝘽𝙚𝙨𝙩 𝙋𝙧𝙖𝙘𝙩𝙞𝙘𝙚𝙨 𝙍𝙚𝙨𝙚𝙖𝙧𝙘𝙝 𝙄𝙣𝙞𝙩𝙞𝙖𝙩𝙞𝙫𝙚) 𝙖𝙣𝙙 𝙖𝙩 𝙡𝙤𝙘𝙖𝙡, 𝙥𝙧𝙤𝙫𝙞𝙣𝙘𝙞𝙖𝙡 𝙖𝙣𝙙 𝙣𝙖𝙩𝙞𝙤𝙣𝙖𝙡 𝙢𝙤𝙙𝙚𝙡𝙨 𝙤𝙛 𝙘𝙖𝙧𝙚 𝙞𝙣𝙞𝙩𝙞𝙖𝙩𝙞𝙫𝙚𝙨.

🎧 🎉Dr. Thorne is an Assistant Professor at the University of Toronto, and is on the Consultant Staff at Southlake Regional Health Centre in Newmarket, Ontario where he was Chief of the Division of Rheumatology and Director of The Arthritis Program; the latter is a unique Inter-Professional care program established to optimize outcomes for people who have arthritis and other rheumatic disorders. He is sought for his expertise in developing Outcome Based clinical Programs, not only in Arthritis Care, but also Shared Care in a Comprehensive Musculoskeletal Program, Wound Management and NeuroRehab/Stroke Care.

He is active in Clinical Research as Principal Investigator with The Arthritis Program Research Group Inc. As part of a strategic interest in identifying ‘Best Practices’, he has established an Early Arthritis Clinic, collaborating with a national initiative, CATCH of which he is a member of the Scientific Advisory Committee and Operations Director, and an Osteoporosis Intervention Clinic. He sits on the Steering and Scientific Committee of the Ontario Best Practices Research Initiative, a collaborative attempt among stakeholders to describe and disseminate outcomes and best practices, in the management of Rheumatoid Arthritis. He was an active Investigator and participant in the successful Canadian Rheumatology Research Consortium and served as Secretary-Treasurer, until its conclusion in 2014. He is a founding member of the Ontario Rheumatology Association and Past-President (2006-10). He is past President of the Canadian Rheumatology Association (2012-2014) and past Secretary-Treasurer (1996-2004). He is past Secretary-Treasurer of PANLAR, and has served on the Steering Committee of CARE, a European-based group interested in the non-pharmacologic management of arthritis. He was a member of the Rehab Committee of the American College of Rheumatology 2003-09 and served as Chair pf the Committee, till its dissolution.

He has been involved in improving care for those with arthritis through the above initiatives, and his work with CRA and ORA, in Best Practices identification and dissemination strategies, and development of Models of Care frameworks (ORA); and improving the health of the community, as a past member of the York Region District Health Council (DHC) and past-Chair of the amalgamated Simcoe-York DHC. Since the recent cancellation of TAP by Southlake, he has become energized in the establishment of a Not-for-Profit organization (Centre of Arthritis Excellence - CArE) to develop a community-based MSK program, the first of its kind supported by the Ontario Ministry of Health, as a Portal of MSK Care, utilizing an Inter-Professional MoC, opening September 2022.

Dr. Thorne has been recognized by his colleagues and peers, with the ORA Distinguished Rheumatologist Award (2010), the CRA Distinguished Rheumatologist Award (2015), and the Queen Elizabeth II Diamond Jubilee Medal (2012), and has been recognized as a Master of the American College of Rheumatology (2016), in Washington DC.

Episode Learning Objectives

In this podcast episode, we will explore the value of Real-World Evidence (RWE) in biosimilars for daily clinical practice decisions. Our discussion will be divided into two parts: the first part will focus on RWE, and the second part will center on the biosimilar switch experience.

By the end of this episode, listeners should be able to:

• Understand the concept of Real-World Evidence (RWE) in the biosimilar space and its significance for healthcare professionals.
• Recognize the benefits and advantages of RWE, such as switch data and varying patient demographics.
• Analyze the impact of RWE on therapeutic decision-making for inflammatory joint management.
• Differentiate between various types of RWE in the biosimilar space (e.g., registry CATCH cohort, data based on patient records, health economic research) and evaluate their credibility and methodology.
• Discuss the future of TNFA-i and RWE in clinical practice.
• Identify factors to consider when differentiating between biosimilars during a switch.
• Address potential pain points during the biosimilar switch process, such as managing patient expectations, mitigating the nocebo effect, and navigating access.
• Share insights and strategies for healthcare professionals to approach the biosimilar switch process effectively in their clinic and practice workflow

View Details

🔊🎧 DR.GOODERHAM AND DR.YADAV ARE BACK! BRACE YOUR EARS FOR #ROUND 2 🎧🔊

💡💼🌐 Prepare for an enlightening dive as we continue to explore the intricacies of roflumilast NOW AVAILABLE! The last mini series sparked many questions from our HCP listeners and this is where we try to answer including - what happens when topical roflumilast interacts with systemic CYP3A4, such as oral contraceptives that contain estradiol?

Does this co-administration lead to an increased systemic exposure and more adverse events?

🎧🔊 Moreover, we tackle the practical aspects of this conversation, providing actionable insights that will help guide you in your decisions.

🎧We delve firsthand about the implications between investigators' and patients' perspectives.

🩺🌊Lastly-how would you consider using roflumilast for psoriasis on uncommon sites such as the scalp, palms, or soles, given that these areas were not included in the trial primary analysis?

💡💼🌐This episode promises to be a comprehensive exploration of roflumilast, providing practical points and illuminating hidden facets to guide your confidence in it's real world usage.

🗓️👂So, mark your calendars, grab your favorite beverage, and tune in!

SkinAndJointsPodcast #Dermatology #Psoriasis #Roflumilast #Healthcare #StayTuned #Podcast #Medicine #SkinHealth #PSO #PDE4inhibitor #innovationmattersOnly on the Skin and Joints Podcast !

SkinAndJointsPodcast #Dermatology #Psoriasis #Roflumilast #Healthcare #StayTuned #Podcast #Medicine #SkinHealth #PSO #PDE4inhibitor #innovationmatters

Only on the Skin and Joints Podcast !

▶️Episode supported by Arcutis.

ABOUT Dr.Melinda Gooderham, MD, FRCPC ( Dermatology)

Toronto, ON

Melinda Gooderham MD MSc FRCPC Dr. Gooderham is a Dermatologist and Medical Director at the SKiN Centre for Dermatology and an Investigator with Probity Medical Research. She is an Assistant Professor at Queens University and a Consultant Physician at the Peterborough Regional Health Centre. She is a fellow of the Royal College of Physicians and Surgeons of Canada.

Dr. Gooderham has been the principal investigator for over 200 clinical trials and she practices with a focus on inflammatory diseases of the skin. She also contributes to several peer-reviewed dermatology publications as an associate editor, reviewer, and has been an author of 205 articles. She enjoys lecturing to global audiences on new therapies for skin diseases.

ABOUT Dr. Geeta Yadav, MSc, MD, FRCPC ( Dermatology)

Toronto, ON

Dr. Geeta Yadav is an expert in both medical and cosmetic dermatology and founder of FACET Dermatology in Toronto. . A second-generation Canadian, her interest in under-serviced communities and treating BIPOC patients was inspired by her childhood travels to India. She holds a master’s degree in International Health from Johns Hopkins and completed her dermatology training at the University of Toronto, where she still teaches today. Dr. Yadav is a fellow of the Royal College of Physicians and Surgeons, the American Academy of Dermatology, and the European Academy of Dermatology and Venereology. She has a special interest in skin of color and has been quoted in numerous main stream publications including the New York Times, Wall Street Journal, Allure, Vanity Fair and Cosmopolitan.

When she’s not working, she volunteers as an Alumni Governor at the University of Toronto. She also loves running, dancing, and spending time with her husband and three young children.

▶️Episode supported by Arcutis.

View Details

🎧 🎉🎙️ Breaking Ground: A Co-Managed Approach to Psoriatic Arthritis - Real World Insights from Dr. Jan Dutz and Dr. Jonathan Chan PART 2

🎙️ Tune in to learn how real-world validated tools can revolutionize psoriatic arthritis management, and the potential for enduring change within the dermatology community in PART 2.

🎧 🎉The discussion takes a significant turn as we delve into the complexities that emerge in treatment strategies, especially in the gap between patient referrals and confirmations of diagnosis. The challenge of masking symptoms and determining the right treatment pathway is examined, stressing the importance of understanding both skin and joint conditions in these patients.

🧵Join us for a dive with eminent psoriatic arthritis experts, Dr. Jan Dutz and Dr. Jonathan Chan. Their unique real-world model of care has caught the attention of our listeners, and in this episode, we finally unravel the inner workings of their combined dermatology and rheumatology clinic.

🫳After countless requests, we've garnered insights into how they run their clinic, how they manage their team, and if this model is sustainable? But that's not all.

🛎️Our dynamic derm-rheum tag team outline compare the practical utility of three different screening tools, in over 50 dermatologists' offices nationwide. Before participating in the project, some dermatologists expressed reservations regarding the perceived time-consuming nature of these tools, the potential for low yield in their population, and a general lack of habitual use or reminders.

• Is this model scalable? What potential barriers stand in its way?
• And we delve into the intricacies of PSA screening tools – where's the optimal place for deployment? Where can they make the most impact?

🎙️🎙️Looking Forward: A critical question remains whether this change is short-term or will translate into long-term behavioral change?

Warm up those ear phones for PART 2!

Exclusive to the Skin and Joints Podcast.

Episode supported by Novartis.

View Details

🎧 🎉🎙️ Breaking Ground: A Co-Managed Approach to Psoriatic Arthritis - Real World Insights from Dr. Jan Dutz and Dr. Jonathan Chan PART 1

🎧 🎉We're excited to bring you a first-hand look at a unique model of care that's transforming the lives of psoriatic arthritis patients.

🧵Join us for a dive with eminent psoriatic arthritis experts, Dr. Jan Dutz and Dr. Jonathan Chan. Their unique real-world model of care has caught the attention of our listeners, and in this episode, we finally unravel the inner workings of their combined dermatology and rheumatology clinic.

🫳After countless requests, we've garnered insights into how they run their clinic, how they manage their team, and if this model is sustainable? But that's not all.

🛎️Be the first to hear the exclusive findings from a trailblazing real world study that the collaboration of over 50 dermatologists. The focus? The real world use of PsA screening tools and the early detection of psoriatic arthritis that has the potential to revolutionize psoriatic arthritis detection in clinic.

🛎️This episode is an extension of our conversation with Dr. Dutz from last year, where he unveiled the concept of their model and discussed the validated tools used within their practice. Now, they've turned concept into reality, and we're here to unpack it all.

• Is this model scalable? What potential barriers stand in its way?
• And we delve into the intricacies of PSA screening tools – where's the optimal place for deployment? Where can they make the most impact?

🎙️🎙️This episode is more than just a conversation - it's a paradigm shift in the treatment of psoriatic disease and psoriatic arthritis.

🎙️🎙️Get ready for a world-exclusive reveal as we break the results of this ground-breaking real world study right here on our podcast for the first time.

Episode supported by Novartis.

View Details

🔊🎧 BRACE YOUR EARS FOR #ROUND 2 🎧🔊

💡💼🌐 We're thrilled to announce the Skin and Joints Podcast back on the airwaves this week with dynamic #dermatology duo, Dr.Melinda Gooderham and Dr.Geeta Yadav for round 2! 🩺

🌊💡Join us as we sail the "#Psoriasis Sea" as we navigate what you need to know #roflumilast's long-term performance.

🎧Not only are we dropping anchor to delve into what you need to know about its #side effects, but we're also setting up the lighthouse to guide you through their manageability

🧑‍🦱🧭We've got the lifeboat you need: our experts will peel back the layers and offer insights into the #topical cream's effectiveness in #plaquePsO #skin #clearance and #itch #reduction. So, if you've been scratching your head 🧑‍🦱 over #psoriasis, it's time to stop!

𝙀𝙫𝙤𝙡𝙪𝙩𝙞𝙤𝙣? 𝙊𝙧 𝙥𝙤𝙨𝙨𝙞𝙗𝙡𝙮 #𝙧𝙚𝙫𝙤𝙡𝙪𝙩𝙞𝙤𝙣 𝙞𝙣 the way we treat #𝙋𝙨𝙤𝙧𝙞𝙖𝙨𝙞𝙨?

🧐🔬🦠 Dr.Geeta Yadav and Dr. Melinda Gooderham are 𝘀𝗼𝗼𝗻 𝗴𝗼𝗶𝗻𝗴 𝘁𝗼 𝘀𝗽𝗶𝗹𝗹 𝘁𝗵𝗲 𝗯𝗲𝗮𝗻𝘀 𝗼𝗻 𝘄𝗵𝗲𝗿𝗲 𝘁𝗵𝗲𝘆 𝘀𝗲𝗲 𝘁𝗵𝗶𝘀 𝗻𝗲𝘄 𝘁𝗵𝗲𝗿𝗮𝗽𝘆'𝘀 𝗽𝗼𝘁𝗲𝗻𝘁𝗶𝗮𝗹 𝗶𝗻 𝗺𝗮𝗸𝗶𝗻𝗴 𝗮 𝗱𝗶𝗳𝗳𝗲𝗿𝗲𝗻𝗰𝗲 𝗳𝗼𝗿 𝗼𝘂𝗿 #𝗽𝗹𝗮𝗾𝘂𝗲𝗣𝘀𝗢 𝗽𝗮𝘁𝗶𝗲𝗻𝘁𝘀

⛵🧭Get ready to set sail with us. This is a conversation that's more than just skin-deep! 🗓️👂

SkinAndJointsPodcast #Dermatology #Psoriasis #Roflumilast #Healthcare #StayTuned #Podcast #Medicine #SkinHealth #PSO #PDE4inhibitor #innovationmatters

Only on the Skin and Joints Podcast !

ABOUT Dr.Melinda Gooderham, MD, FRCPC ( Dermatology)

Toronto, ON

Melinda Gooderham MD MSc FRCPC Dr. Gooderham is a Dermatologist and Medical Director at the SKiN Centre for Dermatology and an Investigator with Probity Medical Research. She is an Assistant Professor at Queens University and a Consultant Physician at the Peterborough Regional Health Centre. She is a fellow of the Royal College of Physicians and Surgeons of Canada.

Dr. Gooderham has been the principal investigator for over 200 clinical trials and she practices with a focus on inflammatory diseases of the skin. She also contributes to several peer-reviewed dermatology publications as an associate editor, reviewer, and has been an author of 205 articles. She enjoys lecturing to global audiences on new therapies for skin diseases.

ABOUT Dr. Geeta Yadav, MSc, MD, FRCPC ( Dermatology)

Toronto, ON

Dr. Geeta Yadav is an expert in both medical and cosmetic dermatology and founder of FACET Dermatology in Toronto. . A second-generation Canadian, her interest in under-serviced communities and treating BIPOC patients was inspired by her childhood travels to India. She holds a master’s degree in International Health from Johns Hopkins and completed her dermatology training at the University of Toronto, where she still teaches today. Dr. Yadav is a fellow of the Royal College of Physicians and Surgeons, the American Academy of Dermatology, and the European Academy of Dermatology and Venereology. She has a special interest in skin of color and has been quoted in numerous main stream publications including the New York Times, Wall Street Journal, Allure, Vanity Fair and Cosmopolitan.

When she’s not working, she volunteers as an Alumni Governor at the University of Toronto. She also loves running, dancing, and spending time with her husband and three young children.

▶️Episode supported by Arcutis.

View Details

🔔 🔔 🔔 𝗪𝗲'𝗿𝗲 𝘁𝗵𝗿𝗶𝗹𝗹𝗲𝗱 𝘁𝗼 𝗮𝗻𝗻𝗼𝘂𝗻𝗰𝗲 𝘁𝗵𝗲 𝗮𝗿𝗿𝗶𝘃𝗮𝗹 𝗼𝗳 𝗼𝘂𝗿 𝘁𝗮𝗴-𝘁𝗲𝗮𝗺 #𝗱𝘆𝗻𝗮𝗺𝗶𝗰 #𝗱𝗲𝗿𝗺𝗮𝘁𝗼𝗹𝗼𝗴𝗶𝘀𝘁 𝗱𝘂𝗼, Dr.Melinda Gooderham 𝗮𝗻𝗱 Dr. Geeta Yadav as Skin and Joints Podcast 𝗙𝗮𝗰𝘂𝗹𝘁𝘆!

🟢⏰ The clock is ticking, and the #skincare world is listening, keeping an eye on a new #nonsteroidal topical! A potential breakthrough for millions of patients with #psoriasis. 💪

🌋💁‍♀️Because we're not just talking a subtle shift here. We're talking about a seismic shift in #dermatology! A game-changer? A standard-setter?

🐎But hold your horses! Is this merely an #evolution? Or could it possibly be a #revolution, a turning point that will rewrite the way we approach #Psoriasis treatments?

🧐🔬🦠Hang in there, guys. 🏄‍♀️ Dr.Geeta Yadav and Dr.Melinda Gooderham are going to spill the beans on where they see this new therapy's potential in making a difference for our #plaquePsO patients.

🗣️𝗦𝘁𝗮𝘆 𝘁𝘂𝗻𝗲𝗱 𝗮𝘀 𝗠𝗲𝗹𝗶𝗻𝗱𝗮 𝗮𝗻𝗱 𝗚𝗲𝗲𝘁𝗮 𝘀𝗵𝗮𝗿𝗲 𝘄𝗵𝗲𝗿𝗲 𝘁𝗵𝗲𝘆 𝗽𝗲𝗿𝘀𝗼𝗻𝗮𝗹𝗹𝘆 𝘀𝗲𝗲 𝗶𝘁’𝘀 𝗰𝘂𝗿𝗿𝗲𝗻𝘁 𝗿𝗼𝗹𝗲 𝗮𝘀 𝗮 𝘁𝗵𝗲𝗿𝗮𝗽𝘆 𝗳𝗼𝗿 𝗽𝗮𝘁𝗶𝗲𝗻𝘁𝘀 𝘄𝗶𝘁𝗵 #plaque #𝗣𝘀𝗢

Only on the Skin and Joints Podcast !

🧪 #Dermatology#PsoriasisTreatment#nonsteroidal#roflumilast

ABOUT Dr.Melinda Gooderham, MD, FRCPC ( Dermatology)

Toronto, ON

Melinda Gooderham MD MSc FRCPC Dr. Gooderham is a Dermatologist and Medical Director at the SKiN Centre for Dermatology and an Investigator with Probity Medical Research. She is an Assistant Professor at Queens University and a Consultant Physician at the Peterborough Regional Health Centre. She is a fellow of the Royal College of Physicians and Surgeons of Canada.

Dr. Gooderham has been the principal investigator for over 200 clinical trials and she practices with a focus on inflammatory diseases of the skin. She also contributes to several peer-reviewed dermatology publications as an associate editor, reviewer, and has been an author of 205 articles. She enjoys lecturing to global audiences on new therapies for skin diseases.

ABOUT Dr. Geeta Yadav, MSc, MD, FRCPC ( Dermatology)

Toronto, ON

Dr. Geeta Yadav is an expert in both medical and cosmetic dermatology and founder of FACET Dermatology in Toronto. . A second-generation Canadian, her interest in under-serviced communities and treating BIPOC patients was inspired by her childhood travels to India. She holds a master’s degree in International Health from Johns Hopkins and completed her dermatology training at the University of Toronto, where she still teaches today. Dr. Yadav is a fellow of the Royal College of Physicians and Surgeons, the American Academy of Dermatology, and the European Academy of Dermatology and Venereology. She has a special interest in skin of color and has been quoted in numerous main stream publications including the New York Times, Wall Street Journal, Allure, Vanity Fair and Cosmopolitan.

When she’s not working, she volunteers as an Alumni Governor at the University of Toronto. She also loves running, dancing, and spending time with her husband and three young children.

▶️Episode supported by Arcutis.

View Details

🎧 🎉TYK-TOK we’re ready to rock PART 2!

🎙️🎙️ The Skin and Joints Podcast Team continues the conversation with dermatologist dynamic duo Dr.Chih-Ho Hong and Dr.Irina Turchin who respectively lend their real world perspectives on a brand new oral therapy for our patients with moderate to severe psoriasis.

🛎️ Deucravacitinib is finally here! And we're going to be looking at fresh new data that could change your clinical practice. We also break it down with our expert Faculty so you don't need to :)

🧵Where do our experts see the overall place deucravacitinib in the therapeutic treatment pathway for moderate to severe psoriasis in the real world?

🧵How does it compare with other biologics and non-biologic treatments?

🫳 How effective is it for patients specifically with moderate to severe scalp, nail and palmoplantar psoriasis?

Episode Learning Objectives

• Describe the overall place of deucravacitinib in the therapeutic treatment pathway for moderate to severe psoriasis in the real world
• Examine the clinical efficacy associated with deucravacitinib and other select biologic and nonbiologic treatments in patients with moderate to severe PsO
• Explore the correlations between responses on clinical and patient reported outcome (PRO) measures from pooled data from POETYK PSO-1 and PSO-2 pivotal trials
• Evaluate the efficacy of deucravacitinib treatment in patients with moderate to severe scalp, nail, and palmoplantar psoriasis subgroup analyses pooled PSO-1 and PSO-2 data

View Details

🎧 🎉TYK-TOK we’re ready to rock.

🎙️🎙️ The Skin and Joints Podcast Team is starting 2023 off strong with dermatologist dynamic duo Dr.Chih-Ho Hong and Dr.Irina Turchin who respectively lend their real world perspectives on a brand new oral therapy for our patients with moderate to severe psoriasis.

🛎️ Deucravacitinib is finally here! And we're going to be looking at. some fresh new data that could change your clinical practice.

🧵How does it compare with other biologics and non-biologic treatments?

🫳 How effective is it for patients specifically with moderate to severe scalp, nail and palmoplantar psoriasis?

Episode Learning Objectives

• Apply current evidence as well as shared decision-making to individualize therapy decisions for patients with moderate to severe plaque psoriasis; specifically deucravacitinib, a novel oral TYK2 inhibitor
• Examine the clinical efficacy associated with deucravacitinib and other select biologic and nonbiologic treatments in patients with moderate to severe PsO
• Explore the correlations between responses on clinical and PRO measures in pooled data from POETYK PSO-1 and PSO-2
• Evaluate the efficacy of deucravacitinib treatment in patients with moderate to severe scalp, nail, and palmoplantar psoriasis subgroup analyses pooled PSO-1 and PSO-2 data

View Details

🔥🎙️Welcome to 𝗣𝗔𝗥𝗧 2 𝗼𝗳 𝗪𝗵𝗮𝘁'𝘀 𝗡𝗲𝘄 𝗶𝗻 #𝗛𝗶𝗱𝗿𝗮𝗱𝗲𝗻𝗶𝘁𝗶𝘀 #𝗦𝘂𝗽𝗽𝘂𝗿𝗮𝘁𝗶𝘃𝗮 𝘄𝗶𝘁𝗵 #dermatologist tag-team duo 𝗗𝗿.𝗟𝗮𝘂𝗿𝗲𝗻 𝗟𝗮𝗺 𝗮𝗻𝗱 𝗗𝗿.𝗦𝘂𝘀𝗮𝗻 𝗣𝗼𝗲𝗹𝗺𝗮𝗻

Did you know that on average, literature has demonstrated that patients go undiagnosed for 8 years and see 5 physicians over 17 visits before receiving a proper HS diagnosis?

💡💡 #𝐃𝐞𝐫𝐦𝐚𝐭𝐨𝐥𝐨𝐠𝐢𝐬𝐭𝐬 𝐚𝐥𝐬𝐨 𝐚𝐫𝐞 𝐚𝐰𝐚𝐫𝐞 𝐭𝐡𝐚𝐭 𝐭𝐡𝐞𝐫𝐞 𝐚𝐫𝐞𝐧’𝐭 𝐫𝐞𝐚𝐥𝐥𝐲 𝐦𝐚𝐧𝐲 𝐞𝐟𝐟𝐞𝐜𝐭𝐢𝐯𝐞 𝐭𝐫𝐞𝐚𝐭𝐦𝐞𝐧𝐭 𝐨𝐩𝐭𝐢𝐨𝐧𝐬 𝐨𝐫 𝐜𝐡𝐨𝐢𝐜𝐞𝐬 𝐭𝐨 𝐩𝐢𝐜𝐤 𝐟𝐫𝐨𝐦.

🎙️🎙️🎙️ 𝐖𝐞 𝐚𝐫𝐞 𝐬𝐮𝐩𝐞𝐫 𝐞𝐱𝐜𝐢𝐭𝐞𝐝 𝐭𝐨 𝐬𝐢𝐭 𝐝𝐨𝐰𝐧 𝐰𝐢𝐭𝐡 𝟐 𝐝𝐞𝐫𝐦𝐚𝐭𝐨𝐥𝐨𝐠𝐢𝐬𝐭 𝐇𝐒 𝐞𝐱𝐩𝐞𝐫𝐭𝐬, Dr.Lauren Lam and Dr.Susan Poelman, 𝐰𝐡𝐨 𝐧𝐨𝐭 𝐨𝐧𝐥𝐲 𝐬𝐡𝐚𝐫𝐞 𝐭𝐡𝐞𝐢𝐫 clinical 𝐬𝐞𝐜𝐫𝐞𝐭𝐬 𝐟𝐨𝐫 𝐇𝐒 𝐛𝐮𝐭 𝐚𝐥𝐬𝐨 𝐜𝐡𝐚𝐭 𝐚𝐛𝐨𝐮𝐭 𝐞𝐯𝐞𝐫𝐲𝐭𝐡𝐢𝐧𝐠 𝐲𝐨𝐮 𝐧𝐞𝐞𝐝 𝐭𝐨 𝐤𝐧𝐨𝐰 𝐚𝐛𝐨𝐮𝐭 𝐟𝐮𝐭𝐮𝐫𝐞 𝐭𝐫𝐞𝐚𝐭𝐦𝐞𝐧𝐭𝐬 𝐭𝐨𝐨𝐥𝐬 𝐭𝐡𝐚𝐭 𝐦𝐚𝐲 𝐛𝐞 𝐚 𝐩𝐚𝐫𝐭 𝐨𝐟 𝐲𝐨𝐮𝐫 𝐭𝐨𝐨𝐥𝐤𝐢𝐭

🟢 TIME STAMPS

01:33 SUNSHINE and SUNRISE: Findings from EADV

07:49 Managing Pain Associated with HS

10:14 QoL, DLQI and Secukinumab for HS

13:24 ASK THE EXPERT and the Dr.Poelman method for identifying patients with HS

19:28 Will this trial change the way dermatologists treat HS?

22:02 Post-Podcast Analysis

🟢 What's the latest data demonstrate around secukinumab as a new tool in the toolkit for managing patients with HS?

🎙️🤩 𝐀 𝐛𝐢𝐭 𝐨𝐟 𝐚 𝐞𝐮𝐫𝐞𝐤𝐚 𝐦𝐨𝐦𝐞𝐧𝐭 𝐨𝐧 𝐭𝐡𝐞 Skin and Joints Podcast 𝐚𝐬 𝐰𝐞 𝐡𝐞𝐚𝐫 𝐟𝐫𝐨𝐦 𝐃𝐫.𝐒𝐮𝐬𝐚𝐧 𝐏𝐨𝐞𝐥𝐦𝐚𝐧 𝐨𝐧 𝐡𝐞𝐫 #𝐬𝐞𝐜𝐫𝐞𝐭 𝐭𝐨 𝐝𝐢𝐚𝐠𝐧𝐨𝐬𝐢𝐧𝐠 #hidradenitis #suppurativa:

💭 𝙄𝙨 𝙞𝙩 𝙖𝙨 𝙨𝙞𝙢𝙥𝙡𝙚 𝙖𝙨 1-2-3?💭 𝙊𝙧 𝙢𝙖𝙮𝙗𝙚 2-4-6?

Did you know that one of our guest experts actually was in a Hollywood movie production?

Episode Learning Objectives

• Review the clinical presentation and patient impacts of hidradenitis suppurative (HS)
• Describe SUNSHINE and SUNRISE and what it means for frontline healthcare providers in the dermatology community
• Discuss the emerging treatment options for managing HS

ABOUT Dr. Lauren Lam BScH, MD, FRCPC Medical, Surgical & Cosmetic Dermatologist

Calgary,AB

Clinical Lecturer | Division of Dermatology, Department of Medicine | University of Alberta

Dr. Lam is a Canadian board-certified dermatologist. She completed her medical school training at the University of Calgary & her dermatology residency at the University of Alberta. Since graduating, Dr. Lam has become a Clinical Lecturer with the University of Alberta. Her particular passions in dermatology are acne & hidradenitis suppurativa deroofings.

In addition to her regular practice, she volunteers on overseas medical trips. Her passion for providing care for under-served populations has taken her to Nunavut & rural Fiji. Outside of medicine, Dr. Lam is a proud aunt to 4 dogs, culinary enthusiast & international explorer.

ABOUT Dr.Susan Poelman, MSc, MD, FRCP(C), FCDA

Calgary,AB

Dr. Poelman is a Canadian and U.S. board-certified Dermatologist specializing in medical, surgical and cosmetic dermatology. After getting a Master's degree in Cancer Biology and a Medical Degree from the University of Calgary, she went on to complete her dermatology residency at McGill University and the University of British Columbia. She has established a women's health clinic at Beacon Dermatology which includes treatment for acne, rosacea, vulvar (female genital) skin conditions, hidradenitis suppurativa, and cosmetic procedures.

She is very active on provincial, national and international committees and advisory boards and is currently Chair of the Pharmacy and Therapeutics Committee of the Canadian Dermatology Association and President of the Canadian Hidradenitis Suppurativa Foundation. She enjoys teaching and serves as a Clinical Assistant Professor at the University of Calgary Cumming School of Medicine. She lives just outside Calgary with her husband and three children and enjoys hiking, tennis and skating on her outdoor rink in her backyard in the winter.

▶️Episode supported by an educational Grant from NOVARTIS

View Details

💡💡💡 HS is a debilitating, and poorly understood condition sub optimally diagnosed, managed, and treated.

Did you know that on average, literature has demonstrated that patients go undiagnosed for 8 years and see 5 physicians over 17 visits before receiving a proper HS diagnosis?

💡💡 #𝐃𝐞𝐫𝐦𝐚𝐭𝐨𝐥𝐨𝐠𝐢𝐬𝐭𝐬 𝐚𝐥𝐬𝐨 𝐚𝐫𝐞 𝐚𝐰𝐚𝐫𝐞 𝐭𝐡𝐚𝐭 𝐭𝐡𝐞𝐫𝐞 𝐚𝐫𝐞𝐧’𝐭 𝐫𝐞𝐚𝐥𝐥𝐲 𝐦𝐚𝐧𝐲 𝐞𝐟𝐟𝐞𝐜𝐭𝐢𝐯𝐞 𝐭𝐫𝐞𝐚𝐭𝐦𝐞𝐧𝐭 𝐨𝐩𝐭𝐢𝐨𝐧𝐬 𝐨𝐫 𝐜𝐡𝐨𝐢𝐜𝐞𝐬 𝐭𝐨 𝐩𝐢𝐜𝐤 𝐟𝐫𝐨𝐦.

🎙️🎙️🎙️ 𝐖𝐞 𝐚𝐫𝐞 𝐬𝐮𝐩𝐞𝐫 𝐞𝐱𝐜𝐢𝐭𝐞𝐝 𝐭𝐨 𝐬𝐢𝐭 𝐝𝐨𝐰𝐧 𝐰𝐢𝐭𝐡 𝟐 𝐝𝐞𝐫𝐦𝐚𝐭𝐨𝐥𝐨𝐠𝐢𝐬𝐭 𝐇𝐒 𝐞𝐱𝐩𝐞𝐫𝐭𝐬, Dr.Lauren Lam and Dr.Susan Poelman, 𝐰𝐡𝐨 𝐧𝐨𝐭 𝐨𝐧𝐥𝐲 𝐬𝐡𝐚𝐫𝐞 𝐭𝐡𝐞𝐢𝐫 clinical 𝐬𝐞𝐜𝐫𝐞𝐭𝐬 𝐟𝐨𝐫 𝐇𝐒 𝐛𝐮𝐭 𝐚𝐥𝐬𝐨 𝐜𝐡𝐚𝐭 𝐚𝐛𝐨𝐮𝐭 𝐞𝐯𝐞𝐫𝐲𝐭𝐡𝐢𝐧𝐠 𝐲𝐨𝐮 𝐧𝐞𝐞𝐝 𝐭𝐨 𝐤𝐧𝐨𝐰 𝐚𝐛𝐨𝐮𝐭 𝐟𝐮𝐭𝐮𝐫𝐞 𝐭𝐫𝐞𝐚𝐭𝐦𝐞𝐧𝐭𝐬 𝐭𝐨𝐨𝐥𝐬 𝐭𝐡𝐚𝐭 𝐦𝐚𝐲 𝐛𝐞 𝐚 𝐩𝐚𝐫𝐭 𝐨𝐟 𝐲𝐨𝐮𝐫 𝐭𝐨𝐨𝐥𝐤𝐢𝐭

🟢 What's the latest data demonstrate around secukinumab as a new tool in the toolkit for managing patients with HS?

🟢 Is there a role for ultrasound for grading HS?

🎙️🤩 𝐀 𝐛𝐢𝐭 𝐨𝐟 𝐚 𝐞𝐮𝐫𝐞𝐤𝐚 𝐦𝐨𝐦𝐞𝐧𝐭 𝐨𝐧 𝐭𝐡𝐞 Skin and Joints Podcast 𝐚𝐬 𝐰𝐞 𝐡𝐞𝐚𝐫 𝐟𝐫𝐨𝐦 𝐃𝐫.𝐒𝐮𝐬𝐚𝐧 𝐏𝐨𝐞𝐥𝐦𝐚𝐧 𝐨𝐧 𝐡𝐞𝐫 #𝐬𝐞𝐜𝐫𝐞𝐭 𝐭𝐨 𝐝𝐢𝐚𝐠𝐧𝐨𝐬𝐢𝐧𝐠 #hidradenitis #suppurativa:

💭 𝙄𝙨 𝙞𝙩 𝙖𝙨 𝙨𝙞𝙢𝙥𝙡𝙚 𝙖𝙨 1-2-3?💭 𝙊𝙧 𝙢𝙖𝙮𝙗𝙚 2-4-6?

Did you know that one of our guest experts actually was in a Hollywood movie production?

Episode Learning Objectives

• Review the clinical presentation and patient impacts of hidradenitis suppurative (HS)
• Describe SUNSHINE and SUNRISE and what it means for frontline healthcare providers in the dermatology community
• Discuss the emerging treatment options for managing HS

ABOUT Dr. Lauren Lam BScH, MD, FRCPC Medical, Surgical & Cosmetic Dermatologist

Calgary,AB

Clinical Lecturer | Division of Dermatology, Department of Medicine | University of Alberta

Dr. Lam is a Canadian board-certified dermatologist. She completed her medical school training at the University of Calgary & her dermatology residency at the University of Alberta. Since graduating, Dr. Lam has become a Clinical Lecturer with the University of Alberta. Her particular passions in dermatology are acne & hidradenitis suppurativa deroofings.

In addition to her regular practice, she volunteers on overseas medical trips. Her passion for providing care for under-served populations has taken her to Nunavut & rural Fiji. Outside of medicine, Dr. Lam is a proud aunt to 4 dogs, culinary enthusiast & international explorer.

ABOUT Dr.Susan Poelman, MSc, MD, FRCP(C), FCDA

Calgary,AB

Dr. Poelman is a Canadian and U.S. board-certified Dermatologist specializing in medical, surgical and cosmetic dermatology. After getting a Master's degree in Cancer Biology and a Medical Degree from the University of Calgary, she went on to complete her dermatology residency at McGill University and the University of British Columbia. She has established a women's health clinic at Beacon Dermatology which includes treatment for acne, rosacea, vulvar (female genital) skin conditions, hidradenitis suppurativa, and cosmetic procedures.

She is very active on provincial, national and international committees and advisory boards and is currently Chair of the Pharmacy and Therapeutics Committee of the Canadian Dermatology Association and President of the Canadian Hidradenitis Suppurativa Foundation. She enjoys teaching and serves as a Clinical Assistant Professor at the University of Calgary Cumming School of Medicine. She lives just outside Calgary with her husband and three children and enjoys hiking, tennis and skating on her outdoor rink in her backyard in the winter.

▶️Episode supported by an educational Grant from NOVARTIS

View Details

🎙️🎙️ 📭 🎙️ 𝑾𝒆’𝒓𝒆 𝒆𝒙𝒄𝒊𝒕𝒆𝒅 𝒕𝒐 𝒔𝒉𝒂𝒓𝒆 𝒂 𝒇𝒊𝒓𝒔𝒕 𝒐𝒏 𝒕𝒉𝒆 Skin and Joints Podcast 𝒃𝒓𝒊𝒏𝒈𝒊𝒏𝒈 𝒕𝒐𝒈𝒆𝒕𝒉𝒆𝒓 𝒂 #𝒅𝒆𝒓𝒎𝒂𝒕𝒐𝒍𝒐𝒈𝒊𝒔𝒕 𝒂𝒏𝒅 𝒂 #𝒓𝒉𝒆𝒖𝒎𝒂𝒕𝒐𝒍𝒐𝒈𝒊𝒔𝒕 𝒕𝒐 𝒅𝒖𝒌𝒆 𝒊𝒕 𝒐𝒖𝒕 𝒐𝒏 𝒂𝒏 𝒆𝒑𝒊𝒔𝒐𝒅𝒆.

𝗢𝗻𝘁𝗮𝗿𝗶𝗼 𝗵𝗲𝗮𝗹𝘁𝗵𝗰𝗮𝗿𝗲 𝗽𝗿𝗼𝘃𝗶𝗱𝗲𝗿𝘀, 𝗶𝗻𝗰𝗹𝘂𝗱𝗶𝗻𝗴 #𝗱𝗲𝗿𝗺𝗮𝘁𝗼𝗹𝗼𝗴𝗶𝘀𝘁𝘀 𝗮𝗻𝗱 #𝗿𝗵𝗲𝘂𝗺𝗮𝘁𝗼𝗹𝗼𝗴𝗶𝘀𝘁𝘀, 𝗮𝗿𝗲 𝗹𝗶𝗸𝗲𝗹𝘆 𝘁𝗼 𝗲𝘅𝗽𝗲𝗿𝗶𝗲𝗻𝗰𝗲 𝘁𝗵𝗲 𝗶𝗻𝘁𝗿𝗼𝗱𝘂𝗰𝘁𝗶𝗼𝗻 𝗼𝗳 𝗯𝗶𝗼𝘀𝗶𝗺𝗶𝗹𝗮𝗿 𝘁𝗿𝗮𝗻𝘀𝗶𝘁𝗶𝗼𝗻𝗶𝗻𝗴 𝗹𝗲𝗴𝗶𝘀𝗹𝗮𝘁𝗶𝗼𝗻 𝗼𝗻 𝘁𝗵𝗲 𝗵𝗲𝗲𝗹𝘀 𝗼𝗳 𝘀𝗶𝗺𝗶𝗹𝗮𝗿 𝗮𝗻𝗻𝗼𝘂𝗻𝗰𝗲𝗺𝗲𝗻𝘁𝘀 𝗮𝗹𝗿𝗲𝗮𝗱𝘆 𝗺𝗮𝗱𝗲 𝗮𝗰𝗿𝗼𝘀𝘀 𝗺𝗮𝗻𝘆 𝗼𝘁𝗵𝗲𝗿 𝗣𝗿𝗼𝘃𝗶𝗻𝗰𝗲𝘀 𝗮𝗰𝗿𝗼𝘀𝘀 𝗖𝗮𝗻𝗮𝗱𝗮.

🎙️ 𝗪𝗲 𝗵𝗲𝗮𝗿 𝗳𝗿𝗼𝗺 𝗮𝗻 𝗮𝗹𝗹-𝘀𝘁𝗮𝗿𝘁 𝗿𝗵𝗲𝘂𝗺𝗮𝘁𝗼𝗹𝗼𝗴𝗶𝘀𝘁, 𝗗𝗿.𝗔𝗻𝘁𝗵𝗼𝗻𝘆 𝗥𝘂𝘀𝘀𝗲𝗹𝗹, 𝗮𝗻𝗱 𝘁𝗵𝗿𝗲𝗲 -𝘁𝗶𝗺𝗲 𝗽𝗼𝗱𝗰𝗮𝘀𝘁 𝗮𝗹𝗹 𝘀𝘁𝗮𝗿, 𝗗𝗿.𝗝𝗮𝗴𝗴𝗶 𝗥𝗮𝗼, 𝗼𝗻 𝘁𝗵𝗲𝗶𝗿 𝗳𝗿𝗼𝗻𝘁𝗹𝗶𝗻𝗲 𝗲𝘅𝗽𝗲𝗿𝗶𝗲𝗻𝗰𝗲𝘀 𝗮𝗻𝗱 𝗵𝗼𝘄 𝘁𝗵𝗲𝘆 𝗿𝗲𝘀𝗽𝗲𝗰𝘁𝗶𝘃𝗲𝗹𝘆 𝗮𝗽𝗽𝗿𝗼𝗮𝗰𝗵𝗲𝗱 #𝗯𝗶𝗼𝘀𝗶𝗺𝗶𝗹𝗮𝗿 𝘀𝘄𝗶𝘁𝗰𝗵𝗲𝘀 𝗶𝗻 𝘁𝗵𝗲𝗶𝗿 𝗿𝗲𝗮𝗹 𝘄𝗼𝗿𝗹𝗱 𝗽𝗿𝗮𝗰𝘁𝗶𝗰𝗲𝘀.

👉 𝗧𝗵𝗲 𝗽𝗶𝘁𝗳𝗮𝗹𝗹𝘀 𝘁𝗼 𝗮𝘃𝗼𝗶𝗱, 𝗵𝗼𝘄 𝘁𝗵𝗲𝗶𝗿 𝘄𝗼𝗿𝗸𝗳𝗹𝗼𝘄𝘀 𝗻𝗲𝗲𝗱𝗲𝗱 𝘁𝗼 𝗮𝗱𝗮𝗽𝘁 𝗮𝗻𝗱 𝘀𝘁𝗲𝗽𝘀 𝘁𝗮𝗸𝗶𝗻𝗴 𝘁𝗼 𝗺𝗮𝗻𝗮𝗴𝗲 𝘀𝘄𝗶𝘁𝗰𝗵𝗶𝗻𝗴 𝗮 𝗹𝗮𝗿𝗴𝗲 𝘃𝗼𝗹𝘂𝗺𝗲 𝗼𝗳 𝗽𝗮𝘁𝗶𝗲𝗻𝘁𝘀.

🌐 🌐 🧵 🧵 🧵 𝙒𝙞𝙩𝙝 8 𝙗𝙞𝙤𝙨𝙞𝙢𝙞𝙡𝙖𝙧𝙨 𝙖𝙫𝙖𝙞𝙡𝙖𝙗𝙡𝙚 𝙛𝙤𝙧 𝙖𝙙𝙖𝙡𝙞𝙢𝙪𝙢𝙖𝙗 𝙣𝙤𝙬, 𝙬𝙝𝙖𝙩 𝙠𝙚𝙮 𝙘𝙤𝙣𝙨𝙞𝙙𝙚𝙧𝙖𝙩𝙞𝙤𝙣𝙨 𝙖𝙧𝙚 𝙖𝙩 𝙥𝙡𝙖𝙮 𝙬𝙝𝙚𝙣 𝙨𝙚𝙡𝙚𝙘𝙩𝙞𝙣𝙜 𝙩𝙝𝙚𝙧𝙖𝙥𝙮 𝙛𝙤𝙧 𝙖 𝙥𝙖𝙩𝙞𝙚𝙣𝙩? 𝘼𝙧𝙚 𝙩𝙝𝙚𝙧𝙚 𝙖𝙣𝙮 𝙙𝙞𝙛𝙛𝙚𝙧𝙚𝙣𝙘𝙚𝙨?

🔑🔑 🎧 𝐋𝐞𝐭'𝐬 𝐡𝐞𝐚𝐫 𝐟𝐫𝐨𝐦 𝐚 𝐝𝐞𝐫𝐦 𝐚𝐧𝐝 𝐚 𝐫𝐡𝐞𝐮𝐦 𝐰𝐡𝐨 𝐬𝐡𝐚𝐫𝐞 𝐭𝐡𝐞𝐢𝐫 𝐬𝐞𝐜𝐫𝐞𝐭𝐬:

😉 𝐘𝐨𝐮 𝐨𝐧𝐥𝐲 𝐥𝐞𝐚𝐫𝐧 𝐭𝐡𝐢𝐬 𝐬𝐭𝐮𝐟𝐟 𝐢𝐟 𝐲𝐨𝐮 𝐰𝐨𝐫𝐤 𝐚𝐥𝐨𝐧𝐠𝐬𝐢𝐝𝐞 𝐃𝐫.Rao, 𝐨𝐫, of course, 𝐢𝐟 𝐲𝐨𝐮 𝐥𝐢𝐬𝐭𝐞𝐧 𝐭𝐨 𝐭𝐡𝐞 Skin and Joints Podcast

Episode supported by Sandoz Canada.

📻www.skinandjoints.ca

✉️info@skinandjoints.ca

About Dr.Anthony Russell, MD, FRCPC Dr. Anthony Russell is an experienced rheumatologist at the University of Alberta, who has a focus on fibromyalgia and general rheumatology

After qualifying in the UK from Cambridge then Guy's hospital, Dr.Russell trained in rheumatology with Prof Bywaters and Barbara Ansell, then moved to Dallas, TX for a research fellowship with Morris Ziff, and back to the UK at the Kennedy institute.

Following these peregrinations he settled in Edmonton, married had a family and has been enjoying it there ever since.

Hope the above suffices! Tony

About Dr.Jaggi Rao, MD, FRCPC Dermatologist | Edmonton

Dr. Jaggi Rao is a double board certified dermatologist (Canada and USA) and a certified cosmetic surgeon. He completed his dermatology training at the University of Alberta, followed by an accredited fellowship with the American Academy of Cosmetic Surgery in Southern California. Dr. Rao is a full Clinical Professor of Medicine at the University of Alberta.

Dr. Rao has won several accolades for research and teaching, including the Canadian Dermatology Association’s Teacher of the Year Award.

In 2011, he was the recipient of Avenue Magazine’s Top 40 under 40 Award. He has authored over 50 scientific papers and textbook chapters, and has been an invited speaker for over 500 lectures worldwide to physicians, other professionals, and the general public.

Dr. Rao continues to lend his expertise to various organizations. He sits on the board of directors for CAAM( Canadian Association of Aesthetics Medicine) and acts as a consultant to the government (such as the Canadian Standards Association), laser and pharmaceutical industry, and professional sports teams.

Switching from One Biosimilar to Another Biosimilar of the Same Reference Biologic: A Systematic Review of Studies

View Details

🎙️🎙️ 📭 🎙️ 𝑾𝒆’𝒓𝒆 𝒆𝒙𝒄𝒊𝒕𝒆𝒅 𝒕𝒐 𝒔𝒉𝒂𝒓𝒆 𝒂 𝒇𝒊𝒓𝒔𝒕 𝒐𝒏 𝒕𝒉𝒆 Skin and Joints Podcast 𝒃𝒓𝒊𝒏𝒈𝒊𝒏𝒈 𝒕𝒐𝒈𝒆𝒕𝒉𝒆𝒓 𝒂 #𝒅𝒆𝒓𝒎𝒂𝒕𝒐𝒍𝒐𝒈𝒊𝒔𝒕 𝒂𝒏𝒅 𝒂 #𝒓𝒉𝒆𝒖𝒎𝒂𝒕𝒐𝒍𝒐𝒈𝒊𝒔𝒕 𝒕𝒐 𝒅𝒖𝒌𝒆 𝒊𝒕 𝒐𝒖𝒕 𝒐𝒏 𝒂𝒏 𝒆𝒑𝒊𝒔𝒐𝒅𝒆.

𝗢𝗻𝘁𝗮𝗿𝗶𝗼 𝗵𝗲𝗮𝗹𝘁𝗵𝗰𝗮𝗿𝗲 𝗽𝗿𝗼𝘃𝗶𝗱𝗲𝗿𝘀, 𝗶𝗻𝗰𝗹𝘂𝗱𝗶𝗻𝗴 #𝗱𝗲𝗿𝗺𝗮𝘁𝗼𝗹𝗼𝗴𝗶𝘀𝘁𝘀 𝗮𝗻𝗱 #𝗿𝗵𝗲𝘂𝗺𝗮𝘁𝗼𝗹𝗼𝗴𝗶𝘀𝘁𝘀, 𝗮𝗿𝗲 𝗹𝗶𝗸𝗲𝗹𝘆 𝘁𝗼 𝗲𝘅𝗽𝗲𝗿𝗶𝗲𝗻𝗰𝗲 𝘁𝗵𝗲 𝗶𝗻𝘁𝗿𝗼𝗱𝘂𝗰𝘁𝗶𝗼𝗻 𝗼𝗳 𝗯𝗶𝗼𝘀𝗶𝗺𝗶𝗹𝗮𝗿 𝘁𝗿𝗮𝗻𝘀𝗶𝘁𝗶𝗼𝗻𝗶𝗻𝗴 𝗹𝗲𝗴𝗶𝘀𝗹𝗮𝘁𝗶𝗼𝗻 𝗼𝗻 𝘁𝗵𝗲 𝗵𝗲𝗲𝗹𝘀 𝗼𝗳 𝘀𝗶𝗺𝗶𝗹𝗮𝗿 𝗮𝗻𝗻𝗼𝘂𝗻𝗰𝗲𝗺𝗲𝗻𝘁𝘀 𝗮𝗹𝗿𝗲𝗮𝗱𝘆 𝗺𝗮𝗱𝗲 𝗮𝗰𝗿𝗼𝘀𝘀 𝗺𝗮𝗻𝘆 𝗼𝘁𝗵𝗲𝗿 𝗣𝗿𝗼𝘃𝗶𝗻𝗰𝗲𝘀 𝗮𝗰𝗿𝗼𝘀𝘀 𝗖𝗮𝗻𝗮𝗱𝗮.

🎙️ 𝗪𝗲 𝗵𝗲𝗮𝗿 𝗳𝗿𝗼𝗺 𝗮𝗻 𝗮𝗹𝗹-𝘀𝘁𝗮𝗿𝘁 𝗿𝗵𝗲𝘂𝗺𝗮𝘁𝗼𝗹𝗼𝗴𝗶𝘀𝘁, 𝗗𝗿.𝗔𝗻𝘁𝗵𝗼𝗻𝘆 𝗥𝘂𝘀𝘀𝗲𝗹𝗹, 𝗮𝗻𝗱 𝘁𝗵𝗿𝗲𝗲 -𝘁𝗶𝗺𝗲 𝗽𝗼𝗱𝗰𝗮𝘀𝘁 𝗮𝗹𝗹 𝘀𝘁𝗮𝗿, 𝗗𝗿.𝗝𝗮𝗴𝗴𝗶 𝗥𝗮𝗼, 𝗼𝗻 𝘁𝗵𝗲𝗶𝗿 𝗳𝗿𝗼𝗻𝘁𝗹𝗶𝗻𝗲 𝗲𝘅𝗽𝗲𝗿𝗶𝗲𝗻𝗰𝗲𝘀 𝗮𝗻𝗱 𝗵𝗼𝘄 𝘁𝗵𝗲𝘆 𝗿𝗲𝘀𝗽𝗲𝗰𝘁𝗶𝘃𝗲𝗹𝘆 𝗮𝗽𝗽𝗿𝗼𝗮𝗰𝗵𝗲𝗱 #𝗯𝗶𝗼𝘀𝗶𝗺𝗶𝗹𝗮𝗿 𝘀𝘄𝗶𝘁𝗰𝗵𝗲𝘀 𝗶𝗻 𝘁𝗵𝗲𝗶𝗿 𝗿𝗲𝗮𝗹 𝘄𝗼𝗿𝗹𝗱 𝗽𝗿𝗮𝗰𝘁𝗶𝗰𝗲𝘀.

👉 𝗧𝗵𝗲 𝗽𝗶𝘁𝗳𝗮𝗹𝗹𝘀 𝘁𝗼 𝗮𝘃𝗼𝗶𝗱, 𝗵𝗼𝘄 𝘁𝗵𝗲𝗶𝗿 𝘄𝗼𝗿𝗸𝗳𝗹𝗼𝘄𝘀 𝗻𝗲𝗲𝗱𝗲𝗱 𝘁𝗼 𝗮𝗱𝗮𝗽𝘁 𝗮𝗻𝗱 𝘀𝘁𝗲𝗽𝘀 𝘁𝗮𝗸𝗶𝗻𝗴 𝘁𝗼 𝗺𝗮𝗻𝗮𝗴𝗲 𝘀𝘄𝗶𝘁𝗰𝗵𝗶𝗻𝗴 𝗮 𝗹𝗮𝗿𝗴𝗲 𝘃𝗼𝗹𝘂𝗺𝗲 𝗼𝗳 𝗽𝗮𝘁𝗶𝗲𝗻𝘁𝘀.

🌐 🌐 🧵 🧵 🧵 𝙒𝙞𝙩𝙝 8 𝙗𝙞𝙤𝙨𝙞𝙢𝙞𝙡𝙖𝙧𝙨 𝙖𝙫𝙖𝙞𝙡𝙖𝙗𝙡𝙚 𝙛𝙤𝙧 𝙖𝙙𝙖𝙡𝙞𝙢𝙪𝙢𝙖𝙗 𝙣𝙤𝙬, 𝙬𝙝𝙖𝙩 𝙠𝙚𝙮 𝙘𝙤𝙣𝙨𝙞𝙙𝙚𝙧𝙖𝙩𝙞𝙤𝙣𝙨 𝙖𝙧𝙚 𝙖𝙩 𝙥𝙡𝙖𝙮 𝙬𝙝𝙚𝙣 𝙨𝙚𝙡𝙚𝙘𝙩𝙞𝙣𝙜 𝙩𝙝𝙚𝙧𝙖𝙥𝙮 𝙛𝙤𝙧 𝙖 𝙥𝙖𝙩𝙞𝙚𝙣𝙩? 𝘼𝙧𝙚 𝙩𝙝𝙚𝙧𝙚 𝙖𝙣𝙮 𝙙𝙞𝙛𝙛𝙚𝙧𝙚𝙣𝙘𝙚𝙨?

🔑🔑 🎧 𝐋𝐞𝐭'𝐬 𝐡𝐞𝐚𝐫 𝐟𝐫𝐨𝐦 𝐚 𝐝𝐞𝐫𝐦 𝐚𝐧𝐝 𝐚 𝐫𝐡𝐞𝐮𝐦 𝐰𝐡𝐨 𝐬𝐡𝐚𝐫𝐞 𝐭𝐡𝐞𝐢𝐫 𝐬𝐞𝐜𝐫𝐞𝐭𝐬:

😉 𝐘𝐨𝐮 𝐨𝐧𝐥𝐲 𝐥𝐞𝐚𝐫𝐧 𝐭𝐡𝐢𝐬 𝐬𝐭𝐮𝐟𝐟 𝐢𝐟 𝐲𝐨𝐮 𝐰𝐨𝐫𝐤 𝐚𝐥𝐨𝐧𝐠𝐬𝐢𝐝𝐞 𝐃𝐫.Rao, 𝐨𝐫, of course, 𝐢𝐟 𝐲𝐨𝐮 𝐥𝐢𝐬𝐭𝐞𝐧 𝐭𝐨 𝐭𝐡𝐞 Skin and Joints Podcast

Episode supported by Sandoz Canada.

📻www.skinandjoints.ca

✉️info@skinandjoints.ca

About Dr.Anthony Russell, MD, FRCPC Dr. Anthony Russell is an experienced rheumatologist at the University of Alberta, who has a focus on fibromyalgia and general rheumatology

After qualifying in the UK from Cambridge then Guy's hospital, Dr.Russell trained in rheumatology with Prof Bywaters and Barbara Ansell, then moved to Dallas, TX for a research fellowship with Morris Ziff, and back to the UK at the Kennedy institute.

Following these peregrinations he settled in Edmonton, married had a family and has been enjoying it there ever since.

Hope the above suffices! Tony

About Dr.Jaggi Rao, MD, FRCPC Dermatologist | Edmonton

Dr. Jaggi Rao is a double board certified dermatologist (Canada and USA) and a certified cosmetic surgeon. He completed his dermatology training at the University of Alberta, followed by an accredited fellowship with the American Academy of Cosmetic Surgery in Southern California. Dr. Rao is a full Clinical Professor of Medicine at the University of Alberta.

Dr. Rao has won several accolades for research and teaching, including the Canadian Dermatology Association’s Teacher of the Year Award.

In 2011, he was the recipient of Avenue Magazine’s Top 40 under 40 Award. He has authored over 50 scientific papers and textbook chapters, and has been an invited speaker for over 500 lectures worldwide to physicians, other professionals, and the general public.

Dr. Rao continues to lend his expertise to various organizations. He sits on the board of directors for CAAM( Canadian Association of Aesthetics Medicine) and acts as a consultant to the government (such as the Canadian Standards Association), laser and pharmaceutical industry, and professional sports teams.

Switching from One Biosimilar to Another Biosimilar of the Same Reference Biologic: A Systematic Review of Studies

View Details

💡💡💡 𝐃𝐫.𝐘𝐚𝐝𝐚𝐯 𝐚𝐧𝐝 𝐃𝐫.𝐉𝐨𝐬𝐞𝐩𝐡 𝐥𝐨𝐨𝐤 𝐭𝐨 𝐬𝐞𝐭𝐭𝐥𝐞 𝐭𝐡𝐞 𝐝𝐞𝐛𝐚𝐭𝐞 𝐢𝐧 𝐏𝐀𝐑𝐓 𝐈𝐈 𝐨𝐟 𝑰𝑻 𝑻𝑨𝑲𝑬𝑺 2 𝑻𝑶 𝑻𝒀𝑲 2.

🟢𝐇𝐚𝐯𝐞 𝐲𝐨𝐮 𝐛𝐞𝐞𝐧 𝐰𝐨𝐧𝐝𝐞𝐫𝐢𝐧𝐠 𝐰𝐡𝐚𝐭'𝐬 𝐭𝐡𝐞 𝐫𝐞𝐚𝐥 𝐝𝐢𝐟𝐟𝐞𝐫𝐞𝐧𝐜𝐞 𝐛𝐞𝐭𝐰𝐞𝐞𝐧 #𝐉𝐀𝐊 𝐢𝐧𝐡𝐢𝐛𝐢𝐭𝐢𝐨𝐧 𝐚𝐧𝐝 #𝐓𝐘𝐊-𝟐 𝐢𝐧𝐡𝐢𝐛𝐢𝐭𝐢𝐨𝐧? 𝐀𝐫𝐞𝐧'𝐭 𝐭𝐡𝐞𝐲 𝐩𝐚𝐫𝐭 𝐨𝐟 𝐭𝐡𝐞 𝐬𝐚𝐦𝐞 𝐩𝐚𝐭𝐡𝐰𝐚𝐲?

𝗪𝗲𝗹𝗹 𝘄𝗲 𝘁𝗮𝗸𝗲 𝗮 𝗱𝗲𝗲𝗽 𝗱𝗶𝘃𝗲 𝗶𝗻𝘁𝗼 𝘁𝗵𝗲 𝘀𝗮𝗳𝗲𝘁𝘆 𝗰𝗼𝗻𝘃𝗲𝗿𝘀𝗮𝘁𝗶𝗼𝗻 𝗮𝗻𝗱 seek clarify for you when it comes to all you need to know about key 𝗧𝗬𝗞 𝘃𝘀 𝗝𝗔𝗞 𝘀𝗶𝗱𝗲 𝗲𝗳𝗳𝗲𝗰𝘁 𝗮𝗻𝗱 𝗺𝗼𝗻𝗶𝘁𝗼𝗿𝗶𝗻𝗴 𝗰𝗼𝗻𝘀𝗶𝗱𝗲𝗿𝗮𝘁𝗶𝗼𝗻𝘀.

Our experts 𝗮𝗹𝘀𝗼 𝗯𝗿𝗲𝗮𝗸𝗱𝗼𝘄𝗻 𝗣𝗢𝗘𝗧𝗬𝗞-𝟭 𝗮𝗻𝗱 𝗣𝗢𝗘𝗧𝗬𝗞-𝟮 𝗮𝗻𝗱 𝘀𝗵𝗮𝗿𝗲 𝘁𝗵𝗲𝗶𝗿 𝗰𝗮𝗻𝗱𝗶𝗱 𝘁𝗵𝗼𝘂𝗴𝗵𝘁𝘀 𝗼𝗻 𝘄𝗵𝗲𝗿𝗲 𝘁𝗵𝗲𝘆 𝘀𝗲𝗲 𝘁𝗵𝗲 𝗽𝗹𝗮𝗰𝗲 𝗼𝗳 𝗮 𝗧𝗬𝗞-𝟮 𝗶𝗻𝗵𝗶𝗯𝗶𝘁𝗼𝗿, 𝗶𝗻 𝘁𝗵𝗲𝗶𝗿 𝗽𝗿𝗮𝗰𝘁𝗶𝗰𝗲𝘀, 𝗳𝗼𝗿 𝘁𝗵𝗲 𝘁𝗿𝗲𝗮𝘁𝗺𝗲𝗻𝘁 𝗼𝗳 𝗺𝗼𝗱𝗲𝗿𝗮𝘁𝗲 𝘁𝗼 𝘀𝗲𝘃𝗲𝗿𝗲 𝗽𝘀𝗼𝗿𝗶𝗮𝘀𝗶𝘀.

🟢𝘼𝙧𝙚 𝙩𝙝𝙚𝙧𝙚 𝙖𝙣𝙮 𝙥𝙧𝙖𝙘𝙩𝙞𝙘𝙖𝙡 𝙘𝙤𝙣𝙨𝙞𝙙𝙚𝙧𝙖𝙩𝙞𝙤𝙣𝙨 𝙛𝙤𝙧 𝙥𝙖𝙩𝙞𝙚𝙣𝙩𝙨 𝙬𝙝𝙤 𝙖𝙧𝙚 𝙗𝙞𝙤𝙡𝙤𝙜𝙞𝙘 𝙣𝙖ï𝙫𝙚 𝙫𝙚𝙧𝙨𝙪𝙨 𝙗𝙞𝙤 𝙚𝙭𝙥𝙚𝙧𝙞𝙚𝙣𝙘𝙚𝙙?

🟢What 𝐝𝐨𝐞𝐬 #TYK-2 #inhibition mean for 𝐭𝐡𝐞 #𝐩𝐬𝐨𝐫𝐢𝐚𝐬𝐢𝐬 𝐩𝐚𝐭𝐢𝐞𝐧𝐭 treatment landscape?

🟢And when do I recommend an i𝐧𝐣𝐞𝐜𝐭𝐚𝐛𝐥𝐞 𝐯𝐞𝐫𝐬𝐮𝐬 𝐨𝐫𝐚𝐥 therapy 𝐟𝐨𝐫 𝐦𝐲 𝐩𝐚𝐭𝐢𝐞𝐧𝐭?

🎫 𝗧𝗵𝗶𝘀 𝗺𝗮𝗿𝗸𝘀 𝗮 𝗳𝗶𝗿𝘀𝘁 𝗳𝗼𝗿 𝘁𝗵𝗲 𝗦𝗸𝗶𝗻 𝗮𝗻𝗱 𝗝𝗼𝗶𝗻𝘁𝘀 𝗣𝗼𝗱𝗰𝗮𝘀𝘁- 𝘄𝗲 𝗵𝗮𝘃𝗲 𝘁𝘄𝗼 𝗴𝘂𝗲𝘀𝘁 𝗲𝘅𝗽𝗲𝗿𝘁𝘀 𝗼𝗻 𝘁𝗵𝗲 𝘀𝗵𝗼𝘄 𝗮𝘁 𝘁𝗵𝗲 𝘀𝗮𝗺𝗲 𝘁𝗶𝗺𝗲!

𝗪𝗲 𝗮𝗿𝗲 𝗴𝗼𝗶𝗻𝗴 𝘁𝗼 𝗹𝗼𝗼𝗸 𝗮𝘁 𝗧𝗬𝗞𝟮 𝗶𝗻𝗵𝗶𝗯𝗶𝘁𝗶𝗼𝗻, 𝗮𝗻𝗱 𝗶𝘁’𝘀 𝗿𝗼𝗹𝗲 𝗶𝗻 𝘁𝗵𝗲 𝗽𝘀𝗼𝗿𝗶𝗮𝘀𝗶𝘀 𝘁𝗿𝗲𝗮𝘁𝗺𝗲𝗻𝘁 𝗹𝗮𝗻𝗱𝘀𝗰𝗮𝗽𝗲 𝘄𝗶𝘁𝗵 𝗮 𝗳𝗼𝗰𝘂𝘀 𝗼𝗻 𝗮 𝗻𝗲𝘄 𝗼𝗿𝗮𝗹 𝘀𝗲𝗹𝗲𝗰𝘁𝗶𝘃𝗲 𝗧𝗬𝗞𝟮 𝗶𝗻𝗵𝗶𝗯𝗶𝘁𝗼𝗿 𝗮𝗴𝗲𝗻𝘁 𝗰𝗮𝗹𝗹𝗲𝗱 𝗱𝗲𝘂𝗰𝗿𝗮𝘃𝗮𝗰𝗶𝘁𝗶𝗻𝗶𝗯 𝗮𝗻𝗱 𝘄𝗵𝗮𝘁 𝘁𝗵𝗶𝘀 𝘀𝗲𝗹𝗲𝗰𝘁𝗶𝘃𝗲𝗹𝘆 𝗰𝗼𝗻𝗳𝗲𝗿𝘀 𝗳𝗿𝗼𝗺 𝗮 𝘀𝗮𝗳𝗲𝘁𝘆 𝗽𝗿𝗼𝗳𝗶𝗹𝗲.

𝗗𝗼𝗲𝘀 𝗶𝘁 𝗧𝗬𝗞 𝗮𝗹𝗹 𝘁𝗵𝗲 𝗯𝗼𝘅𝗲𝘀? 𝗟𝗲𝘁’𝘀 𝗳𝗶𝗻𝗱 𝗼𝘂𝘁!

🎙️🎙️🎙️ 𝐏𝐚𝐫𝐭 II with Dr.Geeta Yadav and Dr.Marissa Joseph!

Episode Learning Objectives

• ​​Apply current evidence to key efficacy and safety considerations for the oral, selective allosteric tyrosine kinase 2 (TYK2) inhibitor deucravacitinib
• Describe the summary details and potential clinical implications of the pivotal trials POETYK-1 and POETYK-2
• Discuss the role of TYK-2 inhibition in moderate to severe psoriasis and the patient journey

ABOUT Dr. Marissa Joseph, MSc, MD, FRCPC ( Pediatrics), FRCPC ( Dermatology)

Toronto, ON

Dr. Marissa Joseph is a board certified Pediatrician and Dermatologist and completed her Pediatric training at the Hospital For Sick Children, followed by her Dermatology residency at the University of Toronto. She completed a MSc in Community Health at the Dalla Lana School of Public Health.

Dr. Joseph is full time academic faculty at the University of Toronto. She has received and has been nominated for teaching awards in both undergraduate and postgraduate medical education.

Dr. Joseph is the Medical Director of the Ricky Kanee Schachter Dermatology Centre at Women's College Hospital. She also works at the Hospital For Sick Children where she manages children with complex dermatologic disease in outpatient and inpatient settings, as well as a pediatric laser treatment program. Dr. Joseph enjoys her diverse practice in general adult, pediatric and surgical dermatology. Her clinical and research interests include inflammatory skin disorders such as psoriasis, atopic dermatitis, and hidradenitis suppurativa; genodermatoses, and equity, diversity and inclusivity.

ABOUT Dr. Geeta Yadav, MSc, MD, FRCPC ( Pediatrics), FRCPC ( Dermatology)

Toronto, ON

Dr. Geeta Yadav is an expert in both medical and cosmetic dermatology. A second-generation Canadian, her interest in under-serviced communities and treating BIPOC patients was inspired by her childhood travels to India. She holds a master’s degree in International Health from Johns Hopkins and completed her dermatology training at the University of Toronto, where she still teaches today. Dr. Yadav is a fellow of the Royal College of Physicians and Surgeons, the American Academy of Dermatology, and the European Academy of Dermatology and Venereology.

When she’s not working, she volunteers as an Alumni Governor at the University of Toronto. She also loves running, dancing, and spending time with her husband and three young children.

▶️Episode supported by an IME Grant from Bristol Myers Squibb

View Details

💡💡💡𝐇𝐚𝐯𝐞 𝐲𝐨𝐮 𝐛𝐞𝐞𝐧 𝐰𝐨𝐧𝐝𝐞𝐫𝐢𝐧𝐠 𝐰𝐡𝐚𝐭'𝐬 𝐭𝐡𝐞 𝐫𝐞𝐚𝐥 𝐝𝐢𝐟𝐟𝐞𝐫𝐞𝐧𝐜𝐞 𝐛𝐞𝐭𝐰𝐞𝐞𝐧 #𝐉𝐀𝐊 𝐢𝐧𝐡𝐢𝐛𝐢𝐭𝐢𝐨𝐧 𝐚𝐧𝐝 #𝐓𝐘𝐊-𝟐 𝐢𝐧𝐡𝐢𝐛𝐢𝐭𝐢𝐨𝐧? 𝐀𝐫𝐞𝐧'𝐭 𝐭𝐡𝐞𝐲 𝐩𝐚𝐫𝐭 𝐨𝐟 𝐭𝐡𝐞 𝐬𝐚𝐦𝐞 𝐩𝐚𝐭𝐡𝐰𝐚𝐲?

🟢What 𝐝𝐨𝐞𝐬 #TYK-2 #inhibition mean for 𝐭𝐡𝐞 #𝐩𝐬𝐨𝐫𝐢𝐚𝐬𝐢𝐬 𝐩𝐚𝐭𝐢𝐞𝐧𝐭 treatment landscape?

🟢And when do I recommend an i𝐧𝐣𝐞𝐜𝐭𝐚𝐛𝐥𝐞 𝐯𝐞𝐫𝐬𝐮𝐬 𝐨𝐫𝐚𝐥 therapy 𝐟𝐨𝐫 𝐦𝐲 𝐩𝐚𝐭𝐢𝐞𝐧𝐭?

🎫 𝗧𝗵𝗶𝘀 𝗺𝗮𝗿𝗸𝘀 𝗮 𝗳𝗶𝗿𝘀𝘁 𝗳𝗼𝗿 𝘁𝗵𝗲 𝗦𝗸𝗶𝗻 𝗮𝗻𝗱 𝗝𝗼𝗶𝗻𝘁𝘀 𝗣𝗼𝗱𝗰𝗮𝘀𝘁- 𝘄𝗲 𝗵𝗮𝘃𝗲 𝘁𝘄𝗼 𝗴𝘂𝗲𝘀𝘁 𝗲𝘅𝗽𝗲𝗿𝘁𝘀 𝗼𝗻 𝘁𝗵𝗲 𝘀𝗵𝗼𝘄 𝗮𝘁 𝘁𝗵𝗲 𝘀𝗮𝗺𝗲 𝘁𝗶𝗺𝗲!

𝗪𝗲 𝗮𝗿𝗲 𝗴𝗼𝗶𝗻𝗴 𝘁𝗼 𝗹𝗼𝗼𝗸 𝗮𝘁 𝗧𝗬𝗞𝟮 𝗶𝗻𝗵𝗶𝗯𝗶𝘁𝗶𝗼𝗻, 𝗮𝗻𝗱 𝗶𝘁’𝘀 𝗿𝗼𝗹𝗲 𝗶𝗻 𝘁𝗵𝗲 𝗽𝘀𝗼𝗿𝗶𝗮𝘀𝗶𝘀 𝘁𝗿𝗲𝗮𝘁𝗺𝗲𝗻𝘁 𝗹𝗮𝗻𝗱𝘀𝗰𝗮𝗽𝗲 𝘄𝗶𝘁𝗵 𝗮 𝗳𝗼𝗰𝘂𝘀 𝗼𝗻 𝗮 𝗻𝗲𝘄 𝗼𝗿𝗮𝗹 𝘀𝗲𝗹𝗲𝗰𝘁𝗶𝘃𝗲 𝗧𝗬𝗞𝟮 𝗶𝗻𝗵𝗶𝗯𝗶𝘁𝗼𝗿 𝗮𝗴𝗲𝗻𝘁 𝗰𝗮𝗹𝗹𝗲𝗱 𝗱𝗲𝘂𝗰𝗿𝗮𝘃𝗮𝗰𝗶𝘁𝗶𝗻𝗶𝗯 𝗮𝗻𝗱 𝘄𝗵𝗮𝘁 𝘁𝗵𝗶𝘀 𝘀𝗲𝗹𝗲𝗰𝘁𝗶𝘃𝗲𝗹𝘆 𝗰𝗼𝗻𝗳𝗲𝗿𝘀 𝗳𝗿𝗼𝗺 𝗮 𝘀𝗮𝗳𝗲𝘁𝘆 𝗽𝗿𝗼𝗳𝗶𝗹𝗲.

𝗗𝗼𝗲𝘀 𝗶𝘁 𝗧𝗬𝗞 𝗮𝗹𝗹 𝘁𝗵𝗲 𝗯𝗼𝘅𝗲𝘀? 𝗟𝗲𝘁’𝘀 𝗳𝗶𝗻𝗱 𝗼𝘂𝘁!

🎙️🎙️🎙️ 𝐏𝐚𝐫𝐭 𝐈 with Dr.Geeta Yadav and Dr.Marissa Joseph!

Episode Learning Objectives

• Discuss patient unmet needs as well as appropriate assessment strategies to guide treatment decisions for moderate to severe psoriasis
• ​​Apply current evidence as well as shared decision-making to individualize oral and injectable therapy decisions for patients with moderate to severe plaque psoriasis
• Describe the role and pathophysiology of TYK-2 (tyrosine kinase 2) inhibition in the clinical manifestation of psoriasis

ABOUT Dr. Marissa Joseph, MSc, MD, FRCPC ( Pediatrics), FRCPC ( Dermatology)

Toronto, ON

Dr. Marissa Joseph is a board certified Pediatrician and Dermatologist and completed her Pediatric training at the Hospital For Sick Children, followed by her Dermatology residency at the University of Toronto. She completed a MSc in Community Health at the Dalla Lana School of Public Health.

Dr. Joseph is full time academic faculty at the University of Toronto. She has received and has been nominated for teaching awards in both undergraduate and postgraduate medical education.

Dr. Joseph is the Medical Director of the Ricky Kanee Schachter Dermatology Centre at Women's College Hospital. She also works at the Hospital For Sick Children where she manages children with complex dermatologic disease in outpatient and inpatient settings, as well as a pediatric laser treatment program. Dr. Joseph enjoys her diverse practice in general adult, pediatric and surgical dermatology. Her clinical and research interests include inflammatory skin disorders such as psoriasis, atopic dermatitis, and hidradenitis suppurativa; genodermatoses, and equity, diversity and inclusivity.

ABOUT Dr. Geeta Yadav, MSc, MD, FRCPC ( Pediatrics), FRCPC ( Dermatology)

Toronto, ON

Dr. Geeta Yadav is an expert in both medical and cosmetic dermatology. A second-generation Canadian, her interest in under-serviced communities and treating BIPOC patients was inspired by her childhood travels to India. She holds a master’s degree in International Health from Johns Hopkins and completed her dermatology training at the University of Toronto, where she still teaches today. Dr. Yadav is a fellow of the Royal College of Physicians and Surgeons, the American Academy of Dermatology, and the European Academy of Dermatology and Venereology.

When she’s not working, she volunteers as an Alumni Governor at the University of Toronto. She also loves running, dancing, and spending time with her husband and three young children.

▶️Episode supported by an IME Grant from Bristol Myers Squibb

View Details

About Dr.Jessica Asgarpour, MD, FRCPCDermatologist | Toronto

Dr. Jessica Asgarpour is a Canadian and American board-certified dermatologist. She completed her medical school at the Cumming School of Medicine, in Calgary, Alberta, where she was born and raised. She went on to the University of Alberta for her residency training in dermatology, where she acted as co-chief resident from 2019-2020, and was awarded the Dr. Andrew Lin Dermatology Scholar award. She has also been awarded multiple scholarships to conferences to keep her up-to-date with the ever changing medical literature.

She has published in many peer-reviewed journals, and practices medicine with this same evidence-based approach. She practices medical, surgical and cosmetic dermatology. When she is not practicing dermatology, she enjoys keeping active and loves to run, spin and hike.

EPISODE DETAILS:

𝐖𝐞'𝐫𝐞 𝐚𝐢𝐫𝐢𝐧𝐠 𝐨𝐮𝐭 𝐬𝐨𝐦𝐞 𝐝𝐢𝐫𝐭𝐲 𝐥𝐚𝐮𝐧𝐝𝐫𝐲 𝐨𝐧 𝐭𝐡𝐞 𝐒𝐤𝐢𝐧 𝐚𝐧𝐝 𝐉𝐨𝐢𝐧𝐭𝐬 𝐏𝐨𝐝𝐜𝐚𝐬𝐭.

𝐓𝐡𝐢𝐬 𝐞𝐩𝐢𝐬𝐨𝐝𝐞 𝐢𝐬 𝐚 𝐛𝐢𝐭 𝐨𝐟 𝐚 𝐝𝐞𝐩𝐚𝐫𝐭𝐮𝐫𝐞 𝐟𝐫𝐨𝐦 𝐨𝐮𝐫 𝐮𝐬𝐮𝐚𝐥 𝐟𝐨𝐜𝐮𝐬 𝐨𝐧 𝐢𝐧𝐟𝐥𝐚𝐦𝐦𝐚𝐭𝐨𝐫𝐲 𝐬𝐤𝐢𝐧 𝐚𝐧𝐝 𝐣𝐨𝐢𝐧𝐭 𝐝𝐢𝐬𝐞𝐚𝐬𝐞. 𝐖𝐞'𝐥𝐥 𝐛𝐞 𝐭𝐚𝐤𝐢𝐧𝐠 𝐚 𝐬𝐭𝐫𝐨𝐥𝐥 📍 𝐢𝐧 𝐭𝐡𝐞 𝐥𝐚𝐮𝐧𝐝𝐫𝐲 𝐝𝐞𝐭𝐞𝐫𝐠𝐞𝐧𝐭 𝐚𝐢𝐬𝐥𝐞 𝐭𝐨 𝐞𝐱𝐩𝐥𝐨𝐫𝐞 𝐬𝐞𝐧𝐬𝐢𝐭𝐢𝐯𝐞 𝐬𝐤𝐢𝐧 𝐚𝐧𝐝 𝐢𝐭𝐬 𝐫𝐞𝐥𝐚𝐭𝐢𝐨𝐧𝐬𝐡𝐢𝐩 𝐰𝐢𝐭𝐡 𝐲𝐨𝐮𝐫 𝐥𝐚𝐮𝐧𝐝𝐫𝐲 𝐝𝐞𝐭𝐞𝐫𝐠𝐞𝐧𝐭.

𝐈𝐟 𝐲𝐨𝐮 𝐡𝐚𝐯𝐞 𝐬𝐞𝐧𝐬𝐢𝐭𝐢𝐯𝐞 𝐬𝐤𝐢𝐧, 𝐲𝐨𝐮 𝐦𝐢𝐠𝐡𝐭 𝐮𝐬𝐞 𝐬𝐩𝐞𝐜𝐢𝐚𝐥 𝐜𝐥𝐞𝐚𝐧𝐬𝐞𝐫𝐬, 𝐥𝐨𝐭𝐢𝐨𝐧𝐬, 𝐨𝐭𝐡𝐞𝐫 𝐬𝐤𝐢𝐧𝐜𝐚𝐫𝐞 𝐢𝐭𝐞𝐦𝐬 𝐭𝐨 𝐡𝐞𝐥𝐩 𝐤𝐞𝐞𝐩 𝐲𝐨𝐮𝐫 𝐟𝐥𝐚𝐫𝐞𝐮𝐩𝐬 𝐚𝐭 𝐛𝐚𝐲. 𝐎𝐧𝐞 𝐩𝐫𝐨𝐝𝐮𝐜𝐭 𝐭𝐡𝐚𝐭 𝐰𝐞 𝐟𝐢𝐧𝐝 𝐢𝐬 𝐨𝐟𝐭𝐞𝐧 𝐨𝐯𝐞𝐫𝐥𝐨𝐨𝐤𝐞𝐝 𝐢𝐬 𝐭𝐡𝐞 𝐥𝐚𝐮𝐧𝐝𝐫𝐲 𝐝𝐞𝐭𝐞𝐫𝐠𝐞𝐧𝐭 𝐰𝐞'𝐫𝐞 𝐮𝐬𝐢𝐧𝐠. 𝐖𝐡𝐞𝐧 𝐲𝐨𝐮 𝐭𝐨𝐬𝐬 𝐲𝐨𝐮𝐫 𝐜𝐥𝐨𝐭𝐡𝐞𝐬 𝐚𝐧𝐝 𝐥𝐢𝐧𝐞𝐧𝐬 𝐢𝐧 𝐭𝐡𝐞 𝐰𝐚𝐬𝐡, 𝐲𝐨𝐮 𝐦𝐢𝐠𝐡𝐭 𝐭𝐡𝐢𝐧𝐤 𝐭𝐡𝐚𝐭 𝐚𝐥𝐥 𝐭𝐡𝐞 𝐢𝐫𝐫𝐢𝐭𝐚𝐧𝐭𝐬 𝐚𝐫𝐞 𝐜𝐨𝐦𝐩𝐥𝐞𝐭𝐞𝐥𝐲 𝐞𝐥𝐢𝐦𝐢𝐧𝐚𝐭𝐞𝐝 𝐢𝐧 𝐭𝐡𝐞 𝐫𝐢𝐧𝐬𝐞 𝐜𝐲𝐜𝐥𝐞.

𝐁𝐮𝐭 𝐬𝐨𝐦𝐞𝐭𝐢𝐦𝐞𝐬 𝐰𝐡𝐚𝐭'𝐬 𝐢𝐧 𝐲𝐨𝐮𝐫 𝐝𝐞𝐭𝐞𝐫𝐠𝐞𝐧𝐭 𝐜𝐚𝐧 𝐚𝐥𝐬𝐨 𝐮𝐩𝐬𝐞𝐭 𝐲𝐨𝐮𝐫 𝐬𝐤𝐢𝐧 𝐚𝐧𝐝 𝐭𝐫𝐚𝐜𝐞 𝐚𝐦𝐨𝐮𝐧𝐭𝐬 𝐜𝐚𝐧 𝐫𝐞𝐦𝐚𝐢𝐧 𝐨𝐧 𝐭𝐡𝐞 𝐟𝐚𝐛𝐫𝐢𝐜 𝐥𝐞𝐚𝐝𝐢𝐧𝐠 𝐭𝐨 𝐢𝐭𝐜𝐡𝐢𝐧𝐠, 𝐢𝐧𝐟𝐥𝐚𝐦𝐞𝐝 𝐬𝐤𝐢𝐧, 𝐚𝐧𝐝 𝐞𝐯𝐞𝐧 𝐛𝐥𝐢𝐬𝐭𝐞𝐫𝐢𝐧𝐠. 𝐎𝐧 𝐚𝐯𝐞𝐫𝐚𝐠𝐞, 𝐢𝐭 𝐬𝐚𝐢𝐝 𝐭𝐡𝐚𝐭 𝐮𝐩 𝐭𝐨 𝐭𝐰𝐨 𝐚𝐧𝐝 𝐚 𝐡𝐚𝐥𝐟 𝐩𝐞𝐫𝐜𝐞𝐧𝐭 𝐨𝐟 𝐝𝐞𝐭𝐞𝐫𝐠𝐞𝐧𝐭 𝐚𝐜𝐭𝐮𝐚𝐥𝐥𝐲 𝐫𝐞𝐦𝐚𝐢𝐧𝐬 𝐨𝐧 𝐟𝐚𝐛𝐫𝐢𝐜 𝐚𝐟𝐭𝐞𝐫 𝐰𝐚𝐬𝐡𝐢𝐧𝐠 𝐚𝐧𝐝 𝐚𝐟𝐭𝐞𝐫 𝐭𝐰𝐨 𝐫𝐢𝐧𝐬𝐞 𝐜𝐲𝐜𝐥𝐞𝐬.

𝐀𝐧𝐝 𝐰𝐡𝐚𝐭 𝐝𝐨𝐞𝐬 𝐬𝐞𝐧𝐬𝐢𝐭𝐢𝐯𝐞 𝐬𝐤𝐢𝐧 𝐚𝐜𝐭𝐮𝐚𝐥𝐥𝐲 𝐦𝐞𝐚𝐧?

View Details

About Dr.Peter Vadas, MD, FRCPC, PhD.Dr. Vadas is Division Head of the Division of Clinical Immunology and Allergy and a senior scientist at St. Michael's Hospital Research Institute, with a focus on basic, translational and clinical research in the areas of biochemical and clinical risk factors predisposing to severe and fatal multi-system allergic reactions and mechanisms of induction of tolerance. His office practice at St. Michael's Hospital in Toronto specifically includes investigation and treatment of allergic rhinitis, urticaria and angioedema, anaphylaxis, mastocytosis, asthma, adverse drug reactions and reactions to stinging insects, including venom immunotherapyIn addition to his clinical practice as an allergist and clinical immunologist, Dr. Vadas is an experienced legal medicine specialist in the areas of life-threatening anaphylaxis and anaphylactic shock, food allergies, adverse drug reactions and severe reactions to stinging insects. He provides litigation support as an expert medical witness for both defence and plaintiffs.Episode Learning Objectives Discuss appropriate assessment strategies for disease activity and prognosis to guide treatment decisions for CSU * Apply current evidence and guidelines as well as shared decision-making to make effective individualized topical treatment decisions for CSU * Implement strategies to improve multidisciplinary care coordination between primary care providers and allergists to address the needs of patients*

Episode supported by an Independent Medical Educational Grant from Miravo Health.

💡 🔋 𝐀𝐭 𝐭𝐡𝐞 Skin and Joints Podcast 𝐰𝐞 𝐥𝐢𝐤𝐞 𝐭𝐨 𝐞𝐱𝐩𝐥𝐨𝐫𝐞 𝐭𝐡𝐞 𝐦𝐮𝐥𝐭𝐢𝐝𝐢𝐬𝐜𝐢𝐩𝐥𝐢𝐧𝐚𝐫𝐲 𝐢𝐧𝐭𝐞𝐫𝐟𝐚𝐜𝐞𝐬 𝐨𝐟 𝐜𝐚𝐫𝐞 𝐝𝐞𝐥𝐢𝐯𝐞𝐫𝐲 𝐰𝐡𝐞𝐫𝐞 #𝐢𝐧𝐧𝐨𝐯𝐚𝐭𝐢𝐨𝐧 𝐡𝐚𝐩𝐩𝐞𝐧𝐬.

🆕 𝐓𝐡𝐚𝐭’𝐬’ 𝐰𝐡𝐲 𝐰𝐞'𝐫𝐞 𝐞𝐱𝐜𝐢𝐭𝐞𝐝 𝐭𝐨 𝐡𝐚𝐯𝐞 𝐃𝐫.𝐏𝐞𝐭𝐞𝐫 𝐕𝐚𝐝𝐚𝐬, MD, FRCPC, PhD, 𝐣𝐨𝐢𝐧 𝐮𝐬 𝐚𝐬 𝐅𝐚𝐜𝐮𝐥𝐭𝐲 𝐭𝐨 𝐬𝐡𝐞𝐝 𝐥𝐢𝐠𝐡𝐭 𝐨𝐧 𝐦𝐚𝐧𝐚𝐠𝐢𝐧𝐠 𝐜𝐫𝐨𝐬𝐬 𝐫𝐞𝐟𝐞𝐫𝐫𝐚𝐥𝐬 𝐛𝐞𝐭𝐰𝐞𝐞𝐧 #𝐝𝐞𝐫𝐦𝐚𝐭𝐨𝐥𝐨𝐠𝐲 𝐚𝐧𝐝 #𝐚𝐥𝐥𝐞𝐫𝐠𝐲. He takes along on a MasterClass with reveal key practical, real-world clinical secrets when it comes to identifying and managing CSU or Chronic Spontaneous Urticaria.

🆕🆕 𝐃𝐫.𝐕𝐚𝐝𝐚𝐬 𝐚𝐧 #𝐚𝐥𝐥𝐞𝐫𝐠𝐢𝐬𝐭 𝐚𝐧𝐝 𝐜𝐥𝐢𝐧𝐢𝐜𝐚𝐥 𝐢𝐦𝐦𝐮𝐧𝐨𝐥𝐨𝐠𝐢𝐬𝐭, 𝐚𝐧𝐝 𝐇𝐞𝐚𝐝 𝐨𝐟 𝐭𝐡𝐞 𝐃𝐢𝐯𝐢𝐬𝐢𝐨𝐧 𝐨𝐟 𝐀𝐥𝐥𝐞𝐫𝐠𝐲 𝐚𝐧𝐝 𝐂𝐥𝐢𝐧𝐢𝐜𝐚𝐥 𝐈𝐦𝐦𝐮𝐧𝐨𝐥𝐨𝐠𝐲 𝐚𝐧𝐝 𝐌𝐞𝐝𝐢𝐜𝐚𝐥 𝐃𝐢𝐫𝐞𝐜𝐭𝐨𝐫 𝐨𝐟 𝐭𝐡𝐞 𝐑𝐞𝐠𝐢𝐨𝐧𝐚𝐥 𝐀𝐧𝐚𝐩𝐡𝐲𝐥𝐚𝐱𝐢𝐬 𝐂𝐥𝐢𝐧𝐢𝐜 𝐚𝐭 St. Michael's Hospital in Toronto.

View Details

We sit down with Vancouver-based dermatologist and Skin and Joints Podcast Faculty, Dr.Angela Law, to explore the role of topical formulation design and the impact it can have in the management of mild to moderate plaque psoriasis.

Can a change in vehicle result in a change in efficacy and safety? Dr.Law delivers a masterclass-ie we take a comparative deep dive look into new data on calcipotriol/betamethasone dipropionate topical formulations in psoriasis.

Dr.Law also drops her clinical treatment secrets when it comes to optimizing her patient's psoriasis that you do not want to miss.

So should you reach for that gel, foam or ointment? Let's find out!

You'll also hear the (soothing) voice of Dermatology Resident Co-Host Touraj Khosravi for the first time.

About Dr.Angela Law, MD, FRCPC Dermatologist | Vancouver

Dr.Angela Law is a dually certified dermatologist in Canada and the US. She completed her medical school training at the University of British Columbia and was accepted into the joint Dermatology program between the University of Saskatchewan and Dalhousie University. She opened SkinSense Dermatology in Saskatoon after residency and practiced medical and aesthetic dermatology for six years before moving back to Vancouver during the COVID pandemic.

She is a Clinical Instructor in the Department of Dermatology and Skin Sciences at UBC and sits on the Undergraduate Education Committee in Dermatology. She has a special interest in pediatric and adolescent dermatology but has been trained in all aspects of medical, surgical and cosmetic dermatology. She splits her time between her new medical clinic with a group of seasoned plastic surgeons at Clinic One Three Eight in downtown Vancouver, aesthetics at Dermapure and a Dermatology rapid access clinic at Mount St. Joseph’s Hospital through Providence Health.

Episode supported by an independent grant from LEO Pharma.

📻www.skinandjoints.ca

✉️info@skinandjoints.ca

View Details

🎙️🎙️ 📭 𝐓𝐡𝐞 𝐩𝐞𝐨𝐩𝐥𝐞 𝐡𝐚𝐯𝐞 𝐬𝐩𝐨𝐤𝐞𝐧, 𝐚𝐧𝐝 𝐬𝐨 𝐰𝐞 𝐡𝐚𝐝 𝐭𝐨 𝐥𝐢𝐬𝐭𝐞𝐧. 𝐀 𝐟𝐢𝐫𝐬𝐭 𝐨𝐟 𝐬𝐨𝐫𝐭𝐬 𝐟𝐨𝐫 𝐭𝐡𝐞 Skin and Joints Podcast, 𝐃𝐫.𝐉𝐚𝐠𝐠𝐢 𝐑𝐚𝐨 𝐛𝐞𝐜𝐨𝐦𝐞𝐬 𝐭𝐡𝐞 𝐟𝐢𝐫𝐬𝐭 𝐫𝐞𝐭𝐮𝐫𝐧𝐢𝐧𝐠 Faculty 𝐞𝐱𝐩𝐞𝐫𝐭 𝐨𝐧 𝐭𝐡𝐞 𝐏𝐨𝐝𝐜𝐚𝐬𝐭! (𝑾𝒆 𝒕𝒉𝒊𝒏𝒌 𝒊𝒕'𝒔 𝒃𝒆𝒄𝒂𝒖𝒔𝒆 𝒐𝒇 𝒉𝒊𝒔 𝒔𝒐𝒐𝒕𝒉𝒊𝒏𝒈 𝒓𝒂𝒅𝒊𝒐 𝒗𝒐𝒊𝒄𝒆).

🌐 🌐 𝐇𝐚𝐯𝐞 𝐲𝐨𝐮 𝐡𝐞𝐚𝐫𝐝 𝐨𝐟 𝐇𝐎𝐑𝐈𝐙𝐎𝐍?

𝐃𝐫.𝐑𝐚𝐨 𝐠𝐮𝐢𝐝𝐞𝐬 𝐮𝐬 𝐭𝐡𝐫𝐨𝐮𝐠𝐡 𝐚 𝐧𝐨𝐯𝐞𝐥 𝐜𝐨𝐧𝐬𝐞𝐧𝐬𝐮𝐬 𝐩𝐫𝐨𝐭𝐨𝐜𝐨𝐥 𝐨𝐧 𝐭𝐡𝐞 #𝐛𝐢𝐨𝐥𝐨𝐠𝐢𝐜 𝐦𝐚𝐧𝐚𝐠𝐞𝐦𝐞𝐧𝐭 𝐚𝐧𝐝 𝐭𝐫𝐞𝐚𝐭𝐦𝐞𝐧𝐭 𝐨𝐟 𝐦𝐨𝐝𝐞𝐫𝐚𝐭𝐞-𝐭𝐨-𝐬𝐞𝐯𝐞𝐫𝐞 #𝐩𝐬𝐨𝐫𝐢𝐚𝐬𝐢𝐬 𝐚𝐜𝐡𝐢𝐞𝐯𝐞𝐝 𝐛𝐲 𝐚 𝐩𝐚𝐧𝐞𝐥 𝐨𝐟 39 leading 𝐂𝐚𝐧𝐚𝐝𝐢𝐚𝐧 #𝐝𝐞𝐫𝐦𝐚𝐭𝐨𝐥𝐨𝐠𝐢𝐬𝐭𝐬

🔑🔑💡 𝗪𝗵𝗮𝘁 𝗹𝗮𝘁𝗲𝘀𝘁 #𝘁𝗿𝗲𝗮𝘁𝗺𝗲𝗻𝘁 𝗼𝗽𝘁𝗶𝗼𝗻𝘀 𝗰𝗮𝗺𝗲 𝗼𝘂𝘁 𝗼𝗻 𝘁𝗼𝗽 𝗳𝗼𝗿 𝗣𝘀𝗢 +/- 𝘄𝗶𝘁𝗵 𝗻𝗮𝗶𝗹 𝘃𝘀 𝘀𝗰𝗮𝗹𝗽 𝘃𝘀 #𝗽𝗮𝗹𝗺𝗼𝗽𝗹𝗮𝗻𝘁𝗮𝗿 𝗶𝗻𝘃𝗼𝗹𝘃𝗲𝗺𝗲𝗻𝘁? 𝗪𝗵𝗮𝘁 𝘁𝗿𝗲𝗮𝘁𝗺𝗲𝗻𝘁s did 𝘁𝗵𝗶𝘀 𝗴𝗿𝗼𝘂𝗽 𝗼𝗳 #𝗱𝗲𝗿𝗺𝗮𝘁𝗼𝗹𝗼𝗴𝗶𝘀𝘁𝘀 𝗮𝗴𝗿𝗲𝗲 𝗼𝗻 𝘄𝗵𝗲𝗻 𝘁𝗵𝗲 #𝗷𝗼𝗶𝗻𝘁𝘀 𝗮𝗿𝗲 𝗶𝗻𝘃𝗼𝗹𝘃𝗲𝗱?

😉 𝐘𝐨𝐮 𝐨𝐧𝐥𝐲 𝐥𝐞𝐚𝐫𝐧 𝐭𝐡𝐢𝐬 𝐬𝐭𝐮𝐟𝐟 𝐢𝐟 𝐲𝐨𝐮 𝐰𝐨𝐫𝐤 𝐚𝐥𝐨𝐧𝐠𝐬𝐢𝐝𝐞 𝐃𝐫.Rao, 𝐨𝐫, of course, 𝐢𝐟 𝐲𝐨𝐮 𝐥𝐢𝐬𝐭𝐞𝐧 𝐭𝐨 𝐭𝐡𝐞 Skin and Joints Podcast

Episode supported by Novartis Canada

📻www.skinandjoints.ca

✉️info@skinandjoints.ca

About Dr.Jaggi Rao, MD, FRCPC Dermatologist | Edmonton

Dr. Jaggi Rao is a double board certified dermatologist (Canada and USA) and a certified cosmetic surgeon. He completed his dermatology training at the University of Alberta, followed by an accredited fellowship with the American Academy of Cosmetic Surgery in Southern California. Dr. Rao is a full Clinical Professor of Medicine at the University of Alberta.

Dr. Rao has won several accolades for research and teaching, including the Canadian Dermatology Association’s Teacher of the Year Award.

In 2011, he was the recipient of Avenue Magazine’s Top 40 under 40 Award. He has authored over 50 scientific papers and textbook chapters, and has been an invited speaker for over 500 lectures worldwide to physicians, other professionals, and the general public.

Dr. Rao continues to lend his expertise to various organizations. He sits on the board of directors for CAAM( Canadian Association of Aesthetics Medicine) and acts as a consultant to the government (such as the Canadian Standards Association), laser and pharmaceutical industry, and professional sports teams.

View Details

🎙️🎙️🎙️ 𝗪𝗲 𝘀𝘁𝗮𝗿𝘁 𝟮𝟬𝟮𝟮 𝘀𝘄𝗶𝗻𝗴𝗶𝗻𝗴 𝗳𝗿𝗼𝗺 #𝗱𝗲𝗿𝗺𝗮𝘁𝗼𝗹𝗼𝗴𝘆 to #rheum 𝘄𝗶𝘁𝗵 Vancouver 𝗯𝗮𝘀𝗲𝗱 #rheumatologist and ultrasound aficionado, 𝗗𝗿.Mo Bardi, 𝘄𝗵𝗼 𝘁𝗮𝗸𝗲𝘀 𝘁𝗵𝗲 𝗵𝗲𝗮𝗱𝗮𝗰𝗵𝗲 𝗼𝘂𝘁 𝗼𝗳 𝗱𝗶𝗮𝗴𝗻𝗼𝘀𝗶𝗻𝗴 𝗮𝗻𝗱 𝗺𝗮𝗻𝗮𝗴𝗶𝗻𝗴 #𝘃𝗮𝘀𝗰𝘂𝗹𝗶𝘁𝗶𝘀 𝗮𝗻𝗱 𝗚𝗶𝗮𝗻𝘁 𝗖𝗲𝗹𝗹 𝗔𝗿𝘁𝗲𝗿𝗶𝘁𝗶𝘀 (𝗚𝗖𝗔).

🔑🔑💡 𝗪𝗵𝗮𝘁 𝘀𝗲𝗰𝗿𝗲𝘁𝘀 𝗱𝗼𝗲𝘀 𝗗𝗿.𝗕𝗮𝗿𝗱𝗶 𝗿𝗲𝘃𝗲𝗮𝗹 𝗮𝗯𝗼𝘂𝘁 𝗵𝗶𝘀 𝗿𝗲𝗳𝗲𝗿𝗿𝗮𝗹𝘀?

😉 𝐘𝐨𝐮 𝐨𝐧𝐥𝐲 𝐥𝐞𝐚𝐫𝐧 𝐭𝐡𝐢𝐬 𝐬𝐭𝐮𝐟𝐟 𝐢𝐟 𝐲𝐨𝐮 𝐰𝐨𝐫𝐤 𝐚𝐥𝐨𝐧𝐠𝐬𝐢𝐝𝐞 𝐃𝐫.Bardi, 𝐨𝐫, 𝐢𝐟 𝐲𝐨𝐮 𝐥𝐢𝐬𝐭𝐞𝐧 𝐭𝐨 𝐭𝐡𝐞 Skin and Joints Podcast. 𝗔𝗻𝗱 𝗼𝗳 𝗰𝗼𝘂𝗿𝘀𝗲 𝘁𝗵𝗲 𝗵𝗶𝗴𝗵-𝘃𝗮𝗹𝘂𝗲 𝗰𝗼𝗻𝘁𝗲𝗻𝘁 𝗰𝗼𝗺𝗲𝘀 𝘄𝗶𝘁𝗵 𝗮 𝗵𝗲𝗮𝗹𝘁𝗵𝘆 𝗱𝗼𝘀𝗲 𝗼𝗳 𝗵𝘂𝗺𝗼𝗿.

🎧🎧 𝐘𝐨𝐮'𝐥𝐥 𝐚𝐥𝐬𝐨 𝐧𝐨𝐭𝐢𝐜𝐞 𝐟𝐨𝐫 𝐭𝐡𝐞 𝐟𝐢𝐫𝐬𝐭 𝐭𝐢𝐦𝐞, 𝐭𝐡𝐞 𝐯𝐨𝐢𝐜𝐞 𝐨𝐟 𝐨𝐮𝐫 #𝐫𝐡𝐞𝐮𝐦𝐚𝐭𝐨𝐥𝐨𝐠𝐲 𝐟𝐞𝐥𝐥𝐨𝐰 co-host Dr.Ashley Yip! Episode d𝐫𝐨𝐩𝐩𝐢𝐧𝐠 soon. 👇

PART I focuses on the assessment and diagnosis of GCA.

Episode supported by Eli Lilly and Company and Roche.

📻𝘄𝘄𝘄.𝘀𝗸𝗶𝗻𝗮𝗻𝗱𝗷𝗼𝗶𝗻𝘁𝘀.𝗰𝗮

About Dr.Mo Bardi, MD, FRCPC Rheumatologist | Vancouver

Dr.Mo Bardi completed his training in Internal Medicine and Rheumatology at UBC, including a fellowship in musculoskeletal ultrasound through the American College of Rheumatology USSONAR program.

Further, he has trained internationally in the use of ultrasound for the assessment of large vessel vasculitis and leads a fast-track ultrasound setup in his practice. Dr. Bardi is a Clinical Instructor at the University of British Columbia (UBC) and active rheumatologist staff at Vancouver General Hospital. He is part of the Vasculitis clinic at Mary Pack Arthritis Center with a focus on Giant Cell Arteritis. His ongoing research is in the areas of ultrasound in the assessment of large vessel vasculitis and the diagnostic role of musculoskeletal ultrasound in inflammatory and non-inflammatory joint diseases.

LEARNING OBJECTIVES * Evaluate appropriate strategies for assessing and diagnosing patients with GCA * Describe real world clinical pearls for managing patients with GCA and commons differentials

Rate us on Apple Podcasts, recommend a guest at info@skinandjoints.ca

View Details

🎙️🎙️🎙️ 𝐂𝐫𝐨𝐬𝐬𝐢𝐧𝐠 𝐨𝐯𝐞𝐫 𝐟𝐫𝐨𝐦 𝐭𝐡𝐞 𝐬𝐤𝐢𝐧 𝐭𝐨 𝐭𝐡𝐞 𝐣𝐨𝐢𝐧𝐭𝐬 𝐚𝐧𝐝 𝐞𝐯𝐞𝐫𝐲𝐭𝐡𝐢𝐧𝐠 𝐢𝐧 𝐛𝐞𝐭𝐰𝐞𝐞𝐧, 𝐰𝐞 𝐜𝐡𝐚𝐭 𝐰𝐢𝐭𝐡 𝐕𝐚𝐧𝐜𝐨𝐮𝐯𝐞𝐫-𝐛𝐚𝐬𝐞𝐝 𝐫𝐡𝐞𝐮𝐦𝐚𝐭𝐨𝐥𝐨𝐠𝐢𝐬𝐭, 𝐃𝐫.𝐉𝐨𝐧𝐚𝐭𝐡𝐚𝐧 𝐂𝐡𝐚𝐧, who 𝐭𝐚𝐤𝐞𝐬 𝐮𝐬 𝐨𝐧 𝐚 𝐜𝐥𝐢𝐧𝐢𝐜𝐚𝐥 𝐬𝐞𝐜𝐫𝐞𝐭𝐬 𝐌𝐚𝐬𝐭𝐞𝐫𝐂𝐥𝐚𝐬𝐬.

🔑🔑💡 𝐓𝐍𝐅, 𝐈𝐋, 𝐉𝐀𝐊 -𝐰𝐡𝐚𝐭 and how 𝐝𝐨 I 𝐜𝐡𝐨𝐨𝐬𝐞 therapy for PsA?

🎧🎧 It's a candid conversation where Dr.Chan reveals his psoriatic arthritis PsA clinical secrets ie. the PsA clinical playbook.

We also explore the world of biosimilars, and a one-of-a kind collaborative clinic with Skin and Joints Faculty, Dr.Jan Dutz.

😉 𝐘𝐨𝐮 𝐨𝐧𝐥𝐲 𝐥𝐞𝐚𝐫𝐧 𝐭𝐡𝐢𝐬 𝐬𝐭𝐮𝐟𝐟 𝐢𝐟 𝐲𝐨𝐮 𝐰𝐨𝐫𝐤 𝐚𝐥𝐨𝐧𝐠𝐬𝐢𝐝𝐞 𝐃𝐫.Chan, 𝐨𝐫, of course, 𝐢𝐟 𝐲𝐨𝐮 𝐥𝐢𝐬𝐭𝐞𝐧 𝐭𝐨 𝐭𝐡𝐞 Skin and Joints Podcast.

Email us: info@skinandjoints.ca

About Dr.Jonathan Chan, MD, FRCPC Rheumatologist | Vancouver

Dr. Chan is an assistant clinical professor at the University of British Columbia and an Adult Rheumatologist and Clinical Investigator with Arthritis Research Canada. (ARC). He has a clinical focus and research interest in the areas of axial spondyloarthritis and psoriatic arthritis. He was awarded an Assessment of Spondyloarthritis Society (ASAS) fellowship grant and completed a clinical fellowship at the University of Toronto in axial spondyloarthritis (ankylosing spondylitis). Dr.Chan actively pursues research in this field and has been invited to present on this topic internationally in addition to being the coauthor of the Canadian Spondylitis Treatment Guidelines.

His research focuses on early identification, long term outcomes, radiographic progression, and use of administrative databases. Dr.Chan is the core site leader of the national spondylitis and psoriatic arthritis research cohorts (SPARCC and iPART) which follow patients with spondyloarthritis and psoriatic arthritis. He also participates in clinical trials evaluating the efficacy and safety of mew therapies in these types of inflammatory arthritis.

Learning Objectives * Discuss appropriate strategies for managing patients with moderate to severe psoriatic arthritis (PsA) * Describe real world clinical implications and therapy considerations for managing moderate to severe psoriatic arthritis (PsA) * Implement strategies to improve multidisciplinary care coordination between primary care providers and specialty care providers and address the needs of patients with PsA.

*Episode recorded earlier.

Supported by IME grants from TEVA and Bristol Myers Squibb.
www.skinandjoints.ca

View Details

About Dr.Jaggi Rao, MD, FRCPC Dermatologist | Edmonton

Dr. Jaggi Rao is a double board certified dermatologist (Canada and USA) and a certified cosmetic surgeon. He completed his dermatology training at the University of Alberta, followed by an accredited fellowship with the American Academy of Cosmetic Surgery in Southern California. Dr. Rao is a full Clinical Professor of Medicine at the University of Alberta.

Dr. Rao has won several accolades for research and teaching, including the Canadian Dermatology Association’s Teacher of the Year Award.

In 2011, he was the recipient of Avenue Magazine’s Top 40 under 40 Award. He has authored over 50 scientific papers and textbook chapters, and has been an invited speaker for over 500 lectures worldwide to physicians, other professionals, and the general public.

Dr. Rao continues to lend his expertise to various organizations. He sits on the board of directors for CAAM( Canadian Association of Aesthetics Medicine) and acts as a consultant to the government (such as the Canadian Standards Association), laser and pharmaceutical industry, and professional sports teams.

Learning Objectives * Discuss appropriate strategies for managing patients with moderate to severe acne and associated psychosocial sequelae * Understand practical real world clinical implications and key monitoring considerations for managing severe inflammatory acne with various formulations of isotretinoin * Implement strategies to improve multidisciplinary care coordination between primary care providers and specialty care providers and address the needs of patients with acne

Supported by an IME grant from Cipher Pharmaceuticals.

www.skinandjoints.ca

View Details

About Dr.Perla Lansang, MD, FRCPCDermatologist | Toronto

Dr.Perla Lansang is head of dermatology at Sunnybrook Hospital in Toronto, Ontario and is an assistant professor in the Division of Dermatology, University of Toronto. She has a special interest in pediatric and adolescent dermatology, having done two years of fellowship in paediatric dermatology at The Hospital for Sick Children.

At Sunnybrook, she sees general medical dermatology patients and also holds a pregnancy dermatology clinic and also has a special focus on psoriasis, atopic dermatitis, cutaneous lymphoma, and general medical dermatology. Aside from Sunnybrook Hospital, Dr. Lansang is also affiliated with Women’s College Hospital where she runs a clinic at the Phototherapy Education and Research Centre. She also sees patients at The Hospital for Sick Children, where she has her pediatric dermatology practice.

Dr.Lansang is also a Skin and Joints Podcast Faculty expert.

RESEARCH ARTICLE discussed:

• Management of Plaque Psoriasis With Biologic Therapies in Women of Child-Bearing Potential Consensus Paper
• Jensen Yeung, Melinda J. Gooderham, Parbeer Grewal, Chih-ho Hong, Perla Lansang, Kim A. Papp, Yves Poulin, Irina Turchin, Ronald Vender

Learning Objectives * Discuss appropriate immunotherapy strategies for women of child bearing potential with a focus on safety * Understand practical real world clinical implications for managing moderate to severe plaque psoriasis in women of child bearing potential (WOCBP) pre-partum, pregnancy, and post partum as well as barriers and opportunities for implementation * Implement strategies to improve multidisciplinary care coordination between primary care providers and specialty care providers and address the needs of patients

Supported by an IME grant from UCB Canada.

www.skinandjoints.ca

A big thank you to the thousands of healthcare providers. specialists, and primary care providers, signed up and engaged with the Skin and Joints podcast from across the country!

View Details

About Dr.Jan Dutz, MD, FRCPCDermatologist and Rheumatologist | Vancouver

We're going to talk to a practice expert who literally can provide a perspective from both a rheumatology and dermatology point of view.

Dr. Jan Dutz is a professor of medicine and the current head of dermatology at the university of British Columbia. . He is a Senior Scientist with the Child and Family Research Institute (CFRI) where his research focus is the skin immune system and the manipulation of this system to both promote immune responses and induce tolerance.

Dr.Dutz is one of the few physicians in North America to be board certified and maintain active practice in both rheumatology and dermatology. And he is a Senior Scientist with the Child and Family Research Institute (CFRI) where his research focus is the skin immune system and the manipulation of this system to both promote immune responses and induce tolerance.

Learning Objectives * Discuss appropriate screening strategies for patients with moderate to severe psoriasis suspected of psoriatic arthritis and the patient journey * Understand current evidence and practical real world clinical implications for validated PsA screening tools as well as barriers and opportunities for implementation * Implement strategies to improve multidisciplinary care coordination between primary care providers and specialty care providers and address the needs of patients

NATIONAL PSORIASIS FOUNDATION Psoriatic Arthritis Screening Tool for Providers

• Available from: https://www.psoriasis.org/psoriatic-arthritis-screening-tool-for-providers/

RESEARCH ARTICLE

Psoriatic arthritis screening: A systematic literature review and experts’ recommendations

• Available from: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0248571

Disclaimer: This is an educational podcast only and does not replace professional medical advice. Please consult your healthcare provider for any health issues.

Supported by an IME grant from NOVARTIS.

www.skinandjoints.ca

View Details

Learning Objectives * Discuss appropriate assessment strategies for disease activity and prognosis to guide treatment decisions for moderate to severe plaque psoriasis, Including primary and secondary treatment failures in patients * Understand the role current evidence and real world clinical guidance to make effective individualized treatment decisions for patients with refractory moderate to severe PsO, specifically exploring the role of brodalumab * Implement strategies to improve interprofessional care coordination between primary care providers and specialty care providers and address the needs of patients

About Dr.Elena Netchiporouk, MD, M.Sc., FRCPCDermatologist, Montreal

Dr. Elena Netchiporouk is an Assistant Professor and Director of Undergraduate Medical Education in Dermatology at McGill University. She earned her M.D. degree at Université de Montréal and dermatology residency training at the McGill University Health Centre with an Experimental Medicine M.Sc. degree from McGill University.

Elena is a Junior Scientist within the Infectious Diseases and Immunity in Global Health Program of the MUHC-Research Institute studying cutaneous autoimmunity, scleroderma and chronic urticaria. She leads a complex care, skin fibrosis and chronic urticaria clinics at the Montreal General Hospital Site of the MUHC.

Her research program is supported by several grants from the Canadian Dermatology Foundation, Association des Médecins Spécialistes Dermatologues du Québec, Department of Medicine (McGill University) and Ministère d’Éducation et Innovation du Québec. She is actively involved in Dermatology Residency Training Program and is the founder of the Interactive Dermatology Learning Platform for Dermatology residents and Primary Care Providers Montreal Derm FilEZ© (Montrealdermfilez.ca) set to launch this year.

Disclaimer: This is an educational podcast only and does not replace professional medical advice. Please consult your healthcare provider for any health issues.

Supported by an IME grant from Bausch Health.

www.skinandjoints.ca

View Details

Episode Learning Objectives

· Explore assessment strategies based on disease activity to guide treatment decisions for moderate to severe atopic dermatitis

· Apply current evidence as well as shared decision-making to individualize therapy decisions for patients with moderate to severe atopic dermatitis; specifically real world experience around dupilumab (DUPIXENT) and a recent publication exploring upadacitinib (RINVOQ), an experimental indication for AD vs dupilumab

· Implement strategies to improve interprofessional care coordination between primary care providers and specialty care providers and address the unmet needs of patients

ABOUT DR.ASHLEY O'TOOLE, MHSc, MD, FRCPC:

Dr. O’Toole is a dermatologist with the SKiN Centre for Dermatology in Peterborough, Ontario where she also serves as a sub-investigator for multiple clinical trials. She is an adjunctive professor at Queens University and involved in teaching medical students and residents and holds medical privileges at the Peterborough Regional Health Centre.

After receiving a Master’s of Health Science in Health and Behavioural Communication at Ryerson University in Toronto, Ontario, Dr. O’Toole received her medical degree from McMaster University in Hamilton, Ontario, and completed her residency in dermatology at the University of Ottawa in Ottawa, Ontario.

Dr. O’Toole is the author or co-author of over 20 peer-reviewed publications and has been involved ias a sub-investigator for over 40 clinical trials on atopic dermatitis, psoriasis, alopecia, acne and vitiligo.

Disclaimer: This is an educational podcast only and does not replace professional medical advice. Please consult your healthcare provider for any health issues.

Discussed:

• HEADS UP Trial: https://jamanetwork.com/journals/jamadermatology/fullarticle/2782803
• Real-world experience of dupilumab in the treatment of moderate-to-severe atopic dermatitis: https://onlinelibrary.wiley.com/doi/full/10.1111/ijd.15053

Supported by IMEs from Janssen and Lilly

www.skinandjoints.ca

View Details

Episode Learning Objectives

• Discuss appropriate assessment strategies for disease activity and prognosis to guide treatment decisions for moderate to severe plaque psoriasis
• Apply current evidence and guidelines on targeted biologics with shared decision-making to make effective individualized treatment decisions for patients with moderate-to-severe plaque PsO (specifically ixekizumab and Guselkumab)
• Implement evidence-based and expert consensus strategies to improve interprofessional care coordination and address the needs of patients with comorbidities

ABOUT DR.CHRISTINA HAN, MD, FRCPC:

Dr. Christina Han is a dermatologist practicing medical and surgical dermatology in Vancouver, BC and is certified to practice in both the United States and Canada. She sees a broad range of dermatology patients, including pediatric and adults and focuses her practice on medical dermatology. Her clinical focus includes inflammatory conditions, including psoriasis, atopic dermatitis, and acne. She also teaches medical students and residents and is a Clinical Assistant Professor with the Department of Dermatology at UBC.

Disclaimer: This is an educational podcast only and does not replace professional medical advice. Please consult your healthcare provider for any health issues.

Supported by IMEs from Janssen and Lilly

www.skinandjoints.ca